BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med. 2001;194:1395-1406. [PMID: 11714747 DOI: 10.1084/jem.194.10.1395] [Cited by in Crossref: 862] [Cited by in F6Publishing: 836] [Article Influence: 41.0] [Reference Citation Analysis]
Number Citing Articles
1 Mondelli MU, Cerino A, Cividini A. Acute hepatitis C: diagnosis and management. J Hepatol 2005;42 Suppl:S108-14. [PMID: 15777565 DOI: 10.1016/j.jhep.2004.10.017] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 2.6] [Reference Citation Analysis]
2 Peña-Asensio J, Calvo H, Torralba M, Miquel J, Sanz-de-Villalobos E, Larrubia JR. Gamma-Chain Receptor Cytokines & PD-1 Manipulation to Restore HCV-Specific CD8+ T Cell Response during Chronic Hepatitis C. Cells 2021;10:538. [PMID: 33802622 DOI: 10.3390/cells10030538] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Bailey JR, Laskey S, Wasilewski LN, Munshaw S, Fanning LJ, Kenny-Walsh E, Ray SC. Constraints on viral evolution during chronic hepatitis C virus infection arising from a common-source exposure. J Virol 2012;86:12582-90. [PMID: 22973048 DOI: 10.1128/JVI.01440-12] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
4 Bantel H, Schulze-osthoff K. Apoptosis in hepatitis C virus infection. Cell Death Differ 2003;10:S48-58. [DOI: 10.1038/sj.cdd.4401119] [Cited by in Crossref: 110] [Cited by in F6Publishing: 112] [Article Influence: 5.8] [Reference Citation Analysis]
5 Lalazar G, Ilan Y. Histamine dihydrochloride: actions and efficacy in the treatment of chronic hepatitis C infection. Expert Rev Anti Infect Ther 2006;4:377-85. [PMID: 16771615 DOI: 10.1586/14787210.4.3.377] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
6 Fauvelle C, Lepiller Q, Felmlee DJ, Fofana I, Habersetzer F, Stoll-Keller F, Baumert TF, Fafi-Kremer S. Hepatitis C virus vaccines--progress and perspectives. Microb Pathog 2013;58:66-72. [PMID: 23499591 DOI: 10.1016/j.micpath.2013.02.005] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 3.3] [Reference Citation Analysis]
7 Xie Z, Li Y, Long L, Liang H, Cai W, Shen T. Polymorphisms in the Th17 cell-related RORC gene are associated with spontaneous clearance of HCV in Chinese women. BMC Infect Dis 2018;18:254. [PMID: 29866105 DOI: 10.1186/s12879-018-3153-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 de Oliveria Andrade LJ, D’Oliveira A, Melo RC, De Souza EC, Costa Silva CA, Paraná R. Association between hepatitis C and hepatocellular carcinoma. J Glob Infect Dis. 2009;1:33-37. [PMID: 20300384 DOI: 10.4103/0974-777x.52979] [Cited by in Crossref: 93] [Cited by in F6Publishing: 45] [Article Influence: 8.5] [Reference Citation Analysis]
9 Shin EC, Sung PS, Park SH. Immune responses and immunopathology in acute and chronic viral hepatitis. Nat Rev Immunol. 2016;16:509-523. [PMID: 27374637 DOI: 10.1038/nri.2016.69] [Cited by in Crossref: 152] [Cited by in F6Publishing: 148] [Article Influence: 25.3] [Reference Citation Analysis]
10 Liu L, Nardo D, Li E, Wang GP. CD4+ T-cell recovery with suppressive ART-induced rapid sequence evolution in hepatitis C virus envelope but not NS3. AIDS 2016;30:691-700. [PMID: 26645605 DOI: 10.1097/QAD.0000000000000997] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
11 Afify M, Hamza AH, Alomari RA. Correlation Between Serum Cytokines, Interferons, and Liver Functions in Hepatitis C Virus Patients. J Interferon Cytokine Res 2017;37:32-8. [PMID: 27726476 DOI: 10.1089/jir.2016.0044] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
12 Simon BE, Cornell KA, Clark TR, Chou S, Rosen HR, Barry RA. DNA vaccination protects mice against challenge with Listeria monocytogenes expressing the hepatitis C virus NS3 protein. Infect Immun 2003;71:6372-80. [PMID: 14573658 DOI: 10.1128/IAI.71.11.6372-6380.2003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
13 Kerepesi C, Bakács T, Szabados T. MiStImm: an agent-based simulation tool to study the self-nonself discrimination of the adaptive immune response. Theor Biol Med Model 2019;16:9. [PMID: 31046789 DOI: 10.1186/s12976-019-0105-5] [Reference Citation Analysis]
14 Chigbu DI, Loonawat R, Sehgal M, Patel D, Jain P. Hepatitis C Virus Infection: Host⁻Virus Interaction and Mechanisms of Viral Persistence. Cells 2019;8:E376. [PMID: 31027278 DOI: 10.3390/cells8040376] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 12.0] [Reference Citation Analysis]
15 Tan AC, Eriksson EM, Kedzierska K, Deliyannis G, Valkenburg SA, Zeng W, Jackson DC. Polyfunctional CD8(+) T cells are associated with the vaccination-induced control of a novel recombinant influenza virus expressing an HCV epitope. Antiviral Res 2012;94:168-78. [PMID: 22504097 DOI: 10.1016/j.antiviral.2012.03.009] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
16 van Wilgenburg B, Scherwitzl I, Hutchinson EC, Leng T, Kurioka A, Kulicke C, de Lara C, Cole S, Vasanawathana S, Limpitikul W, Malasit P, Young D, Denney L;  STOP-HCV consortium; Moore MD, Fabris P, Giordani MT, Oo YH, Laidlaw SM, Dustin LB, Ho LP, Thompson FM, Ramamurthy N, Mongkolsapaya J, Willberg CB, Screaton GR, Klenerman P. MAIT cells are activated during human viral infections. Nat Commun. 2016;7:11653. [PMID: 27337592 DOI: 10.1038/ncomms11653] [Cited by in Crossref: 253] [Cited by in F6Publishing: 238] [Article Influence: 42.2] [Reference Citation Analysis]
17 Piasecki BA, Reddy KR, Chang K. Acute hepatitis C: To treat or not to treat?: Acute hepatitis C: To treat or not to treat? Hepatology 2002;35:1538-40. [DOI: 10.1002/hep.510350631] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
18 Capone S, Meola A, Ercole BB, Vitelli A, Pezzanera M, Ruggeri L, Davies ME, Tafi R, Santini C, Luzzago A, Fu TM, Bett A, Colloca S, Cortese R, Nicosia A, Folgori A. A novel adenovirus type 6 (Ad6)-based hepatitis C virus vector that overcomes preexisting anti-ad5 immunity and induces potent and broad cellular immune responses in rhesus macaques. J Virol 2006;80:1688-99. [PMID: 16439526 DOI: 10.1128/JVI.80.4.1688-1699.2006] [Cited by in Crossref: 64] [Cited by in F6Publishing: 36] [Article Influence: 4.0] [Reference Citation Analysis]
19 Klepper A, Eng FJ, Doyle EH, El-Shamy A, Rahman AH, Fiel MI, Avino GC, Lee M, Ye F, Roayaie S, Bansal MB, MacDonald MR, Schiano TD, Branch AD. Hepatitis C virus double-stranded RNA is the predominant form in human liver and in interferon-treated cells. Hepatology 2017;66:357-70. [PMID: 27642141 DOI: 10.1002/hep.28846] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
20 Wang CC, Krantz E, Klarquist J, Krows M, McBride L, Scott EP, Shaw-Stiffel T, Weston SJ, Thiede H, Wald A. Acute hepatitis C in a contemporary US cohort: modes of acquisition and factors influencing viral clearance. J Infect Dis. 2007;196:1474-1482. [PMID: 18008226 DOI: 10.1086/522608] [Cited by in Crossref: 129] [Cited by in F6Publishing: 126] [Article Influence: 8.6] [Reference Citation Analysis]
21 Thimme R, Neumann-haefelin C. Genetics in viral hepatitis: role of HLA class I and II alleles in hepatitis C virus infection. In: Blum HE, Häussinger D, Cox DW, Jansen PLM, Kullak-ublick GA, editors. Genetics in Liver Diseases. Dordrecht: Springer Netherlands; 2007. pp. 18-31. [DOI: 10.1007/978-1-4020-6393-0_4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Leroy V, Vigan I, Mosnier J, Dufeu-duchesne T, Pernollet M, Zarski J, Marche PN, Jouvin-marche E. Phenotypic and functional characterization of intrahepatic T lymphocytes during chronic hepatitis C. Hepatology 2003;38:829-41. [DOI: 10.1002/hep.1840380409] [Cited by in Crossref: 59] [Cited by in F6Publishing: 34] [Article Influence: 3.1] [Reference Citation Analysis]
23 Elsaesser H, Sauer K, Brooks DG. IL-21 is required to control chronic viral infection. Science. 2009;324:1569-1572. [PMID: 19423777 DOI: 10.1126/science.1174182] [Cited by in Crossref: 387] [Cited by in F6Publishing: 377] [Article Influence: 29.8] [Reference Citation Analysis]
24 Dill MT, Makowska Z, Duong FHT, Merkofer F, Filipowicz M, Baumert TF, Tornillo L, Terracciano L, Heim MH. Interferon-γ-stimulated genes, but not USP18, are expressed in livers of patients with acute hepatitis C. Gastroenterology 2012;143:777-786.e6. [PMID: 22677194 DOI: 10.1053/j.gastro.2012.05.044] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 4.6] [Reference Citation Analysis]
25 Luxenburger H, Neumann-Haefelin C, Thimme R, Boettler T. HCV-Specific T Cell Responses During and After Chronic HCV Infection. Viruses 2018;10:E645. [PMID: 30453612 DOI: 10.3390/v10110645] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
26 Shi TD, Wu YZ, Jia ZC, Zhou W, Zou LY. Therapeutic polypeptides based on HBcAg18-27 CTL epitope can induce antigen-specific CD8+ CTL-mediated cytotoxicity in HLA-A2 transgenic mice. World J Gastroenterol 2004; 10(8): 1222-1226 [PMID: 15069731 DOI: 10.3748/wjg.v10.i8.1222] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
27 Sarin SK, Kumar M. Natural history of HCV infection. Hepatol Int 2012;6:684-95. [DOI: 10.1007/s12072-012-9355-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
28 Perrella A, Atripaldi L, Bellopede P, Patarino T, Sbreglia C, Tarantino G, Sorrentino P, Conca P, Ruggiero L, Perrella O. Flow cytometry assay of myeloid dendritic cells (mDCs) in peripheral blood during acute hepatitis C: Possible pathogenetic mechanisms. World J Gastroenterol 2006; 12(7): 1105-1109 [PMID: 16534853 DOI: 10.3748/wjg.v12.i7.1105] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
29 Teixeira R, Marcos LA, Friedman SL. Immunopathogenesis of hepatitis C virus infection and hepatic fibrosis: New insights into antifibrotic therapy in chronic hepatitis C. Hepatology Research 2007;37:579-95. [DOI: 10.1111/j.1872-034x.2007.00085.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
30 Wodarz D. Hepatitis C virus dynamics and pathology: the role of CTL and antibody responses. J Gen Virol. 2003;84:1743-1750. [PMID: 12810868 DOI: 10.1099/vir.0.19118-0] [Cited by in Crossref: 109] [Cited by in F6Publishing: 49] [Article Influence: 5.7] [Reference Citation Analysis]
31 Jin L, Zhang XX, Zeng QL, Feng GH, Zhang JY, Chen LM, Xu XS, Zhang Z, Wang FS. Increased myeloid-derived suppressor cells correlate with viral persistence in patients with chronic hepatitis C. Shijie Huaren Xiaohua Zazhi 2014; 22(11): 1574-1580 [DOI: 10.11569/wcjd.v22.i11.1574] [Reference Citation Analysis]
32 Tester I, Smyk-Pearson S, Wang P, Wertheimer A, Yao E, Lewinsohn DM, Tavis JE, Rosen HR. Immune evasion versus recovery after acute hepatitis C virus infection from a shared source. J Exp Med. 2005;201:1725-1731. [PMID: 15939788 DOI: 10.1084/jem.20042284] [Cited by in Crossref: 135] [Cited by in F6Publishing: 130] [Article Influence: 7.9] [Reference Citation Analysis]
33 Rauch A, Gaudieri S, Thio C, Bochud P. Host genetic determinants of spontaneous hepatitis C clearance. Pharmacogenomics 2009;10:1819-37. [DOI: 10.2217/pgs.09.121] [Cited by in Crossref: 52] [Cited by in F6Publishing: 50] [Article Influence: 4.0] [Reference Citation Analysis]
34 Zeiler I, Langlands T, Murray JM, Ritter A. Optimal targeting of Hepatitis C virus treatment among injecting drug users to those not enrolled in methadone maintenance programs. Drug Alcohol Depend 2010;110:228-33. [PMID: 20430537 DOI: 10.1016/j.drugalcdep.2010.03.006] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 3.0] [Reference Citation Analysis]
35 Hofmann M, Wieland D, Pircher H, Thimme R. Memory vs memory-like: The different facets of CD8 + T-cell memory in HCV infection. Immunol Rev 2018;283:232-7. [DOI: 10.1111/imr.12642] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
36 Wang T, Blatt LM, Seiwert SD. Immunomodulatory Activities of IFN-γ1b in Combination with Type I IFN: Implications for the Use of IFN-γ1b in the Treatment of Chronic HCV Infections. Journal of Interferon & Cytokine Research 2006;26:473-83. [DOI: 10.1089/jir.2006.26.473] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
37 Dustin LB. Reexamining the role of the humoral immune response in control of hepatitis C virus infection. Hepatology 2004;40:756-8. [PMID: 15349916 DOI: 10.1002/hep.20376] [Reference Citation Analysis]
38 Fioravanti J, Medina-echeverz J, Berraondo P. Scavenger receptor class B, type I: a promising immunotherapy target. Immunotherapy 2011;3:395-406. [DOI: 10.2217/imt.10.104] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
39 Aslam R, Raza SM, Naeemi H, Mubarak B, Afzal N, Khaliq S. SOCS3 mRNA expression and polymorphisms as pretreatment predictor of response to HCV genotype 3a IFN-based treatment. Springerplus 2016;5:1826. [PMID: 27818864 DOI: 10.1186/s40064-016-3506-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
40 Perrella A, Grattacaso S, d'Antonio A, Atripaldi L, Sbreglia C, Gnarini M, Conti P, Vecchiet J, Perrella O. Evidence of hepatitis C virus-specific interferon gamma-positive T cells in health care workers in an infectious disease department. Am J Infect Control 2009;37:426-9. [PMID: 19155099 DOI: 10.1016/j.ajic.2008.08.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
41 Neumann-Haefelin C, Thimme R. Adaptive immune responses in hepatitis C virus infection. Curr Top Microbiol Immunol. 2013;369:243-262. [PMID: 23463204 DOI: 10.1007/978-3-642-27340-7_10] [Cited by in Crossref: 15] [Cited by in F6Publishing: 26] [Article Influence: 1.7] [Reference Citation Analysis]
42 Sallie R. Replicative homeostasis II: influence of polymerase fidelity on RNA virus quasispecies biology: implications for immune recognition, viral autoimmunity and other "virus receptor" diseases. Virol J 2005;2:70. [PMID: 16115320 DOI: 10.1186/1743-422X-2-70] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
43 R-viso A, Duarte M, Pagliari C, Fernandes E, Brasil R, Benard G, Romano C, Ogusuku S, Cavalheiro N, Melo C, Barone A. Tissue and serum immune response in chronic hepatitis C with mild histological lesions. Mem Inst Oswaldo Cruz 2010;105:25-32. [DOI: 10.1590/s0074-02762010000100003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
44 Yonkers NL, Sieg S, Rodriguez B, Anthony DD. Reduced naive CD4 T cell numbers and impaired induction of CD27 in response to T cell receptor stimulation reflect a state of immune activation in chronic hepatitis C virus infection. J Infect Dis 2011;203:635-45. [PMID: 21220773 DOI: 10.1093/infdis/jiq101] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 3.5] [Reference Citation Analysis]
45 Ng CT, Snell LM, Brooks DG, Oldstone MB. Networking at the level of host immunity: immune cell interactions during persistent viral infections. Cell Host Microbe 2013;13:652-64. [PMID: 23768490 DOI: 10.1016/j.chom.2013.05.014] [Cited by in Crossref: 59] [Cited by in F6Publishing: 49] [Article Influence: 6.6] [Reference Citation Analysis]
46 Perrella A, Borgia G, Guida GM, Graf M, Gnarini RM, Viola C, Atripaldi L, Sbreglia C, Perrella O. Human immunodeficiency virus and subtype 1B hepatitis C virus: more similarities than differences in T-helper subsets. J Gastroenterol Hepatol 2005;20:1310-2. [PMID: 16048590 DOI: 10.1111/j.1440-1746.2005.03851.x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
47 Park J, Kang W, Ryu SW, Kim WI, Chang DY, Lee DH, Park do Y, Choi YH, Choi K, Shin EC. Hepatitis C virus infection enhances TNFα-induced cell death via suppression of NF-κB. Hepatology. 2012;56:831-840. [PMID: 22430873 DOI: 10.1002/hep.25726] [Cited by in Crossref: 52] [Cited by in F6Publishing: 45] [Article Influence: 5.2] [Reference Citation Analysis]
48 Barrett L, Gallant M, Howley C, Bowmer MI, Hirsch G, Peltekian K, Grant M. Enhanced IL-10 production in response to hepatitis C virus proteins by peripheral blood mononuclear cells from human immunodeficiency virus-monoinfected individuals. BMC Immunol 2008;9:28. [PMID: 18554409 DOI: 10.1186/1471-2172-9-28] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
49 Arribillaga L, Sarobe P, Arina A, Gorraiz M, Borrás-cuesta F, Ruiz J, Prieto J, Chen L, Melero I, Lasarte JJ. Enhancement of CD4 and CD8 immunity by anti-CD137 (4-1BB) monoclonal antibodies during hepatitis C vaccination with recombinant adenovirus. Vaccine 2005;23:3493-9. [DOI: 10.1016/j.vaccine.2005.02.003] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 1.8] [Reference Citation Analysis]
50 Azadniv M, Bowers WJ, Topham DJ, Crispe IN. CD4+ T cell effects on CD8+ T cell location defined using bioluminescence. PLoS One 2011;6:e16222. [PMID: 21283759 DOI: 10.1371/journal.pone.0016222] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
51 Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci 2006;3:47-52. [PMID: 16614742 DOI: 10.7150/ijms.3.47] [Cited by in Crossref: 454] [Cited by in F6Publishing: 431] [Article Influence: 28.4] [Reference Citation Analysis]
52 Cashman SB, Marsden BD, Dustin LB. The Humoral Immune Response to HCV: Understanding is Key to Vaccine Development. Front Immunol. 2014;5:550. [PMID: 25426115 DOI: 10.3389/fimmu.2014.00550] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 5.8] [Reference Citation Analysis]
53 Tsai JP, Tseng KC, Lin MN, Su CC. A high seroprevalence of human herpesvirus type 8 already present in patients with chronic hepatitis before the development of cirrhosis. Pathology 2019;51:86-90. [PMID: 30497802 DOI: 10.1016/j.pathol.2018.10.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
54 Peña-Asensio J, Sanz-de-Villalobos E, Miquel J, Larrubia JR. Tumor necrosis family receptor superfamily member 9/tumor necrosis factor receptor-associated factor 1 pathway on hepatitis C viral persistence and natural history. World J Hepatol 2020; 12(10): 754-765 [PMID: 33200014 DOI: 10.4254/wjh.v12.i10.754] [Reference Citation Analysis]
55 Cachem FCOF, Dias AS, Monteiro C, Castro JR, Fernandes G, Delphim L, Almeida AJ, Tavares F, Maciel AMA, Amendola-Pires MM, Brandão-Mello CE, Bento CAM. The proportion of different interleukin-17-producing T-cell subsets is associated with liver fibrosis in chronic hepatitis C. Immunology 2017;151:167-76. [PMID: 28140446 DOI: 10.1111/imm.12720] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
56 Wang M, Wang J, Zhu Y, Xu Z, Yang K, Yang A, Jin B. Cellular immune response to Hantaan virus nucleocapsid protein in the acute phase of hemorrhagic fever with renal syndrome: correlation with disease severity. J Infect Dis 2009;199:188-95. [PMID: 19072554 DOI: 10.1086/595834] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 2.9] [Reference Citation Analysis]
57 Baumert TF, Fauvelle C, Chen DY, Lauer GM. A prophylactic hepatitis C virus vaccine: a distant peak still worth climbing. J Hepatol. 2014;61:S34-S44. [PMID: 25443345 DOI: 10.1016/j.jhep.2014.09.009] [Cited by in Crossref: 56] [Cited by in F6Publishing: 59] [Article Influence: 7.0] [Reference Citation Analysis]
58 Srivastava R, Aggarwal R, Sachdeva S, Alam MI, Jameel S, Naik S. Adaptive immune responses during acute uncomplicated and fulminant hepatitis E. J Gastroenterol Hepatol. 2011;26:306-311. [PMID: 21143520 DOI: 10.1111/j.1440-1746.2010.06356.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 2.8] [Reference Citation Analysis]
59 Halliday J, Klenerman P, Barnes E. Vaccination for hepatitis C virus: closing in on an evasive target. Expert Rev Vaccines. 2011;10:659-672. [PMID: 21604986 DOI: 10.1586/erv.11.55] [Cited by in Crossref: 80] [Cited by in F6Publishing: 74] [Article Influence: 7.3] [Reference Citation Analysis]
60 Bonilla N, Barget N, Andrieu M, Roulot D, Letoumelin P, Grando V, Trinchet JC, Ganne-carrie N, Beaugrand M, Deny P, Choppin J, Guillet J, Ziol M. Interferon gamma-secreting HCV-specific CD8+ T cells in the liver of patients with chronic C hepatitis: relation to liver fibrosis - ANRS HC EP07 study*. J Viral Hepat 2006;13:474-81. [DOI: 10.1111/j.1365-2893.2005.00711.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
61 Pawlotsky JM. Pathophysiology of hepatitis C virus infection and related liver disease. Trends Microbiol. 2004;12:96-102. [PMID: 15036326 DOI: 10.1016/j.tim.2003.12.005] [Cited by in Crossref: 146] [Cited by in F6Publishing: 134] [Article Influence: 8.1] [Reference Citation Analysis]
62 Fytili P, Dalekos GN, Schlaphoff V, Suneetha PV, Sarrazin C, Zauner W, Zachou K, Berg T, Manns MP, Klade CS, Cornberg M, Wedemeyer H. Cross-genotype-reactivity of the immunodominant HCV CD8 T-cell epitope NS3-1073. Vaccine 2008;26:3818-26. [PMID: 18582999 DOI: 10.1016/j.vaccine.2008.05.045] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 2.4] [Reference Citation Analysis]
63 Wald O, Weiss ID, Galun E, Peled A. Chemokines in hepatitis C virus infection: Pathogenesis, prognosis and therapeutics. Cytokine 2007;39:50-62. [DOI: 10.1016/j.cyto.2007.05.013] [Cited by in Crossref: 49] [Cited by in F6Publishing: 43] [Article Influence: 3.3] [Reference Citation Analysis]
64 Radziewicz H, Ibegbu CC, Hon H, Bédard N, Bruneau J, Workowski KA, Knechtle SJ, Kirk AD, Larsen CP, Shoukry NH. Transient CD86 expression on hepatitis C virus-specific CD8+ T cells in acute infection is linked to sufficient IL-2 signaling. J Immunol. 2010;184:2410-2422. [PMID: 20100932 DOI: 10.4049/jimmunol.0902994] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
65 Major ME. Prophylactic and Therapeutic Vaccination against Hepatitis C Virus (HCV): Developments and Future Perspectives. Viruses 2009;1:144-65. [PMID: 21994543 DOI: 10.3390/v1020144] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
66 Rico MA, Ruiz S, Subirá D, Barril G, Cigarrán S, Castañón S, Quiroga JA, Selgas R, Carreño V. Virus-specific effector CD4 + T-cell responses in hemodialysis patients with hepatitis C virus infection: HCV-Specific CD4 + Th-Cells in Hemodialysis. J Med Virol 2004;72:66-74. [DOI: 10.1002/jmv.10551] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
67 Tomer S, Arora SK. A juggernaut of innate & adaptive immune cells in chronic hepatitis C. Indian J Med Res 2020;151:279-86. [PMID: 32461391 DOI: 10.4103/ijmr.IJMR_1387_17] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
68 Dustin LB. Innate and Adaptive Immune Responses in Chronic HCV Infection. Curr Drug Targets 2017;18:826-43. [PMID: 26302811 DOI: 10.2174/1389450116666150825110532] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 6.5] [Reference Citation Analysis]
69 Wang M, Li JS, Ping Y, Li ZQ, Wang LP, Guo Q, Zhang Z, Yue DL, Wang F, Zhang TF, Islam MS, Zhang Y. The host HLA-A*02 allele is associated with the response to pegylated interferon and ribavirin in patients with chronic hepatitis C virus infection. Arch Virol 2015;160:1043-54. [PMID: 25666200 DOI: 10.1007/s00705-015-2361-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
70 Horras CJ, Lamb CL, Mitchell KA. Regulation of hepatocyte fate by interferon-γ. Cytokine Growth Factor Rev 2011;22:35-43. [PMID: 21334249 DOI: 10.1016/j.cytogfr.2011.01.001] [Cited by in Crossref: 64] [Cited by in F6Publishing: 61] [Article Influence: 5.8] [Reference Citation Analysis]
71 Thimme R. T cell immunity to hepatitis C virus: Lessons for a prophylactic vaccine. J Hepatol 2021;74:220-9. [PMID: 33002569 DOI: 10.1016/j.jhep.2020.09.022] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
72 Liao X, Ren H, Zhao P, Zhu S, Cao J, Chen Z, Zhao L, Pan W, Feitelson MA, Qui Z. Efficient Induction of Mouse Immune Responses to Hepatitis C Virus by Viral Core Protein-Carrying Attenuated Salmonella typhimurium. Viral Immunology 2007;20:469-78. [DOI: 10.1089/vim.2006.0112] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
73 Shen T, Chen X, Chen Y, Xu Q, Lu F, Liu S. Increased PD-L1 expression and PD-L1/CD86 ratio on dendritic cells were associated with impaired dendritic cells function in HCV infection. J Med Virol. 2010;82:1152-1159. [PMID: 20513078 DOI: 10.1002/jmv.21809] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 2.3] [Reference Citation Analysis]
74 Eid AJ, Brown RA, Paya CV, Razonable RR. Association between toll-like receptor polymorphisms and the outcome of liver transplantation for chronic hepatitis C virus. Transplantation. 2007;84:511-516. [PMID: 17713436 DOI: 10.1097/01.tp.0000276960.35313.bf] [Cited by in Crossref: 54] [Cited by in F6Publishing: 54] [Article Influence: 3.6] [Reference Citation Analysis]
75 Ahmad A, Alvarez F. Role of NK and NKT cells in the immunopathogenesis of HCV-induced hepatitis. Journal of Leukocyte Biology 2004;76:743-59. [DOI: 10.1189/jlb.0304197] [Cited by in Crossref: 74] [Cited by in F6Publishing: 66] [Article Influence: 4.1] [Reference Citation Analysis]
76 Spengler U. Hepatic microcirculation – A critical but neglected factor for the outcome of viral hepatitis. Journal of Hepatology 2009;50:631-3. [DOI: 10.1016/j.jhep.2008.12.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
77 Gómez CE, Perdiguero B, Cepeda MV, Mingorance L, García-Arriaza J, Vandermeeren A, Sorzano CÓ, Esteban M. High, broad, polyfunctional, and durable T cell immune responses induced in mice by a novel hepatitis C virus (HCV) vaccine candidate (MVA-HCV) based on modified vaccinia virus Ankara expressing the nearly full-length HCV genome. J Virol. 2013;87:7282-7300. [PMID: 23596307 DOI: 10.1128/jvi.03246-12] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
78 Nouroz F, Shaheen S, Mujtaba G, Noreen S. An overview on hepatitis C virus genotypes and its control. Egyptian Journal of Medical Human Genetics 2015;16:291-8. [DOI: 10.1016/j.ejmhg.2015.05.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 2.1] [Reference Citation Analysis]
79 Yoon JC, Rehermann B. Determination of HCV-specific T-cell activity. Methods Mol Biol 2009;510:403-13. [PMID: 19009278 DOI: 10.1007/978-1-59745-394-3_30] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
80 McCarthy M, Ortega MR. Neurological complications of hepatitis C infection. Curr Neurol Neurosci Rep 2012;12:642-54. [PMID: 22991069 DOI: 10.1007/s11910-012-0311-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
81 Mancini N, Diotti RA, Perotti M, Sautto G, Clementi N, Nitti G, Patel AH, Ball JK, Clementi M, Burioni R. Hepatitis C virus (HCV) infection may elicit neutralizing antibodies targeting epitopes conserved in all viral genotypes. PLoS One. 2009;4:e8254. [PMID: 20011511 DOI: 10.1371/journal.pone.0008254] [Cited by in Crossref: 46] [Cited by in F6Publishing: 50] [Article Influence: 3.5] [Reference Citation Analysis]
82 Yusim K, Fischer W, Yoon H, Thurmond J, Fenimore PW, Lauer G, Korber B, Kuiken C. Genotype 1 and global hepatitis C T-cell vaccines designed to optimize coverage of genetic diversity. J Gen Virol 2010;91:1194-206. [PMID: 20053820 DOI: 10.1099/vir.0.017491-0] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
83 Kadolsky UD, Yates AJ. How is the effectiveness of immune surveillance impacted by the spatial distribution of spreading infections? Philos Trans R Soc Lond B Biol Sci 2015;370:20140289. [PMID: 26150655 DOI: 10.1098/rstb.2014.0289] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
84 Santiago-olivares C, Rivera-toledo E, Gómez B. Nitric oxide production is downregulated during respiratory syncytial virus persistence by constitutive expression of arginase 1. Arch Virol 2019;164:2231-41. [DOI: 10.1007/s00705-019-04259-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
85 Kaźmierczak J, Caraballo Cortes K, Bukowska-Ośko I, Radkowski M. Virus-Specific Cellular Response in Hepatitis C Virus Infection. Arch Immunol Ther Exp (Warsz) 2016;64:101-10. [PMID: 26429740 DOI: 10.1007/s00005-015-0364-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
86 Smith JA, Aberle JH, Fleming VM, Ferenci P, Thomson EC, Karayiannis P, McLean AR, Holzmann H, Klenerman P. Dynamic coinfection with multiple viral subtypes in acute hepatitis C. J Infect Dis 2010;202:1770-9. [PMID: 21067369 DOI: 10.1086/657317] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
87 Villani R, Vendemiale G, Serviddio G. Molecular Mechanisms Involved in HCC Recurrence after Direct-Acting Antiviral Therapy. Int J Mol Sci 2018;20:E49. [PMID: 30583555 DOI: 10.3390/ijms20010049] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
88 Cummings KL, Rosen HR, Hahn YS. Frequency of gC1qR+CD4+ T cells increases during acute hepatitis C virus infection and remains elevated in patients with chronic infection. Clin Immunol 2009;132:401-11. [PMID: 19473882 DOI: 10.1016/j.clim.2009.05.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
89 Rollier C, Depla E, Drexhage JA, Verschoor EJ, Verstrepen BE, Fatmi A, Brinster C, Fournillier A, Whelan JA, Whelan M. Control of heterologous hepatitis C virus infection in chimpanzees is associated with the quality of vaccine-induced peripheral T-helper immune response. J Virol. 2004;78:187-196. [PMID: 14671100 DOI: 10.1128/jvi.78.1.187-196.2004] [Cited by in Crossref: 69] [Cited by in F6Publishing: 35] [Article Influence: 3.8] [Reference Citation Analysis]
90 Quiroga JA, Llorente S, Castillo I, Rodríguez-Iñigo E, López-Alcorocho JM, Pardo M, Carreño V. Virus-specific T-cell responses associated with hepatitis C virus (HCV) persistence in the liver after apparent recovery from HCV infection. J Med Virol 2006;78:1190-7. [PMID: 16847959 DOI: 10.1002/jmv.20680] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
91 Samimi-rad K, Sadeghi F, Amirzargar A, Eshraghian MR, Alavian S, Rahimnia R. Association of HLA class II alleles with hepatitis C virus clearance and persistence in thalassemia patients from Iran: HLA Class II and HCV Infection Outcome. J Med Virol 2015;87:1565-72. [DOI: 10.1002/jmv.24211] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
92 Karacki PS, Gao X, Thio CL, Thomas DL, Goedert JJ, Vlahov D, Kaslow RA, Strathdee S, Hilgartner MW, O’Brien SJ. MICA and recovery from hepatitis C virus and hepatitis B virus infections. Genes Immun. 2004;5:261-266. [PMID: 15029237 DOI: 10.1038/sj.gene.6364065] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.0] [Reference Citation Analysis]
93 Alvarez-Lajonchere L, Shoukry NH, Grá B, Amador-Cañizares Y, Helle F, Bédard N, Guerra I, Drouin C, Dubuisson J, González-Horta EE, Martínez G, Marante J, Cinza Z, Castellanos M, Dueñas-Carrera S. Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a Phase I clinical trial. J Viral Hepat 2009;16:156-67. [PMID: 19017255 DOI: 10.1111/j.1365-2893.2008.01058.x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 58] [Article Influence: 4.4] [Reference Citation Analysis]
94 Jo J, Lohmann V, Bartenschlager R, Thimme R. Experimental models to study the immunobiology of hepatitis C virus. J Gen Virol. 2011;92:477-493. [PMID: 21148278 DOI: 10.1099/vir.0.027987-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
95 Méndez-Lagares G, Lu D, Chen C, Terrault N, Segal MR, Khalili M, Monto A, Shen H, Manos MM, Lanier LL, Ryan JC, McCune JM, Hartigan-O'Connor DJ. Memory T Cell Proliferation before Hepatitis C Virus Therapy Predicts Antiviral Immune Responses and Treatment Success. J Immunol 2018;200:1124-32. [PMID: 29263212 DOI: 10.4049/jimmunol.1701364] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
96 Gao M, Wang H, Wang Y, Zhou Y, Wang Q. HCV-NS3 Th1 minigene vaccine based on invariant chain CLIP genetic substitution enhances CD4+ Th1 cell responses in vivo. Vaccine 2006;24:5491-7. [DOI: 10.1016/j.vaccine.2006.04.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
97 Boyd A, Lacombe K, Miailhes P, Gozlan J, Bonnard P, Molina JM, Lascoux-Combe C, Serfaty L, Gault E, Desvarieux M, Girard PM. Longitudinal evaluation of viral interactions in treated HIV-hepatitis B co-infected patients with additional hepatitis C and D virus. J Viral Hepat 2010;17:65-76. [PMID: 19682317 DOI: 10.1111/j.1365-2893.2009.01153.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
98 Huang J, Huang K, Xu R, Wang M, Liao Q, Xiong H, Li C, Tang X, Shan Z, Zhang M, Rong X, Nelson K, Fu Y. The Associations of HLA-A*02:01 and DRB1*11:01 with Hepatitis C Virus Spontaneous Clearance Are Independent of IL28B in the Chinese Population. Sci Rep 2016;6:31485. [PMID: 27511600 DOI: 10.1038/srep31485] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
99 Wei X, Jia ZS, Lian JQ, Zhang Y, Li J, Ma L, Ye L, Wang JP, Pan L, Wang PZ, Bai XF. Inhibition of hepatitis C virus infection by interferon-gamma through downregulating claudin-1. J Interferon Cytokine Res 2009;29:171-8. [PMID: 19196072 DOI: 10.1089/jir.2008.0040] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
100 Ezelle HJ, Markovic D, Barber GN. Generation of hepatitis C virus-like particles by use of a recombinant vesicular stomatitis virus vector. J Virol. 2002;76:12325-12334. [PMID: 12414973 DOI: 10.1128/jvi.76.23.12325-12334.2002] [Cited by in Crossref: 48] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
101 Jensen PV, Castelruiz Y, Aasted B. Cytokine profiles in adult mink infected with Aleutian mink disease parvovirus. J Virol 2003;77:7444-51. [PMID: 12805443 DOI: 10.1128/jvi.77.13.7444-7451.2003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
102 Sun J, Tumurbaatar B, Jia J, Diao H, Bodola F, Lemon SM, Tang W, Bowen DG, McCaughan GW, Bertolino P, Chan TS. Parenchymal expression of CD86/B7.2 contributes to hepatitis C virus-related liver injury. J Virol 2005;79:10730-9. [PMID: 16051865 DOI: 10.1128/JVI.79.16.10730-10739.2005] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
103 Nascimbeni M, Mizukoshi E, Bosmann M, Major ME, Mihalik K, Rice CM, Feinstone SM, Rehermann B. Kinetics of CD4+ and CD8+ memory T-cell responses during hepatitis C virus rechallenge of previously recovered chimpanzees. J Virol. 2003;77:4781-4793. [PMID: 12663785 DOI: 10.1128/jvi.77.8.4781-4793.2003] [Cited by in Crossref: 144] [Cited by in F6Publishing: 71] [Article Influence: 7.6] [Reference Citation Analysis]
104 Ip PP, Boerma A, Regts J, Meijerhof T, Wilschut J, Nijman HW, Daemen T. Alphavirus-based vaccines encoding nonstructural proteins of hepatitis C virus induce robust and protective T-cell responses. Mol Ther 2014;22:881-90. [PMID: 24370701 DOI: 10.1038/mt.2013.287] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
105 Larrea E, Riezu-Boj JI, Aldabe R, Guembe L, Echeverria I, Balasiddaiah A, Gastaminza P, Civeira MP, Sarobe P, Prieto J. Dysregulation of interferon regulatory factors impairs the expression of immunostimulatory molecules in hepatitis C virus genotype 1-infected hepatocytes. Gut 2014;63:665-73. [PMID: 23787026 DOI: 10.1136/gutjnl-2012-304377] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
106 Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat. 2006;13:34-41. [PMID: 16364080 DOI: 10.1111/j.1365-2893.2005.00651.x] [Cited by in Crossref: 550] [Cited by in F6Publishing: 539] [Article Influence: 34.4] [Reference Citation Analysis]
107 Mount AM, Masson F, Kupresanin F, Smith CM, May JS, van Rooijen N, Stevenson PG, Belz GT. Interference with dendritic cell populations limits early antigen presentation in chronic γ-herpesvirus-68 infection. J Immunol 2010;185:3669-76. [PMID: 20720208 DOI: 10.4049/jimmunol.1001079] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
108 Pishraft Sabet L, Taheri T, Memarnejadian A, Mokhtari Azad T, Asgari F, Rahimnia R, Alavian SM, Rafati S, Samimi Rad K. Immunogenicity of Multi-Epitope DNA and Peptide Vaccine Candidates Based on Core, E2, NS3 and NS5B HCV Epitopes in BALB/c Mice. Hepat Mon. 2014;14:e22215. [PMID: 25419219 DOI: 10.5812/hepatmon.22215] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
109 Zhang Y, Liu Y, Moxley KM, Golden-Mason L, Hughes MG, Liu T, Heemskerk MH, Rosen HR, Nishimura MI. Transduction of human T cells with a novel T-cell receptor confers anti-HCV reactivity. PLoS Pathog. 2010;6:e1001018. [PMID: 20686664 DOI: 10.1371/journal.ppat.1001018] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 3.0] [Reference Citation Analysis]
110 Lang Kuhs KA, Toporovski R, Yan J, Ginsberg AA, Shedlock DJ, Weiner DB. Induction of intrahepatic HCV NS4B, NS5A and NS5B-specific cellular immune responses following peripheral immunization. PLoS One 2012;7:e52165. [PMID: 23284919 DOI: 10.1371/journal.pone.0052165] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
111 Kokordelis P, Krämer B, Körner C, Boesecke C, Voigt E, Ingiliz P, Glässner A, Eisenhardt M, Wolter F, Kaczmarek D. An effective interferon-gamma-mediated inhibition of hepatitis C virus replication by natural killer cells is associated with spontaneous clearance of acute hepatitis C in human immunodeficiency virus-positive patients. Hepatology. 2014;59:814-827. [PMID: 24382664 DOI: 10.1002/hep.26782] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 4.8] [Reference Citation Analysis]
112 Georgel P, Schuster C, Zeisel MB, Stoll-Keller F, Berg T, Bahram S, Baumert TF. Virus-host interactions in hepatitis C virus infection: implications for molecular pathogenesis and antiviral strategies. Trends Mol Med. 2010;16:277-286. [PMID: 20537953 DOI: 10.1016/j.molmed.2010.04.003] [Cited by in Crossref: 50] [Cited by in F6Publishing: 50] [Article Influence: 4.2] [Reference Citation Analysis]
113 Janvier G, Chaix ML, Fontaine H, Bresson JL, Pol S, Riviere Y. The core-specific precursor T cell response is directed to the N-terminal and central parts of the protein and positively correlates to the viral load in chronically HCV-infected patients. Virology 2005;340:318-25. [PMID: 16054187 DOI: 10.1016/j.virol.2005.06.031] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
114 Mazouz S, Boisvert M, Abdel-Hakeem MS, Khedr O, Bruneau J, Shoukry NH. Expansion of Unique Hepatitis C Virus-Specific Public CD8+ T Cell Clonotypes during Acute Infection and Reinfection. J Immunol 2021;207:1180-93. [PMID: 34341170 DOI: 10.4049/jimmunol.2001386] [Reference Citation Analysis]
115 Kiely P, Kay D, Parker S, Piscitelli L. The significance of third-generation HCV RIBA-indeterminate, RNA-negative results in voluntary blood donors screened with sequential third-generation immunoassays: RIBA-3-INDETERMINATE RESULTS IN BLOOD DONORS. Transfusion 2004;44:349-58. [DOI: 10.1111/j.1537-2995.2003.00671.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 1.4] [Reference Citation Analysis]
116 Hood SP, Mee ET, Perkins H, Bowen O, Dale JM, Almond NM, Karayiannis P, Bright H, Berry NJ, Rose NJ. Changes in immune cell populations in the periphery and liver of GBV-B-infected and convalescent tamarins (Saguinus labiatus). Virus Res 2014;179:93-101. [PMID: 24246306 DOI: 10.1016/j.virusres.2013.11.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
117 Ramsay JD, Evanoff R, Wilkinson TE Jr, Divers TJ, Knowles DP, Mealey RH. Experimental transmission of equine hepacivirus in horses as a model for hepatitis C virus. Hepatology 2015;61:1533-46. [PMID: 25580897 DOI: 10.1002/hep.27689] [Cited by in Crossref: 71] [Cited by in F6Publishing: 65] [Article Influence: 10.1] [Reference Citation Analysis]
118 Heim MH, Thimme R. Innate and adaptive immune responses in HCV infections. J Hepatol. 2014;61:S14-S25. [PMID: 25443342 DOI: 10.1016/j.jhep.2014.06.035] [Cited by in Crossref: 170] [Cited by in F6Publishing: 154] [Article Influence: 21.3] [Reference Citation Analysis]
119 Cusick MF, Libbey JE, Cox Gill J, Fujinami RS, Eckels DD. CD4+ T-cell engagement by both wild-type and variant HCV peptides modulates the conversion of viral clearing helper T cells to Tregs. Future Virol 2013;8. [PMID: 24421862 DOI: 10.2217/fvl.13.49] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
120 Atcheson E, Li W, Bliss CM, Chinnakannan S, Heim K, Sharpe H, Hutchings C, Dietrich I, Nguyen D, Kapoor A, Jarvis MA, Klenerman P, Barnes E, Simmonds P. Use of an Outbred Rat Hepacivirus Challenge Model for Design and Evaluation of Efficacy of Different Immunization Strategies for Hepatitis C Virus. Hepatology 2020;71:794-807. [PMID: 31400152 DOI: 10.1002/hep.30894] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
121 Rosen HR. Hepatitis C pathogenesis: mechanisms of viral clearance and liver injury. Liver Transpl. 2003;9:S35-S43. [PMID: 14586893 DOI: 10.1053/jlts.2003.50253] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 1.8] [Reference Citation Analysis]
122 Omata M, Kanda T, Yu M, Yokosuka O, Lim S, Jafri W, Tateishi R, Hamid SS, Chuang W, Chutaputti A, Wei L, Sollano J, Sarin SK, Kao J, Mccaughan GW. APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatol Int 2012;6:409-35. [DOI: 10.1007/s12072-012-9342-y] [Cited by in Crossref: 114] [Cited by in F6Publishing: 128] [Article Influence: 11.4] [Reference Citation Analysis]
123 Lloyd AR, Jagger E, Post JJ, Crooks LA, Rawlinson WD, Hahn YS, Ffrench RA. Host and viral factors in the immunopathogenesis of primary hepatitis C virus infection. Immunol Cell Biol 2007;85:24-32. [PMID: 17130897 DOI: 10.1038/sj.icb.7100010] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 2.5] [Reference Citation Analysis]
124 Crowe JE. Host Defense Mechanisms Against Viruses. Fetal and Neonatal Physiology. Elsevier; 2017. pp. 1175-1197.e7. [DOI: 10.1016/b978-0-323-35214-7.00122-0] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
125 Deterding K, Tegtmeyer B, Cornberg M, Hadem J, Potthoff A, Böker KH, Tillmann HL, Manns MP, Wedemeyer H. Hepatitis A virus infection suppresses hepatitis C virus replication and may lead to clearance of HCV. J Hepatol. 2006;45:770-778. [PMID: 17034895 DOI: 10.1016/j.jhep.2006.07.023] [Cited by in Crossref: 42] [Cited by in F6Publishing: 32] [Article Influence: 2.6] [Reference Citation Analysis]
126 Liang CC, Liu CH, Lin YL, Liu CJ, Chiang BL, Kao JH. Functional impairment of dendritic cells in patients infected with hepatitis C virus genotype 1 who failed peginterferon plus ribavirin therapy. J Med Virol 2011;83:1212-20. [PMID: 21567425 DOI: 10.1002/jmv.22096] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
127 Shen T, Chen X, Xu Q, Lu F, Liu S. Distributional characteristics of CD25 and CD127 on CD4+ T cell subsets in chronic HCV infection. Arch Virol 2010;155:627-34. [PMID: 20204427 DOI: 10.1007/s00705-010-0626-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
128 Ning Q, Berger L, Luo X, Yan W, Gong F, Dennis J, Levy G. STAT1 and STAT3 alpha/beta splice form activation predicts host responses in mouse hepatitis virus type 3 infection. J Med Virol. 2003;69:306-312. [PMID: 12526039 DOI: 10.1002/jmv.10290] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 0.7] [Reference Citation Analysis]
129 Sellau J, Puengel T, Hoenow S, Groneberg M, Tacke F, Lotter H. Monocyte dysregulation: consequences for hepatic infections. Semin Immunopathol 2021. [PMID: 33829283 DOI: 10.1007/s00281-021-00852-1] [Reference Citation Analysis]
130 Zeisel MB, Baumert TF. HCV entry and neutralizing antibodies: lessons from viral variants. Future Microbiol 2009;4:511-7. [PMID: 19492962 DOI: 10.2217/fmb.09.34] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
131 Kamal SM, Kassim SK, Ahmed AI, Mahmoud S, Bahnasy KA, Hafez TA, Aziz IA, Fathelbab IF, Mansour HM. Host and Viral Determinants of the Outcome of Exposure to HCV Infection Genotype 4: A Large Longitudinal Study. American Journal of Gastroenterology 2014;109:199-211. [DOI: 10.1038/ajg.2013.427] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
132 Godkin A, Smith KA. Chronic infections with viruses or parasites: breaking bad to make good. Immunology 2017;150:389-96. [PMID: 28009488 DOI: 10.1111/imm.12703] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
133 Seifert U, Liermann H, Racanelli V, Halenius A, Wiese M, Wedemeyer H, Ruppert T, Rispeter K, Henklein P, Sijts A. Hepatitis C virus mutation affects proteasomal epitope processing. J Clin Invest. 2004;114:250-259. [PMID: 15254592 DOI: 10.1172/jci200420985] [Cited by in Crossref: 109] [Cited by in F6Publishing: 1] [Article Influence: 6.1] [Reference Citation Analysis]
134 Zeremski M, Makeyeva J, Arasteh K, Des Jarlais DC, Talal AH. Hepatitis C virus-specific immune responses in noninjecting drug users. J Viral Hepat 2012;19:554-9. [PMID: 22762139 DOI: 10.1111/j.1365-2893.2011.01573.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
135 McKiernan SM, Hagan R, Curry M, McDonald GS, Kelly A, Nolan N, Walsh A, Hegarty J, Lawlor E, Kelleher D. Distinct MHC class I and II alleles are associated with hepatitis C viral clearance, originating from a single source. Hepatology. 2004;40:108-114. [PMID: 15239092 DOI: 10.1002/hep.20261] [Cited by in Crossref: 169] [Cited by in F6Publishing: 174] [Article Influence: 9.4] [Reference Citation Analysis]
136 Fournillier A, Frelin L, Jacquier E, Ahlén G, Brass A, Gerossier E, Holmström F, Broderick KE, Sardesai NY, Bonnefoy JY, Inchauspé G, Sällberg M. A heterologous prime/boost vaccination strategy enhances the immunogenicity of therapeutic vaccines for hepatitis C virus. J Infect Dis 2013;208:1008-19. [PMID: 23776192 DOI: 10.1093/infdis/jit267] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.4] [Reference Citation Analysis]
137 Houghton M. Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses. Immunol Rev. 2011;239:99-108. [PMID: 21198667 DOI: 10.1111/j.1600-065x.2010.00977.x] [Cited by in Crossref: 112] [Cited by in F6Publishing: 76] [Article Influence: 10.2] [Reference Citation Analysis]
138 Lee J, Suh WI, Shin EC. T-cell dysfunction and inhibitory receptors in hepatitis C virus infection. Immune Netw. 2010;10:120-125. [PMID: 20844736 DOI: 10.4110/in.2010.10.4.120] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
139 Björkström NK, Gonzalez VD, Malmberg K, Falconer K, Alaeus A, Nowak G, Jorns C, Ericzon B, Weiland O, Sandberg JK, Ljunggren H. Elevated Numbers of FcγRIIIA + (CD16 + ) Effector CD8 T Cells with NK Cell-Like Function in Chronic Hepatitis C Virus Infection. J Immunol 2008;181:4219-28. [DOI: 10.4049/jimmunol.181.6.4219] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 2.9] [Reference Citation Analysis]
140 Boettler T, Moeckel F, Cheng Y, Heeg M, Salek-Ardakani S, Crotty S, Croft M, von Herrath MG. OX40 facilitates control of a persistent virus infection. PLoS Pathog 2012;8:e1002913. [PMID: 22969431 DOI: 10.1371/journal.ppat.1002913] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 4.4] [Reference Citation Analysis]
141 Bertoletti A, Ferrari C. Kinetics of the immune response during HBV and HCV infection. Hepatology. 2003;38:4-13. [PMID: 12829979 DOI: 10.1053/jhep.2003.50310] [Cited by in Crossref: 160] [Cited by in F6Publishing: 168] [Article Influence: 8.4] [Reference Citation Analysis]
142 Ratnoglik SL, Jiang DP, Aoki C, Sudarmono P, Shoji I, Deng L, Hotta H. Induction of cell-mediated immune responses in mice by DNA vaccines that express hepatitis C virus NS3 mutants lacking serine protease and NTPase/RNA helicase activities. PLoS One 2014;9:e98877. [PMID: 24901478 DOI: 10.1371/journal.pone.0098877] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
143 Huang J, Xu R, Wang M, Liao Q, Huang K, Shan Z, You Q, Li C, Rong X, Fu Y. Association of HLA-DQB1*03:01 and DRB1*11:01 with spontaneous clearance of hepatitis C virus in Chinese Li ethnicity, an ethnic group genetically distinct from Chinese Han ethnicity and infected with unique HCV subtype. J Med Virol 2019;91:1830-6. [PMID: 31254396 DOI: 10.1002/jmv.25531] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
144 Berzofsky JA, Ahlers JD, Janik J, Morris J, Oh S, Terabe M, Belyakov IM. Progress on new vaccine strategies against chronic viral infections. J Clin Invest. 2004;114:450-462. [PMID: 15314679 DOI: 10.1172/jci200422674] [Cited by in Crossref: 90] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
145 Cox AL, Netski DM, Mosbruger T, Sherman SG, Strathdee S, Ompad D, Vlahov D, Chien D, Shyamala V, Ray SC. Prospective evaluation of community-acquired acute-phase hepatitis C virus infection. Clin Infect Dis. 2005;40:951-958. [PMID: 15824985 DOI: 10.1086/428578] [Cited by in Crossref: 150] [Cited by in F6Publishing: 140] [Article Influence: 8.8] [Reference Citation Analysis]
146 Shoukry NH, Sidney J, Sette A, Walker CM. Conserved hierarchy of helper T cell responses in a chimpanzee during primary and secondary hepatitis C virus infections. J Immunol. 2004;172:483-492. [PMID: 14688358 DOI: 10.4049/jimmunol.172.1.483] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 2.6] [Reference Citation Analysis]
147 Zarife MA, Reis EA, Carmo TM, Lopes GB, Brandão EC, Silva HR, Santana N, Martins-Filho OA, Reis MG. Increased frequency of CD56Bright NK-cells, CD3-CD16+CD56- NK-cells and activated CD4+T-cells or B-cells in parallel with CD4+CDC25High T-cells control potentially viremia in blood donors with HCV. J Med Virol 2009;81:49-59. [PMID: 19031471 DOI: 10.1002/jmv.21340] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
148 Jiménez-Hernández N, Sentandreu V, Castro JA, Torres-Puente M, Bracho A, García-Robles I, Ortega E, Del Olmo J, Carnicer F, González-Candelas F, Moya A. Effect of antiviral treatment and host susceptibility on positive selection in hepatitis C virus (HCV). Virus Res 2008;131:224-32. [PMID: 17980926 DOI: 10.1016/j.virusres.2007.09.012] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
149 Kim AY, Schulze zur Wiesch J, Kuntzen T, Timm J, Kaufmann DE, Duncan JE, Jones AM, Wurcel AG, Davis BT, Gandhi RT. Impaired hepatitis C virus-specific T cell responses and recurrent hepatitis C virus in HIV coinfection. PLoS Med. 2006;3:e492. [PMID: 17194190 DOI: 10.1371/journal.pmed.0030492] [Cited by in Crossref: 65] [Cited by in F6Publishing: 62] [Article Influence: 4.3] [Reference Citation Analysis]
150 Brenndörfer ED, Sällberg M. Hepatitis C virus-mediated modulation of cellular immunity. Arch Immunol Ther Exp (Warsz) 2012;60:315-29. [PMID: 22911132 DOI: 10.1007/s00005-012-0184-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
151 Qiu Q, Wang RY, Jiao X, Jin B, Sugauchi F, Grandinetti T, Alter HJ, Shih JW. Induction of multispecific Th-1 type immune response against HCV in mice by protein immunization using CpG and Montanide ISA 720 as adjuvants. Vaccine. 2008;26:5527-5534. [PMID: 18675871 DOI: 10.1016/j.vaccine.2008.07.034] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
152 Timm J, Li B, Daniels MG, Bhattacharya T, Reyor LL, Allgaier R, Kuntzen T, Fischer W, Nolan BE, Duncan J. Human leukocyte antigen-associated sequence polymorphisms in hepatitis C virus reveal reproducible immune responses and constraints on viral evolution. Hepatology. 2007;46:339-349. [PMID: 17559151 DOI: 10.1002/hep.21702] [Cited by in Crossref: 71] [Cited by in F6Publishing: 74] [Article Influence: 4.7] [Reference Citation Analysis]
153 Lucchesi D, Bombardieri M. The role of viruses in autoreactive B cell activation within tertiary lymphoid structures in autoimmune diseases. J Leukoc Biol 2013;94:1191-9. [PMID: 23812327 DOI: 10.1189/jlb.0413240] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
154 Boukhebza H, Bellon N, Limacher JM, Inchauspé G. Therapeutic vaccination to treat chronic infectious diseases: current clinical developments using MVA-based vaccines. Hum Vaccin Immunother 2012;8:1746-57. [PMID: 22894957 DOI: 10.4161/hv.21689] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
155 Manigold T, Shin EC, Mizukoshi E, Mihalik K, Murthy KK, Rice CM, Piccirillo CA, Rehermann B. Foxp3+CD4+CD25+ T cells control virus-specific memory T cells in chimpanzees that recovered from hepatitis C. Blood. 2006;107:4424-4432. [PMID: 16478885 DOI: 10.1182/blood-2005-09-3903] [Cited by in Crossref: 91] [Cited by in F6Publishing: 78] [Article Influence: 5.7] [Reference Citation Analysis]
156 Wong YC, Tay SS, McCaughan GW, Bowen DG, Bertolino P. Immune outcomes in the liver: Is CD8 T cell fate determined by the environment? J Hepatol 2015;63:1005-14. [PMID: 26103545 DOI: 10.1016/j.jhep.2015.05.033] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.1] [Reference Citation Analysis]
157 Fabien S, Olivier M, Khaldoun G, Vivian V, Lynda A, Laurissa O, Gautier G, Yvon C, Nadira D, Filomena C. CD49b, a major marker of regulatory T-cells type 1, predicts the response to antiviral therapy of recurrent hepatitis C after liver transplantation. Biomed Res Int 2014;2014:290878. [PMID: 24575405 DOI: 10.1155/2014/290878] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
158 Medel MLH, Reyes GG, Porras LM, Bernal AR, Luna JS, Garcia AP, Cordova J, Parra A, Mummidi S, Kershenobich D, Hernández J. Prolactin Induces IL-2 Associated TRAIL Expression on Natural Killer Cells from Chronic Hepatitis C Patients In vivo and In vitro. Endocr Metab Immune Disord Drug Targets 2019;19:975-84. [PMID: 30520386 DOI: 10.2174/1871530319666181206125545] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
159 Osburn WO, Fisher BE, Dowd KA, Urban G, Liu L, Ray SC, Thomas DL, Cox AL. Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology. 2010;138:315-324. [PMID: 19782080 DOI: 10.1053/j.gastro.2009.09.017] [Cited by in Crossref: 250] [Cited by in F6Publishing: 242] [Article Influence: 19.2] [Reference Citation Analysis]
160 Sarobe P, Lasarte JJ, Zabaleta A, Arribillaga L, Arina A, Melero I, Borrás-Cuesta F, Prieto J. Hepatitis C virus structural proteins impair dendritic cell maturation and inhibit in vivo induction of cellular immune responses. J Virol. 2003;77:10862-10871. [PMID: 14512536 DOI: 10.1128/jvi.77.20.10862-10871.2003] [Cited by in Crossref: 98] [Cited by in F6Publishing: 35] [Article Influence: 5.2] [Reference Citation Analysis]
161 Scott R, Guha IN. Non-invasive monitoring of liver fibrosis. British Medical Bulletin 2014;112:97-106. [DOI: 10.1093/bmb/ldu031] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
162 Li W, Krishnadas DK, Li J, Tyrrell DLJ, Agrawal B. Induction of Primary Human T Cell Responses against Hepatitis C Virus-Derived Antigens NS3 or Core by Autologous Dendritic Cells Expressing Hepatitis C Virus Antigens: Potential for Vaccine and Immunotherapy. J Immunol 2006;176:6065-75. [DOI: 10.4049/jimmunol.176.10.6065] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 2.1] [Reference Citation Analysis]
163 Ksiaa L, Ayed-Jendoubi S, Sfar I, Gorgi Y, Najjar HA, Abdallah TB, Ayed K. Clearance and persistence of hepatitis C virus in a Tunisian population: association with HLA class I and class II. Viral Immunol. 2007;20:312-319. [PMID: 17603847 DOI: 10.1089/vim.2006.0060] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
164 Abel M, Sène D, Pol S, Bourlière M, Poynard T, Charlotte F, Cacoub P, Caillat-Zucman S. Intrahepatic virus-specific IL-10-producing CD8 T cells prevent liver damage during chronic hepatitis C virus infection. Hepatology. 2006;44:1607-1616. [PMID: 17133491 DOI: 10.1002/hep.21438] [Cited by in Crossref: 89] [Cited by in F6Publishing: 86] [Article Influence: 5.9] [Reference Citation Analysis]
165 Lapierre P, Lamarre A. Regulatory T Cells in Autoimmune and Viral Chronic Hepatitis. J Immunol Res. 2015;2015:479703. [PMID: 26106627 DOI: 10.1155/2015/479703] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
166 Ishii K, Shinohara M, Kogame M, Shiratori M, Higami K, Kanayama K, Shiozawa K, Wakui N, Nagai H, Watanabe M, Sumino Y. Effects of mutation number in interferon sensitivity determining region on peripheral blood CD4(+) T cell subsets (Th1, Th2) in chronic hepatitis C patients with hepatitis C virus genotype 1b and high viral load. Hepatol Int 2012;6:468-74. [PMID: 21818686 DOI: 10.1007/s12072-011-9305-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
167 Quaranta MG, Mattioli B, Vella S. Glances in Immunology of HIV and HCV Infection. Adv Virol 2012;2012:434036. [PMID: 22754568 DOI: 10.1155/2012/434036] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
168 Kaplan DE. Immunopathogenesis of Hepatitis C Virus Infection. Gastroenterol Clin North Am 2015;44:735-60. [PMID: 26600217 DOI: 10.1016/j.gtc.2015.07.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
169 Wang JH, Pianko MJ, Ke X, Herskovic A, Hershow R, Cotler SJ, Chen W, Chen ZW, Rong L. Characterization of antigenic variants of hepatitis C virus in immune evasion. Virol J 2011;8:377. [PMID: 21801418 DOI: 10.1186/1743-422X-8-377] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
170 Puig M, Mihalik K, Tilton JC, Williams O, Merchlinsky M, Connors M, Feinstone SM, Major ME. CD4+ immune escape and subsequent T-cell failure following chimpanzee immunization against hepatitis C virus. Hepatology 2006;44:736-45. [DOI: 10.1002/hep.21319] [Cited by in Crossref: 56] [Cited by in F6Publishing: 57] [Article Influence: 3.5] [Reference Citation Analysis]
171 Urbani S, Amadei B, Tola D, Massari M, Schivazappa S, Missale G, Ferrari C. PD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-specific CD8 exhaustion. J Virol 2006;80:11398-403. [PMID: 16956940 DOI: 10.1128/JVI.01177-06] [Cited by in Crossref: 408] [Cited by in F6Publishing: 262] [Article Influence: 25.5] [Reference Citation Analysis]
172 Sturm N, Thélu MA, Camous X, Dimitrov G, Ramzan M, Dufeu-Duchesne T, Bonorino P, Guillermet C, Brambilla E, Arvers P, Pernollet M, Leroy V, Zarski JP, Marche PN, Jouvin-Marche E. Characterization and role of intra-hepatic regulatory T cells in chronic hepatitis C pathogenesis. J Hepatol 2010;53:25-35. [PMID: 20452085 DOI: 10.1016/j.jhep.2010.02.024] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 3.5] [Reference Citation Analysis]
173 Fan HZ, Zhang R, Tian T, Zhong YL, Wu MP, Xie CN, Yang JJ, Huang P, Yu RB, Zhang Y, Wang J. CYP24A1 genetic variants in the vitamin D metabolic pathway are involved in the outcomes of hepatitis C virus infection among high-risk Chinese population. Int J Infect Dis 2019;84:80-8. [PMID: 31075507 DOI: 10.1016/j.ijid.2019.04.032] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
174 Himoudi N, Abraham JD, Fournillier A, Lone YC, Joubert A, Op De Beeck A, Freida D, Lemonnier F, Kieny MP, Inchauspé G. Comparative vaccine studies in HLA-A2.1-transgenic mice reveal a clustered organization of epitopes presented in hepatitis C virus natural infection. J Virol 2002;76:12735-46. [PMID: 12438599 DOI: 10.1128/jvi.76.24.12735-12746.2002] [Cited by in Crossref: 31] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
175 Gaudieri S, Rauch A, Park LP, Freitas E, Herrmann S, Jeffrey G, Cheng W, Pfafferott K, Naidoo K, Chapman R. Evidence of viral adaptation to HLA class I-restricted immune pressure in chronic hepatitis C virus infection. J Virol. 2006;80:11094-11104. [PMID: 17071929 DOI: 10.1128/jvi.00912-06] [Cited by in Crossref: 76] [Cited by in F6Publishing: 58] [Article Influence: 4.8] [Reference Citation Analysis]
176 Flynn JK, Dore GJ, Hellard M, Yeung B, Rawlinson WD, White PA, Kaldor JM, Lloyd AR, Ffrench RA; ATAHC Study Group. Early IL-10 predominant responses are associated with progression to chronic hepatitis C virus infection in injecting drug users. J Viral Hepat. 2011;18:549-561. [PMID: 20626625 DOI: 10.1111/j.1365-2893.2010.01335.x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 3.8] [Reference Citation Analysis]
177 Pawlotsky JM. The nature of interferon-alpha resistance in hepatitis C virus infection. Curr Opin Infect Dis. 2003;16:587-592. [PMID: 14624110 DOI: 10.1097/00001432-200312000-00012] [Cited by in Crossref: 50] [Cited by in F6Publishing: 54] [Article Influence: 2.8] [Reference Citation Analysis]
178 Boettler T, Spangenberg HC, Neumann-Haefelin C, Panther E, Urbani S, Ferrari C, Blum HE, von Weizsäcker F, Thimme R. T cells with a CD4+CD25+ regulatory phenotype suppress in vitro proliferation of virus-specific CD8+ T cells during chronic hepatitis C virus infection. J Virol 2005;79:7860-7. [PMID: 15919940 DOI: 10.1128/JVI.79.12.7860-7867.2005] [Cited by in Crossref: 320] [Cited by in F6Publishing: 142] [Article Influence: 18.8] [Reference Citation Analysis]
179 Pachiadakis I, Pollara G, Chain BM, Naoumov NV. Is hepatitis C virus infection of dendritic cells a mechanism facilitating viral persistence? Lancet Infect Dis 2005;5:296-304. [PMID: 15854885 DOI: 10.1016/S1473-3099(05)70114-6] [Cited by in Crossref: 65] [Cited by in F6Publishing: 25] [Article Influence: 3.8] [Reference Citation Analysis]
180 Brooks DG, Walsh KB, Elsaesser H, Oldstone MB. IL-10 directly suppresses CD4 but not CD8 T cell effector and memory responses following acute viral infection. Proc Natl Acad Sci U S A 2010;107:3018-23. [PMID: 20133700 DOI: 10.1073/pnas.0914500107] [Cited by in Crossref: 95] [Cited by in F6Publishing: 97] [Article Influence: 7.9] [Reference Citation Analysis]
181 Luxenburger H, Graß F, Baermann J, Boettler T, Marget M, Emmerich F, Panning M, Thimme R, Nitschke K, Neumann-Haefelin C. Differential virus-specific CD8+ T-cell epitope repertoire in hepatitis C virus genotype 1 versus 4. J Viral Hepat 2018;25:779-90. [PMID: 29397015 DOI: 10.1111/jvh.12874] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
182 Lavillette D, Morice Y, Germanidis G, Donot P, Soulier A, Pagkalos E, Sakellariou G, Intrator L, Bartosch B, Pawlotsky JM. Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection. J Virol. 2005;79:6023-6034. [PMID: 15857988 DOI: 10.1128/jvi.79.10.6023-6034.2005] [Cited by in Crossref: 201] [Cited by in F6Publishing: 97] [Article Influence: 11.8] [Reference Citation Analysis]
183 Lucas M, Vargas-Cuero AL, Lauer GM, Barnes E, Willberg CB, Semmo N, Walker BD, Phillips R, Klenerman P. Pervasive influence of hepatitis C virus on the phenotype of antiviral CD8+ T cells. J Immunol. 2004;172:1744-1753. [PMID: 14734757 DOI: 10.4049/jimmunol.172.3.1744] [Cited by in Crossref: 77] [Cited by in F6Publishing: 75] [Article Influence: 4.3] [Reference Citation Analysis]
184 Filskov J, Andersen P, Agger EM, Bukh J. HCV p7 as a novel vaccine-target inducing multifunctional CD4+ and CD8+ T-cells targeting liver cells expressing the viral antigen. Sci Rep 2019;9:14085. [PMID: 31575882 DOI: 10.1038/s41598-019-50365-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
185 Klenerman P, Cerundolo V, Dunbar PR. Tracking T cells with tetramers: new tales from new tools. Nat Rev Immunol 2002;2:263-72. [DOI: 10.1038/nri777] [Cited by in Crossref: 141] [Cited by in F6Publishing: 126] [Article Influence: 7.1] [Reference Citation Analysis]
186 Racanelli V, Manigold T. Presentation of HCV antigens to naive CD8+T cells: why the where, when, what and how are important for virus control and infection outcome. Clin Immunol 2007;124:5-12. [PMID: 17540619 DOI: 10.1016/j.clim.2007.04.009] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
187 Torre F, Rossol S, Pelli N, Basso M, Delfino A, Picciotto A. Kinetics of soluble tumour necrosis factor (TNF)-alpha receptors and cytokines in the early phase of treatment for chronic hepatitis C: comparison between interferon (IFN)-alpha alone, IFN-alpha plus amantadine or plus ribavirin. Clin Exp Immunol. 2004;136:507-512. [PMID: 15147353 DOI: 10.1111/j.1365-2249.2004.02476.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
188 Fauvelle C, Colpitts CC, Keck ZY, Pierce BG, Foung SK, Baumert TF. Hepatitis C virus vaccine candidates inducing protective neutralizing antibodies. Expert Rev Vaccines 2016;15:1535-44. [PMID: 27267297 DOI: 10.1080/14760584.2016.1194759] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 7.2] [Reference Citation Analysis]
189 Alatrakchi N, Graham CS, van der Vliet HJ, Sherman KE, Exley MA, Koziel MJ. Hepatitis C virus (HCV)-specific CD8+ cells produce transforming growth factor beta that can suppress HCV-specific T-cell responses. J Virol. 2007;81:5882-5892. [PMID: 17376924 DOI: 10.1128/jvi.02202-06] [Cited by in Crossref: 79] [Cited by in F6Publishing: 43] [Article Influence: 5.3] [Reference Citation Analysis]
190 Filskov J, Mikkelsen M, Hansen PR, Christensen JP, Thomsen AR, Andersen P, Bukh J, Agger EM. Broadening CD4+ and CD8+ T Cell Responses against Hepatitis C Virus by Vaccination with NS3 Overlapping Peptide Panels in Cross-Priming Liposomes. J Virol 2017;91:e00130-17. [PMID: 28446674 DOI: 10.1128/JVI.00130-17] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
191 Fuller MJ, Callendret B, Zhu B, Freeman GJ, Hasselschwert DL, Satterfield W, Sharpe AH, Dustin LB, Rice CM, Grakoui A, Ahmed R, Walker CM. Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1). Proc Natl Acad Sci USA. 2013;110:15001-15006. [PMID: 23980172 DOI: 10.1073/pnas.1312772110] [Cited by in Crossref: 133] [Cited by in F6Publishing: 126] [Article Influence: 14.8] [Reference Citation Analysis]
192 Racanelli V, Frassanito MA, Leone P, Brunetti C, Ruggieri S, Dammacco F. Bone marrow of persistently hepatitis C virus-infected individuals accumulates memory CD8+ T cells specific for current and historical viral antigens: a study in patients with benign hematological disorders. J Immunol 2007;179:5387-98. [PMID: 17911625 DOI: 10.4049/jimmunol.179.8.5387] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
193 Keating SM, Dodge JL, Norris PJ, Heitman J, Gange SJ, French AL, Glesby MJ, Edlin BR, Latham PS, Villacres MC, Greenblatt RM, Peters MG; Women’s Interagency HIV Study. The effect of HIV infection and HCV viremia on inflammatory mediators and hepatic injury-The Women's Interagency HIV Study. PLoS One 2017;12:e0181004. [PMID: 28902848 DOI: 10.1371/journal.pone.0181004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
194 Soguero C, Joo M, Chianese-Bullock KA, Nguyen DT, Tung K, Hahn YS. Hepatitis C virus core protein leads to immune suppression and liver damage in a transgenic murine model. J Virol 2002;76:9345-54. [PMID: 12186917 DOI: 10.1128/jvi.76.18.9345-9354.2002] [Cited by in Crossref: 59] [Cited by in F6Publishing: 29] [Article Influence: 3.0] [Reference Citation Analysis]
195 Thomson M, Nascimbeni M, Havert MB, Major M, Gonzales S, Alter H, Feinstone SM, Murthy KK, Rehermann B, Liang TJ. The clearance of hepatitis C virus infection in chimpanzees may not necessarily correlate with the appearance of acquired immunity. J Virol 2003;77:862-70. [PMID: 12502802 DOI: 10.1128/jvi.77.2.862-870.2003] [Cited by in Crossref: 63] [Cited by in F6Publishing: 29] [Article Influence: 3.3] [Reference Citation Analysis]
196 Masavuli MG, Wijesundara DK, Torresi J, Gowans EJ, Grubor-Bauk B. Preclinical Development and Production of Virus-Like Particles As Vaccine Candidates for Hepatitis C. Front Microbiol 2017;8:2413. [PMID: 29259601 DOI: 10.3389/fmicb.2017.02413] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
197 Day CL, Seth NP, Lucas M, Appel H, Gauthier L, Lauer GM, Robbins GK, Szczepiorkowski ZM, Casson DR, Chung RT, Bell S, Harcourt G, Walker BD, Klenerman P, Wucherpfennig KW. Ex vivo analysis of human memory CD4 T cells specific for hepatitis C virus using MHC class II tetramers. J Clin Invest 2003;112:831-42. [DOI: 10.1172/jci200318509] [Cited by in Crossref: 213] [Cited by in F6Publishing: 2] [Article Influence: 11.2] [Reference Citation Analysis]
198 Koh S, Bertoletti A. Viral hepatitis and serotonin: altering cytotoxic T-lymphocyte function in the liver. Expert Review of Vaccines 2014;8:29-32. [DOI: 10.1586/14760584.8.1.29] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
199 Zhou J, Huang Y, Tian D, Xu D, Chen M, Wu H. Expression of toll-like receptor 9 in peripheral blood mononuclear cells from patients with different hepatitis B and C viral loads. J Huazhong Univ Sci Technolog Med Sci 2009;29:313-7. [PMID: 19513613 DOI: 10.1007/s11596-009-0310-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
200 Dustin LB, Charles ED. Primary, post-primary and non-specific immunoglobulin M responses in HCV infection. Antivir Ther 2012;17:1449-52. [PMID: 23322600 DOI: 10.3851/IMP2222] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
201 Perrella A, Arenga G, Pisaniello D, Rampone B, Di Costanzo GG, Atripaldi L, Esposito C, Di Florio E, Perrella O, Cuomo O. Elevated CD4+/CD25+ T-cell frequency and function during hepatitis C virus recurrence after liver transplantation. Transplant Proc. 2009;41:1761-1766. [PMID: 19545723 DOI: 10.1016/j.transproceed.2009.01.112] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
202 Larrubia JR, Benito-Martínez S, Calvino M, Sanz-de-Villalobos E, Parra-Cid T. Role of chemokines and their receptors in viral persistence and liver damage during chronic hepatitis C virus infection. World J Gastroenterol 2008; 14(47): 7149-7159 [PMID: 19084927 DOI: 10.3748/wjg.14.7149] [Cited by in CrossRef: 86] [Cited by in F6Publishing: 85] [Article Influence: 6.1] [Reference Citation Analysis]
203 Rallón NI, Barreiro P, Soriano V, García-Samaniego J, López M, Benito JM. Elevated TGF-β1 levels might protect HCV/ HIV-coinfected patients from liver fibrosis. Eur J Clin Invest 2011;41:70-6. [PMID: 20868448 DOI: 10.1111/j.1365-2362.2010.02381.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
204 Semmo N, Krashias G, Willberg C, Klenerman P. Analysis of the relationship between cytokine secretion and proliferative capacity in hepatitis C virus infection. J Viral Hepat. 2007;14:492-502. [PMID: 17576391 DOI: 10.1111/j.1365-2893.2007.00842.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 1.6] [Reference Citation Analysis]
205 Ip PP, Nijman HW, Wilschut J, Daemen T. Therapeutic vaccination against chronic hepatitis C virus infection. Antiviral Res. 2012;96:36-50. [PMID: 22841700 DOI: 10.1016/j.antiviral.2012.07.006] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
206 Wang S, Buchli R, Schiller J, Gao J, VanGundy RS, Hildebrand WH, Eckels DD. Natural epitope variants of the hepatitis C virus impair cytotoxic T lymphocyte activity. World J Gastroenterol 2010; 16(16): 1953-1969 [PMID: 20419832 DOI: 10.3748/wjg.v16.i16.1953] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
207 Hosseini SY, Sabahi F, Moazzeni SM, Modarressi MH, Saberi Firoozi M, Ravanshad M. Construction and preparation of three recombinant adenoviruses expressing truncated NS3 and core genes of hepatitis C virus for vaccine purposes. Hepat Mon 2012;12:e6130. [PMID: 23087750 DOI: 10.5812/hepatmon.6130] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
208 Allam WR, Barakat A, Zakaria Z, Galal G, Abdel-Ghafar TS, El-Tabbakh M, Mikhail N, Waked I, Abdelwahab SF. Schistosomiasis does not affect the outcome of HCV infection in genotype 4-infected patients. Am J Trop Med Hyg. 2014;90:823-829. [PMID: 24615138 DOI: 10.4269/ajtmh.13-0703] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
209 Lang PA, Recher M, Honke N, Scheu S, Borkens S, Gailus N, Krings C, Meryk A, Kulawik A, Cervantes-Barragan L, Van Rooijen N, Kalinke U, Ludewig B, Hengartner H, Harris N, Häussinger D, Ohashi PS, Zinkernagel RM, Lang KS. Tissue macrophages suppress viral replication and prevent severe immunopathology in an interferon-I-dependent manner in mice. Hepatology 2010;52:25-32. [PMID: 20578253 DOI: 10.1002/hep.23640] [Cited by in Crossref: 54] [Cited by in F6Publishing: 52] [Article Influence: 4.5] [Reference Citation Analysis]
210 Yao ZQ, Eisen-Vandervelde A, Waggoner SN, Cale EM, Hahn YS. Direct binding of hepatitis C virus core to gC1qR on CD4+ and CD8+ T cells leads to impaired activation of Lck and Akt. J Virol. 2004;78:6409-6419. [PMID: 15163734 DOI: 10.1128/jvi.78.12.6409-6419.2004] [Cited by in Crossref: 77] [Cited by in F6Publishing: 43] [Article Influence: 4.3] [Reference Citation Analysis]
211 Martin A, Bodola F, Sangar DV, Goettge K, Popov V, Rijnbrand R, Lanford RE, Lemon SM. Chronic hepatitis associated with GB virus B persistence in a tamarin after intrahepatic inoculation of synthetic viral RNA. Proc Natl Acad Sci U S A 2003;100:9962-7. [PMID: 12907703 DOI: 10.1073/pnas.1731505100] [Cited by in Crossref: 53] [Cited by in F6Publishing: 48] [Article Influence: 2.8] [Reference Citation Analysis]
212 Arribillaga L, de Cerio ALD, Sarobe P, Casares N, Gorraiz M, Vales A, Bruna-romero O, Borrás-cuesta F, Paranhos-baccala G, Prieto J, Ruiz J, Lasarte JJ. Vaccination with an adenoviral vector encoding hepatitis C virus (HCV) NS3 protein protects against infection with HCV-recombinant vaccinia virus. Vaccine 2002;21:202-10. [DOI: 10.1016/s0264-410x(02)00456-5] [Cited by in Crossref: 45] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
213 Petrovic D, Stamataki Z, Dempsey E, Golden-Mason L, Freeley M, Doherty D, Prichard D, Keogh C, Conroy J, Mitchell S. Hepatitis C virus targets the T cell secretory machinery as a mechanism of immune evasion. Hepatology. 2011;53:1846-1853. [PMID: 21452285 DOI: 10.1002/hep.24327] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
214 Neumann-haefelin C, Blum H, Chisari F, Thimme R. T cell response in hepatitis C virus infection. Journal of Clinical Virology 2005;32:75-85. [DOI: 10.1016/j.jcv.2004.05.008] [Cited by in Crossref: 87] [Cited by in F6Publishing: 81] [Article Influence: 5.1] [Reference Citation Analysis]
215 Thurairajah PH, Hegazy D, Chokshi S, Shaw S, Demaine A, Kaminski ER, Naoumov NV, Cramp ME. Hepatitis C virus (HCV)--specific T cell responses in injection drug users with apparent resistance to HCV infection. J Infect Dis 2008;198:1749-55. [PMID: 18959498 DOI: 10.1086/593337] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 3.2] [Reference Citation Analysis]
216 Yao ZQ, King E, Prayther D, Yin D, Moorman J. T cell dysfunction by hepatitis C virus core protein involves PD-1/PDL-1 signaling. Viral Immunol. 2007;20:276-287. [PMID: 17603844 DOI: 10.1089/vim.2006.0096] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 3.7] [Reference Citation Analysis]
217 Bes M, Sauleda S, Campos-varela I, Rodriguez-frias F, Casamitjana N, Homs M, Piron M, Quer J, Tabernero D, Guardia J, Puig L, Esteban JI. IL28B genetic variation and hepatitis C virus-specific CD4 + T-cell responses in anti-HCV-positive blood donors: IL28B and HCV-specific T-cell responses. Journal of Viral Hepatitis 2012;19:867-71. [DOI: 10.1111/j.1365-2893.2012.01631.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
218 Schnuriger A, Dominguez S, Guiguet M, Harfouch S, Samri A, Ouazene Z, Slama L, Simon A, Valantin MA, Thibault V. Acute hepatitis C in HIV-infected patients: rare spontaneous clearance correlates with weak memory CD4 T-cell responses to hepatitis C virus. AIDS. 2009;23:2079-2089. [PMID: 19710595 DOI: 10.1097/qad.0b013e328330ed24] [Cited by in Crossref: 50] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
219 Howell J, Angus P, Gow P, Visvanathan K. Toll-like receptors in hepatitis C infection: Implications for pathogenesis and treatment: Toll-like receptors in hepatitis C. J Gastroenterol Hepatol 2013;28:766-76. [DOI: 10.1111/jgh.12170] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
220 Zabaleta A, Llopiz D, Arribillaga L, Silva L, Riezu-boj JI, Lasarte JJ, Borrás-cuesta F, Prieto J, Sarobe P. Vaccination Against Hepatitis C Virus With Dendritic Cells Transduced With an Adenovirus Encoding NS3 Protein. Molecular Therapy 2008;16:210-7. [DOI: 10.1038/sj.mt.6300333] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 2.0] [Reference Citation Analysis]
221 Wedemeyer H, Jäckel E, Wiegand J, Cornberg M, Manns MP. Whom When How Another piece of evidence for early treatment of acute hepatitis C. Hepatology. 2004;39:1201-1203. [PMID: 15122747 DOI: 10.1002/hep.20221] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 1.7] [Reference Citation Analysis]
222 Xue J, Zhu H, Chen Z. Therapeutic vaccines against hepatitis C virus. Infect Genet Evol 2014;22:120-9. [PMID: 24462908 DOI: 10.1016/j.meegid.2014.01.008] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
223 Rao X, Hoof I, van Baarle D, Keşmir C, Textor J. HLA Preferences for Conserved Epitopes: A Potential Mechanism for Hepatitis C Clearance. Front Immunol 2015;6:552. [PMID: 26579127 DOI: 10.3389/fimmu.2015.00552] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
224 Chattopadhyay PK, Roederer M. Immunophenotyping of T cell subpopulations in HIV disease. Curr Protoc Immunol 2005;Chapter 12:Unit 12.12. [PMID: 18432939 DOI: 10.1002/0471142735.im1212s65] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
225 Isogawa M, Furuichi Y, Chisari FV. Oscillating CD8(+) T cell effector functions after antigen recognition in the liver. Immunity. 2005;23:53-63. [PMID: 16039579 DOI: 10.1016/j.immuni.2005.05.005] [Cited by in Crossref: 140] [Cited by in F6Publishing: 134] [Article Influence: 8.2] [Reference Citation Analysis]
226 Chauvat A, Benhamouda N, Gey A, Lemoine FM, Paulie S, Carrat F, Gougeon ML, Rozenberg F, Krivine A, Cherai M, Lehmann P 5th, Quintin-Colonna F, Launay O, Tartour E. Clinical validation of IFNγ/IL-10 and IFNγ/IL-2 FluoroSpot assays for the detection of Tr1 T cells and influenza vaccine monitoring in humans. Hum Vaccin Immunother 2014;10:104-13. [PMID: 24084262 DOI: 10.4161/hv.26593] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
227 Schulze Zur Wiesch J, Ciuffreda D, Lewis-Ximenez L, Kasprowicz V, Nolan BE, Streeck H, Aneja J, Reyor LL, Allen TM, Lohse AW, McGovern B, Chung RT, Kwok WW, Kim AY, Lauer GM. Broadly directed virus-specific CD4+ T cell responses are primed during acute hepatitis C infection, but rapidly disappear from human blood with viral persistence. J Exp Med 2012;209:61-75. [PMID: 22213804 DOI: 10.1084/jem.20100388] [Cited by in Crossref: 155] [Cited by in F6Publishing: 149] [Article Influence: 15.5] [Reference Citation Analysis]
228 Qian L, Wang N, Tian H, Jin H, Zhao H, Niu C, He H, Ge T, Han W, Hu J, Li D, Han F, Xu J, Ding X, Chen J, Li W, Cui J. Dual Effects of Cellular Immunotherapy in Inhibition of Virus Replication and Prolongation of Survival in HCV-Positive Hepatocellular Carcinoma Patients. J Immunol Res. 2016;2016:6837241. [PMID: 27069936 DOI: 10.1155/2016/6837241] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
229 Brooks DG, Teyton L, Oldstone MB, McGavern DB. Intrinsic functional dysregulation of CD4 T cells occurs rapidly following persistent viral infection. J Virol. 2005;79:10514-10527. [PMID: 16051844 DOI: 10.1128/jvi.79.16.10514-10527.2005] [Cited by in Crossref: 153] [Cited by in F6Publishing: 111] [Article Influence: 9.0] [Reference Citation Analysis]
230 Tarr AW, Urbanowicz RA, Ball JK. The role of humoral innate immunity in hepatitis C virus infection. Viruses. 2012;4:1-27. [PMID: 22355450 DOI: 10.3390/v4010001] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 2.9] [Reference Citation Analysis]
231 Wietzke-Braun P, Mänhardt LB, Rosenberger A, Uy A, Ramadori G, Mihm S. Spontaneous elimination of hepatitis C virus infection: A retrospective study on demographic, clinical, and serological correlates. World J Gastroenterol 2007; 13(31): 4224-4229 [PMID: 17696252 DOI: 10.3748/wjg.v13.i31.4224] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
232 Kuntzen T, Timm J, Berical A, Lewis-Ximenez LL, Jones A, Nolan B, Schulze zur Wiesch J, Li B, Schneidewind A, Kim AY, Chung RT, Lauer GM, Allen TM. Viral sequence evolution in acute hepatitis C virus infection. J Virol 2007;81:11658-68. [PMID: 17699568 DOI: 10.1128/JVI.00995-07] [Cited by in Crossref: 79] [Cited by in F6Publishing: 57] [Article Influence: 5.3] [Reference Citation Analysis]
233 Man John Law L, Landi A, Magee WC, Lorne Tyrrell D, Houghton M. Progress towards a hepatitis C virus vaccine. Emerg Microbes Infect. 2013;2:e79. [PMID: 26038445 DOI: 10.1038/emi.2013.79] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 3.3] [Reference Citation Analysis]
234 Moonka D, Milkovich KA, Rodriguez B, Abouljoud M, Lederman MM, Anthony DD. Hepatitis C virus-specific T-cell gamma interferon and proliferative responses are more common in perihepatic lymph nodes than in peripheral blood or liver. J Virol 2008;82:11742-8. [PMID: 18715927 DOI: 10.1128/JVI.01130-08] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
235 Betts MR, Price DA, Brenchley JM, Loré K, Guenaga FJ, Smed-Sorensen A, Ambrozak DR, Migueles SA, Connors M, Roederer M, Douek DC, Koup RA. The functional profile of primary human antiviral CD8+ T cell effector activity is dictated by cognate peptide concentration. J Immunol 2004;172:6407-17. [PMID: 15128832 DOI: 10.4049/jimmunol.172.10.6407] [Cited by in Crossref: 103] [Cited by in F6Publishing: 103] [Article Influence: 5.7] [Reference Citation Analysis]
236 Kemming J, Thimme R, Neumann-Haefelin C. Adaptive Immune Response against Hepatitis C Virus. Int J Mol Sci 2020;21:E5644. [PMID: 32781731 DOI: 10.3390/ijms21165644] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
237 Petrovic D, Dempsey E, Doherty DG, Kelleher D, Long A. Hepatitis C virus--T-cell responses and viral escape mutations. Eur J Immunol 2012;42:17-26. [PMID: 22125159 DOI: 10.1002/eji.201141593] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 2.6] [Reference Citation Analysis]
238 Mikkelsen M, Holst PJ, Bukh J, Thomsen AR, Christensen JP. Enhanced and Sustained CD8 + T Cell Responses with an Adenoviral Vector-Based Hepatitis C Virus Vaccine Encoding NS3 Linked to the MHC Class II Chaperone Protein Invariant Chain. J I 2011;186:2355-64. [DOI: 10.4049/jimmunol.1001877] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 4.5] [Reference Citation Analysis]
239 Zhang Y, Ma CJ, Ni L, Zhang CL, Wu XY, Kumaraguru U, Li CF, Moorman JP, Yao ZQ. Cross-talk between programmed death-1 and suppressor of cytokine signaling-1 in inhibition of IL-12 production by monocytes/macrophages in hepatitis C virus infection. J Immunol. 2011;186:3093-3103. [PMID: 21263070 DOI: 10.4049/jimmunol.1002006] [Cited by in Crossref: 58] [Cited by in F6Publishing: 67] [Article Influence: 5.3] [Reference Citation Analysis]
240 Park SH, Shin EC, Capone S, Caggiari L, De Re V, Nicosia A, Folgori A, Rehermann B. Successful vaccination induces multifunctional memory T-cell precursors associated with early control of hepatitis C virus. Gastroenterology. 2012;143:1048-60.e4. [PMID: 22705008 DOI: 10.1053/j.gastro.2012.06.005] [Cited by in Crossref: 51] [Cited by in F6Publishing: 51] [Article Influence: 5.1] [Reference Citation Analysis]
241 Gotto J, Dusheiko GM. Hepatitis C and treatment with pegylated interferon and ribavirin. The International Journal of Biochemistry & Cell Biology 2004;36:1874-7. [DOI: 10.1016/j.biocel.2004.03.014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
242 Grubor-Bauk B, Yu W, Wijesundara D, Gummow J, Garrod T, Brennan AJ, Voskoboinik I, Gowans EJ. Intradermal delivery of DNA encoding HCV NS3 and perforin elicits robust cell-mediated immunity in mice and pigs. Gene Ther 2016;23:26-37. [PMID: 26262584 DOI: 10.1038/gt.2015.86] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
243 Delbue S, Comar M, Ferrante P. Review on the relationship between human polyomaviruses-associated tumors and host immune system. Clin Dev Immunol 2012;2012:542092. [PMID: 22489251 DOI: 10.1155/2012/542092] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
244 Li J, Liu Y, Xu F, Chen J, Chen Y. Three polymorphisms in the IL-10 gene and the risk of HCV infection: a meta-analysis plus a Chinese Association Study involving 1140 subjects. Epidemiol Infect 2013;141:893-904. [DOI: 10.1017/s0950268812002154] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
245 Semmo N, Klenerman P. CD4+ T cell responses in hepatitis C virus infection. World J Gastroenterol 2007; 13(36): 4831-4838 [PMID: 17828814 DOI: 10.3748/wjg.v13.i36.4831] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 35] [Article Influence: 2.5] [Reference Citation Analysis]
246 Lambotin M, Baumert TF, Barth H. Distinct intracellular trafficking of hepatitis C virus in myeloid and plasmacytoid dendritic cells. J Virol. 2010;84:8964-8969. [PMID: 20573834 DOI: 10.1128/jvi.00517-10] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
247 Collins ME, Heaney J, Thomas CJ, Brownlie J. Infectivity of pestivirus following persistence of acute infection. Veterinary Microbiology 2009;138:289-96. [DOI: 10.1016/j.vetmic.2009.04.022] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 1.7] [Reference Citation Analysis]
248 Takamizawa S, Yamada T, Kitamura K, Hiraoka E. Difficulty of acute hepatitis C diagnosis in a hospitalised patient. BMJ Case Rep 2018;11:e226907. [PMID: 30567115 DOI: 10.1136/bcr-2018-226907] [Reference Citation Analysis]
249 Tawar RG, Colpitts CC, Timm J, Fehm T, Roggendorf M, Meisel H, Meyer N, Habersetzer F, Cosset FL, Berg T, Zeisel MB, Baumert TF. Acute hepatitis C virus infection induces anti-host cell receptor antibodies with virus-neutralizing properties. Hepatology 2015;62:726-36. [PMID: 26010076 DOI: 10.1002/hep.27906] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
250 Valdez H, Carlson NL, Post AB, Asaad R, Heeger PS, Lederman MM, Lehmann PV, Anthony DD. HIV long-term non-progressors maintain brisk CD8 T cell responses to other viral antigens. AIDS 2002;16:1113-8. [PMID: 12004269 DOI: 10.1097/00002030-200205240-00004] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 2.1] [Reference Citation Analysis]
251 Timm J, Lauer GM, Kavanagh DG, Sheridan I, Kim AY, Lucas M, Pillay T, Ouchi K, Reyor LL, Schulze zur Wiesch J. CD8 epitope escape and reversion in acute HCV infection. J Exp Med. 2004;200:1593-1604. [PMID: 15611288 DOI: 10.1084/jem.20041006] [Cited by in Crossref: 239] [Cited by in F6Publishing: 225] [Article Influence: 14.1] [Reference Citation Analysis]
252 Rehermann B. Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest 2009;119:1745-54. [PMID: 19587449 DOI: 10.1172/JCI39133] [Cited by in Crossref: 379] [Cited by in F6Publishing: 226] [Article Influence: 29.2] [Reference Citation Analysis]
253 Bergthaler A, Flatz L, Hegazy AN, Johnson S, Horvath E, Löhning M, Pinschewer DD. Viral replicative capacity is the primary determinant of lymphocytic choriomeningitis virus persistence and immunosuppression. Proc Natl Acad Sci U S A 2010;107:21641-6. [PMID: 21098292 DOI: 10.1073/pnas.1011998107] [Cited by in Crossref: 64] [Cited by in F6Publishing: 63] [Article Influence: 5.3] [Reference Citation Analysis]
254 Jeong SH, Qiao M, Nascimbeni M, Hu Z, Rehermann B, Murthy K, Liang TJ. Immunization with hepatitis C virus-like particles induces humoral and cellular immune responses in nonhuman primates. J Virol. 2004;78:6995-7003. [PMID: 15194776 DOI: 10.1128/jvi.78.13.6995-7003.2004] [Cited by in Crossref: 87] [Cited by in F6Publishing: 37] [Article Influence: 4.8] [Reference Citation Analysis]
255 Martin P, Simon B, Lone YC, Chatel L, Barry R, Inchauspé G, Fournillier A. A vector-based minigene vaccine approach results in strong induction of T-cell responses specific of hepatitis C virus. Vaccine 2008;26:2471-81. [PMID: 18423948 DOI: 10.1016/j.vaccine.2008.03.028] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
256 Osuch S, Metzner KJ, Caraballo Cortés K. Reversal of T Cell Exhaustion in Chronic HCV Infection. Viruses 2020;12:E799. [PMID: 32722372 DOI: 10.3390/v12080799] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
257 Zhu F, Eckels DD. Functionally distinct helper T-cell epitopes of HCV and their role in modulation of NS3-specific, CD8+/tetramer positive CTL. Human Immunology 2002;63:710-8. [DOI: 10.1016/s0198-8859(02)00430-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
258 Yerly D, Heckerman D, Allen TM, Chisholm JV, Faircloth K, Linde CH, Frahm N, Timm J, Pichler WJ, Cerny A. Increased cytotoxic T-lymphocyte epitope variant cross-recognition and functional avidity are associated with hepatitis C virus clearance. J Virol. 2008;82:3147-3153. [PMID: 18184704 DOI: 10.1128/jvi.02252-07] [Cited by in Crossref: 40] [Cited by in F6Publishing: 29] [Article Influence: 2.9] [Reference Citation Analysis]
259 Ebrahimkhani MR, Mohar I, Crispe IN. Cross-presentation of antigen by diverse subsets of murine liver cells. Hepatology. 2011;54:1379-1387. [PMID: 21721032 DOI: 10.1002/hep.24508] [Cited by in Crossref: 59] [Cited by in F6Publishing: 57] [Article Influence: 5.4] [Reference Citation Analysis]
260 dos Santos DC, Neves PC, Azeredo EL, Pelajo-Machado M, Martinho JM, Pacheco-Moreira LF, Araújo CC, Cruz OG, de Oliveira JM, Pinto MA. Activated lymphocytes and high liver expression of IFN-γ are associated with fulminant hepatic failure in patients. Liver Int. 2012;32:147-157. [PMID: 22098464 DOI: 10.1111/j.1478-3231.2011.02654.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
261 Seigel B, Bengsch B, Lohmann V, Bartenschlager R, Blum HE, Thimme R. Factors that determine the antiviral efficacy of HCV-specific CD8(+) T cells ex vivo. Gastroenterology. 2013;144:426-436. [PMID: 23142136 DOI: 10.1053/j.gastro.2012.10.047] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 3.1] [Reference Citation Analysis]
262 Grebely J, Thomas DL, Dore GJ. HCV reinfection studies and the door to vaccine development. Journal of Hepatology 2009;51:628-31. [DOI: 10.1016/j.jhep.2009.07.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
263 De Maria A, Fogli M, Mazza S, Basso M, Picciotto A, Costa P, Congia S, Mingari M, Moretta L. Increased natural cytotoxicity receptor expression and relevant IL-10 production in NK cells from chronically infected viremic HCV patients. Eur J Immunol 2007;37:445-55. [DOI: 10.1002/eji.200635989] [Cited by in Crossref: 158] [Cited by in F6Publishing: 155] [Article Influence: 10.5] [Reference Citation Analysis]
264 Emara M, Mohsen E, Shawky RM, El-Domany RA. Assessment of the Prevalence of Non-Organ-Specific Autoantibodies in Egyptian Patients with HCV. Immunol Invest 2020;49:676-86. [PMID: 31820668 DOI: 10.1080/08820139.2019.1699108] [Reference Citation Analysis]
265 Tan H, Derrick J, Hong J, Sanda C, Grosse WM, Edenberg HJ, Taylor M, Seiwert S, Blatt LM. Global transcriptional profiling demonstrates the combination of type I and type II interferon enhances antiviral and immune responses at clinically relevant doses. J Interferon Cytokine Res 2005;25:632-49. [PMID: 16241862 DOI: 10.1089/jir.2005.25.632] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 1.4] [Reference Citation Analysis]
266 Larrubia JR, Lokhande MU, García-Garzón S, Miquel J, Subirá D, Sanz-de-Villalobos E. Role of T cell death in maintaining immune tolerance during persistent viral hepatitis. World J Gastroenterol 2013; 19(12): 1877-1889 [PMID: 23569333 DOI: 10.3748/wjg.v19.i12.1877] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
267 Coto-Llerena M, Lepore M, Spagnuolo J, Di Blasi D, Calabrese D, Suslov A, Bantug G, Duong FH, Terracciano LM, De Libero G, Heim MH. Interferon lambda 4 can directly activate human CD19+ B cells and CD8+ T cells. Life Sci Alliance 2021;4:e201900612. [PMID: 33158978 DOI: 10.26508/lsa.201900612] [Reference Citation Analysis]
268 Abdel-Hakeem MS, Bédard N, Murphy D, Bruneau J, Shoukry NH. Signatures of protective memory immune responses during hepatitis C virus reinfection. Gastroenterology 2014;147:870-881.e8. [PMID: 25038432 DOI: 10.1053/j.gastro.2014.07.005] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 4.9] [Reference Citation Analysis]
269 Neumann-Haefelin C, Timm J, Schmidt J, Kersting N, Fitzmaurice K, Oniangue-Ndza C, Kemper MN, Humphreys I, McKiernan S, Kelleher D, Lohmann V, Bowness P, Huzly D, Rosen HR, Kim AY, Lauer GM, Allen TM, Barnes E, Roggendorf M, Blum HE, Thimme R. Protective effect of human leukocyte antigen B27 in hepatitis C virus infection requires the presence of a genotype-specific immunodominant CD8+ T-cell epitope. Hepatology 2010;51:54-62. [PMID: 20034048 DOI: 10.1002/hep.23275] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 3.3] [Reference Citation Analysis]
270 Raghuraman S, Park H, Osburn WO, Winkelstein E, Edlin BR, Rehermann B. Spontaneous clearance of chronic hepatitis C virus infection is associated with appearance of neutralizing antibodies and reversal of T-cell exhaustion. J Infect Dis 2012;205:763-71. [PMID: 22293431 DOI: 10.1093/infdis/jir835] [Cited by in Crossref: 111] [Cited by in F6Publishing: 111] [Article Influence: 11.1] [Reference Citation Analysis]
271 Nanda S, Havert MB, Calderón GM, Thomson M, Jacobson C, Kastner D, Liang TJ. Hepatic transcriptome analysis of hepatitis C virus infection in chimpanzees defines unique gene expression patterns associated with viral clearance. PLoS One 2008;3:e3442. [PMID: 18927617 DOI: 10.1371/journal.pone.0003442] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
272 Wolski D, Lauer GM. Hepatitis C Virus as a Unique Human Model Disease to Define Differences in the Transcriptional Landscape of T Cells in Acute versus Chronic Infection. Viruses 2019;11:E683. [PMID: 31357397 DOI: 10.3390/v11080683] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
273 Hajarizadeh B, Grebely J, Applegate T, Matthews GV, Amin J, Petoumenos K, Hellard M, Rawlinson W, Lloyd A, Kaldor J, Dore GJ; ATAHC study group. Dynamics of HCV RNA levels during acute hepatitis C virus infection. J Med Virol 2014;86:1722-9. [PMID: 25042465 DOI: 10.1002/jmv.24010] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
274 Wölk B, Trautwein C, Büchele B, Kersting N, Blum HE, Rammensee HG, Cerny A, Stevanovic S, Moradpour D, Brass V. Identification of naturally processed hepatitis C virus-derived major histocompatibility complex class I ligands. PLoS One 2012;7:e29286. [PMID: 22235280 DOI: 10.1371/journal.pone.0029286] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
275 Gerlach JT, Ulsenheimer A, Grüner NH, Jung MC, Schraut W, Schirren CA, Heeg M, Scholz S, Witter K, Zahn R. Minimal T-cell-stimulatory sequences and spectrum of HLA restriction of immunodominant CD4+ T-cell epitopes within hepatitis C virus NS3 and NS4 proteins. J Virol. 2005;79:12425-12433. [PMID: 16160170 DOI: 10.1128/jvi.79.19.12425-12433.2005] [Cited by in Crossref: 47] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
276 Neumann-haefelin C, Mckiernan S, Ward S, Viazov S, Spangenberg HC, Killinger T, Baumert TF, Nazarova N, Sheridan I, Pybus O, von Weizsäcker F, Roggendorf M, Kelleher D, Klenerman P, Blum HE, Thimme R. Dominant influence of an HLA-B27 restricted CD8+ T cell response in mediating HCV clearance and evolution. Hepatology 2006;43:563-72. [DOI: 10.1002/hep.21049] [Cited by in Crossref: 151] [Cited by in F6Publishing: 149] [Article Influence: 9.4] [Reference Citation Analysis]
277 Boonstra A, Woltman AM, Janssen HL. Immunology of hepatitis B and hepatitis C virus infections. Best Pract Res Clin Gastroenterol. 2008;22:1049-1061. [PMID: 19187866 DOI: 10.1016/j.bpg.2008.11.015] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 2.6] [Reference Citation Analysis]
278 Raghuraman S, Abraham P, Daniel HD, Ramakrishna BS, Sridharan G. Characterization of soluble FAS, FAS ligand and tumour necrosis factor-alpha in patients with chronic HCV infection. J Clin Virol. 2005;34:63-70. [PMID: 16087126 DOI: 10.1016/j.jcv.2005.01.009] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
279 Barth H, Schnober EK, Neumann-Haefelin C, Thumann C, Zeisel MB, Diepolder HM, Hu Z, Liang TJ, Blum HE, Thimme R, Lambotin M, Baumert TF. Scavenger receptor class B is required for hepatitis C virus uptake and cross-presentation by human dendritic cells. J Virol 2008;82:3466-79. [PMID: 18216094 DOI: 10.1128/JVI.02478-07] [Cited by in Crossref: 68] [Cited by in F6Publishing: 31] [Article Influence: 4.9] [Reference Citation Analysis]
280 Bialek SR, Terrault NA. The Changing Epidemiology and Natural History of Hepatitis C Virus Infection. Clinics in Liver Disease 2006;10:697-715. [DOI: 10.1016/j.cld.2006.08.003] [Cited by in Crossref: 73] [Cited by in F6Publishing: 63] [Article Influence: 4.6] [Reference Citation Analysis]
281 Shin EC, Seifert U, Kato T, Rice CM, Feinstone SM, Kloetzel PM, Rehermann B. Virus-induced type I IFN stimulates generation of immunoproteasomes at the site of infection. J Clin Invest. 2006;116:3006-3014. [PMID: 17039255 DOI: 10.1172/jci29832] [Cited by in Crossref: 110] [Cited by in F6Publishing: 70] [Article Influence: 6.9] [Reference Citation Analysis]
282 Zhang H, Zhang J, Chen L, Weng Z, Tian Y, Zhao H, Li Y, Chen L, Liang Z, Zheng H, Zhao W, Zhong S, Li Y. Targeting naturally occurring epitope variants of hepatitis C virus with high-affinity T-cell receptors. J Gen Virol 2017;98:374-84. [PMID: 27902325 DOI: 10.1099/jgv.0.000656] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
283 Dominguez-villar M, Fernandez-ponce C, Munoz-suano A, Gomez E, Rodríguez-iglesias M, Garcia-cozar F. Up-regulation of FOXP3 and induction of suppressive function in CD4+ Jurkat T-cells expressing hepatitis C virus core protein. Clinical Science 2012;123:15-27. [DOI: 10.1042/cs20110631] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
284 Dabo S, Meurs EF. dsRNA-dependent protein kinase PKR and its role in stress, signaling and HCV infection. Viruses 2012;4:2598-635. [PMID: 23202496 DOI: 10.3390/v4112598] [Cited by in Crossref: 112] [Cited by in F6Publishing: 106] [Article Influence: 11.2] [Reference Citation Analysis]
285 Singh S, Vedi S, Li W, Samrat SK, Kumar R, Agrawal B. Recombinant adenoviral vector expressing HCV NS4 induces protective immune responses in a mouse model of Vaccinia-HCV virus infection: a dose and route conundrum. Vaccine 2014;32:2712-21. [PMID: 24631092 DOI: 10.1016/j.vaccine.2014.02.080] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
286 Satake S, Nagaki M, Kimura K, Naiki T, Hayashi H, Sugihara J, Tomita E, Moriwaki H. Significant effect of hepatitis C virus specific CTLs on viral clearance in patients with type C chronic hepatitis treated with antiviral agents. Hepatol Res. 2008;38:491-500. [PMID: 18034809 DOI: 10.1111/j.1872-034X.2007.00291.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
287 Terajima M, Ennis FA. T cells and pathogenesis of hantavirus cardiopulmonary syndrome and hemorrhagic fever with renal syndrome. Viruses 2011;3:1059-73. [PMID: 21994770 DOI: 10.3390/v3071059] [Cited by in Crossref: 62] [Cited by in F6Publishing: 55] [Article Influence: 5.6] [Reference Citation Analysis]
288 Racanelli V, Leone P, Grakoui A. A spatial view of the CD8+ T-cell response: the case of HCV. Rev Med Virol 2011;21:347-57. [PMID: 21732472 DOI: 10.1002/rmv.702] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
289 Sugden PB, Cameron B, Mina M, Lloyd AR; HITS investigators. Protection against hepatitis C infection via NK cells in highly-exposed uninfected injecting drug users. J Hepatol 2014;61:738-45. [PMID: 24845613 DOI: 10.1016/j.jhep.2014.05.013] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
290 El-gogo S, Staib C, Lasarte JJ, Sutter G, Adler H. Protective vaccination with hepatitis C virus NS3 but not core antigen in a novel mouse challenge model. J Gene Med 2008;10:177-86. [DOI: 10.1002/jgm.1144] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
291 Keoshkerian E, Helbig K, Beard M, Zaunders J, Seddiki N, Kelleher A, Hampartzoumian T, Zekry A, Lloyd AR. A novel assay for detection of hepatitis C virus-specific effector CD4(+) T cells via co-expression of CD25 and CD134. J Immunol Methods. 2012;375:148-158. [PMID: 22019644 DOI: 10.1016/j.jim.2011.10.004] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
292 Omata M, Kanda T, Wei L, Yu ML, Chuang WL, Ibrahim A, Lesmana CR, Sollano J, Kumar M, Jindal A. APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing. Hepatol Int. 2016;10:681-701. [PMID: 27229718 DOI: 10.1007/s12072-016-9736-3] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 8.0] [Reference Citation Analysis]
293 Thimme R, Neumann-Haefelin C, Boettler T, Blum HE. Adaptive immune responses to hepatitis C virus: from viral immunobiology to a vaccine. Biol Chem. 2008;389:457-467. [PMID: 18953713 DOI: 10.1515/BC.2008.061] [Cited by in Crossref: 27] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
294 Wiegand J, Potthoff A, Manns MP, Wedemeyer H. Acute hepatitis C infection: Can immunology teach us the right way to treat? Curr hepatitis rep 2004;3:148-56. [DOI: 10.1007/s11901-004-0025-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
295 Wiegand J, Jäckel E, Cornberg M, Hinrichsen H, Dietrich M, Kroeger J, Fritsch WP, Kubitschke A, Aslan N, Tillmann HL, Manns MP, Wedemeyer H. Long-term follow-up after successful interferon therapy of acute hepatitis C. Hepatology 2004;40:98-107. [DOI: 10.1002/hep.20291] [Cited by in Crossref: 69] [Cited by in F6Publishing: 63] [Article Influence: 3.8] [Reference Citation Analysis]
296 Beinhardt S, Aberle JH, Strasser M, Dulic-Lakovic E, Maieron A, Kreil A, Rutter K, Staettermayer AF, Datz C, Scherzer TM. Serum level of IP-10 increases predictive value of IL28B polymorphisms for spontaneous clearance of acute HCV infection. Gastroenterology. 2012;142:78-85.e2. [PMID: 22192885 DOI: 10.1053/j.gastro.2011.09.039] [Cited by in Crossref: 68] [Cited by in F6Publishing: 68] [Article Influence: 6.2] [Reference Citation Analysis]
297 Shaked A. The interrelation between recurrent hepatitis C, alloimmune response, and immunosuppression. Liver Transpl. 2005;11:1329-1331. [PMID: 16237699 DOI: 10.1002/lt.20588] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
298 McCaughan GW, Zekry A. Pathogenesis of hepatitis C virus recurrence in the liver allograft. Liver Transpl 2002;8:S7-S13. [PMID: 12362292 DOI: 10.1053/jlts.2002.35856] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 2.3] [Reference Citation Analysis]
299 Jagannathan P, Eccles-James I, Bowen K, Nankya F, Auma A, Wamala S, Ebusu C, Muhindo MK, Arinaitwe E, Briggs J, Greenhouse B, Tappero JW, Kamya MR, Dorsey G, Feeney ME. IFNγ/IL-10 co-producing cells dominate the CD4 response to malaria in highly exposed children. PLoS Pathog 2014;10:e1003864. [PMID: 24415936 DOI: 10.1371/journal.ppat.1003864] [Cited by in Crossref: 84] [Cited by in F6Publishing: 83] [Article Influence: 10.5] [Reference Citation Analysis]
300 Hong X, Yu RB, Sun NX, Wang B, Xu YC, Wu GL. Human leukocyte antigen class II DQB1*0301, DRB1*1101 alleles and spontaneous clearance of hepatitis C virus infection: a meta-analysis. World J Gastroenterol 2005;11:7302-7. [PMID: 16437632 DOI: 10.3748/wjg.v11.i46.7302] [Cited by in CrossRef: 51] [Cited by in F6Publishing: 54] [Article Influence: 3.2] [Reference Citation Analysis]
301 Puig M, Major ME, Mihalik K, Feinstone SM. Immunization of chimpanzees with an envelope protein-based vaccine enhances specific humoral and cellular immune responses that delay hepatitis C virus infection. Vaccine. 2004;22:991-1000. [PMID: 15161076 DOI: 10.1016/j.vaccine.2003.09.010] [Cited by in Crossref: 60] [Cited by in F6Publishing: 57] [Article Influence: 3.3] [Reference Citation Analysis]
302 Shin EC, Seifert U, Kato T, Rice CM, Feinstone SM, Kloetzel PM, Rehermann B. Virus-induced type I IFN stimulates generation of immunoproteasomes at the site of infection. J Clin Invest. 2006;116:3006-3014. [PMID: 17039255 DOI: 10.1172/jci2983] [Cited by in Crossref: 28] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
303 Amador-Cañizares Y, Alvarez-Lajonchere L, Guerra I, Rodríguez-Alonso I, Martínez-Donato G, Triana J, González-Horta EE, Pérez A, Dueñas-Carrera S. Induction of IgA and sustained deficiency of cell proliferative response in chronic hepatitis C. World J Gastroenterol 2008; 14(44): 6844-6852 [PMID: 19058312 DOI: 10.3748/wjg.14.6844] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
304 Forman MS, Valsamakis A. Hepatitis C Virus. In: Jorgensen JH, Carroll KC, Funke G, Pfaller MA, Landry ML, Richter SS, Warnock DW, editors. Manual of Clinical Microbiology. Washington: ASM Press; 2015. pp. 1599-616. [DOI: 10.1128/9781555817381.ch92] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
305 Johnson S, Bergthaler A, Graw F, Flatz L, Bonilla WV, Siegrist CA, Lambert PH, Regoes RR, Pinschewer DD. Protective efficacy of individual CD8+ T cell specificities in chronic viral infection. J Immunol 2015;194:1755-62. [PMID: 25567678 DOI: 10.4049/jimmunol.1401771] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
306 Shoukry NH. Towards a Systems Immunology Approach to Understanding Correlates of Protective Immunity against HCV. Viruses 2021;13:1871. [PMID: 34578451 DOI: 10.3390/v13091871] [Reference Citation Analysis]
307 Wodarz D. Ecological and evolutionary principles in immunology. Ecol Letters 2006;9:694-705. [DOI: 10.1111/j.1461-0248.2006.00921.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
308 Larsson M, Babcock E, Grakoui A, Shoukry N, Lauer G, Rice C, Walker C, Bhardwaj N. Lack of phenotypic and functional impairment in dendritic cells from chimpanzees chronically infected with hepatitis C virus. J Virol. 2004;78:6151-6161. [PMID: 15163708 DOI: 10.1128/jvi.78.12.6151-6161.2004] [Cited by in Crossref: 51] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
309 Gowans EJ, Roberts S, Jones K, Dinatale I, Latour PA, Chua B, Eriksson EM, Chin R, Li S, Wall DM. A phase I clinical trial of dendritic cell immunotherapy in HCV-infected individuals. J Hepatol. 2010;53:599-607. [PMID: 20667615 DOI: 10.1016/j.jhep.2010.05.007] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 3.8] [Reference Citation Analysis]
310 Stamataki Z, Coates S, Evans MJ, Wininger M, Crawford K, Dong C, Fong YL, Chien D, Abrignani S, Balfe P. Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies. Vaccine. 2007;25:7773-7784. [PMID: 17919789 DOI: 10.1016/j.vaccine.2007.08.053] [Cited by in Crossref: 69] [Cited by in F6Publishing: 65] [Article Influence: 4.6] [Reference Citation Analysis]
311 Younes S, Trautmann L, Yassine-diab B, Kalfayan LH, Kernaleguen A, Cameron TO, Boulassel R, Stern LJ, Routy J, Grossman Z, Dumont AR, Sekaly R. The Duration of Exposure to HIV Modulates the Breadth and the Magnitude of HIV-Specific Memory CD4 + T Cells. J Immunol 2007;178:788-97. [DOI: 10.4049/jimmunol.178.2.788] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.5] [Reference Citation Analysis]
312 Radziewicz H, Ibegbu CC, Hon H, Osborn MK, Obideen K, Wehbi M, Freeman GJ, Lennox JL, Workowski KA, Hanson HL, Grakoui A. Impaired hepatitis C virus (HCV)-specific effector CD8+ T cells undergo massive apoptosis in the peripheral blood during acute HCV infection and in the liver during the chronic phase of infection. J Virol. 2008;82:9808-9822. [PMID: 18667503 DOI: 10.1128/jvi.01075-08] [Cited by in Crossref: 73] [Cited by in F6Publishing: 48] [Article Influence: 5.2] [Reference Citation Analysis]
313 Pillai V, Lee WM, Thiele DL, Karandikar NJ. Clinical responders to antiviral therapy of chronic HCV infection show elevated antiviral CD4+ and CD8+ T-cell responses. J Viral Hepat 2007;14:318-29. [PMID: 17439521 DOI: 10.1111/j.1365-2893.2006.00804.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
314 Xia Y, Pan W, Ke X, Skibbe K, Walker A, Hoffmann D, Lu Y, Yang X, Feng X, Tong Q, Timm J, Yang D. Differential escape of HCV from CD8+ T cell selection pressure between China and Germany depends on the presenting HLA class I molecule. J Viral Hepat 2019;26:73-82. [PMID: 30260541 DOI: 10.1111/jvh.13011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
315 Saeed M, Shiina M, Date T, Akazawa D, Watanabe N, Murayama A, Suzuki T, Watanabe H, Hiraga N, Imamura M, Chayama K, Choi Y, Krawczynski K, Liang TJ, Wakita T, Kato T. In vivo adaptation of hepatitis C virus in chimpanzees for efficient virus production and evasion of apoptosis. Hepatology 2011;54:425-33. [PMID: 21538444 DOI: 10.1002/hep.24399] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
316 Brown KS, Keogh MJ, Owsianka AM, Adair R, Patel AH, Arnold JN, Ball JK, Sim RB, Tarr AW, Hickling TP. Specific interaction of hepatitis C virus glycoproteins with mannan binding lectin inhibits virus entry. Protein Cell 2010;1:664-74. [PMID: 21203938 DOI: 10.1007/s13238-010-0088-9] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 3.5] [Reference Citation Analysis]
317 Ashfaq UA, Javed T, Rehman S, Nawaz Z, Riazuddin S. An overview of HCV molecular biology, replication and immune responses. Virol J. 2011;8:161. [PMID: 21477382 DOI: 10.1186/1743-422x-8-161] [Cited by in Crossref: 89] [Cited by in F6Publishing: 65] [Article Influence: 8.1] [Reference Citation Analysis]
318 Gerlach JT, Diepolder HM, Zachoval R, Gruener NH, Jung MC, Ulsenheimer A, Schraut WW, Schirren CA, Waechtler M, Backmund M. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology. 2003;125:80-88. [PMID: 12851873 DOI: 10.1016/s0016-5085(03)00668-1] [Cited by in Crossref: 343] [Cited by in F6Publishing: 122] [Article Influence: 18.1] [Reference Citation Analysis]
319 Rollier CS, Paranhos-baccala G, Verschoor EJ, Verstrepen BE, Drexhage JAR, Fagrouch Z, Berland J, Komurian-pradel F, Duverger B, Himoudi N, Staib C, Meyr M, Whelan M, Whelan JA, Adams VA, Larrea E, Riezu JI, Lasarte JJ, Bartosch B, Cosset F, Spaan WJM, Diepolder HM, Pape GR, Sutter G, Inchauspe G, Heeney JL. Vaccine-induced early control of hepatitis C virus infection in chimpanzees fails to impact on hepatic PD-1 and chronicity. Hepatology 2007;45:602-13. [DOI: 10.1002/hep.21573] [Cited by in Crossref: 69] [Cited by in F6Publishing: 70] [Article Influence: 4.6] [Reference Citation Analysis]
320 Urbani S, Amadei B, Tola D, Pedrazzi G, Sacchelli L, Cavallo MC, Orlandini A, Missale G, Ferrari C. Restoration of HCV-specific T cell functions by PD-1/PD-L1 blockade in HCV infection: effect of viremia levels and antiviral treatment. J Hepatol. 2008;48:548-558. [PMID: 18280607 DOI: 10.1016/j.jhep.2007.12.014] [Cited by in Crossref: 91] [Cited by in F6Publishing: 91] [Article Influence: 6.5] [Reference Citation Analysis]
321 McCaughan GW, Omata M, Amarapurkar D, Bowden S, Chow WC, Chutaputti A, Dore G, Gane E, Guan R, Hamid SS. Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J Gastroenterol Hepatol. 2007;22:615-633. [PMID: 17444847 DOI: 10.1111/j.1440-1746.2007.04883.x] [Cited by in Crossref: 111] [Cited by in F6Publishing: 111] [Article Influence: 7.4] [Reference Citation Analysis]
322 Blackard JT, Shata MT, Shire NJ, Sherman KE. Acute hepatitis C virus infection: a chronic problem. Hepatology. 2008;47:321-331. [PMID: 18161707 DOI: 10.1002/hep.21902] [Cited by in Crossref: 77] [Cited by in F6Publishing: 61] [Article Influence: 5.5] [Reference Citation Analysis]
323 Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, Wieland SF, Uprichard SL, Wakita T, Chisari FV. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A. 2005;102:9294-9299. [PMID: 15939869 DOI: 10.1073/pnas.0503596102.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
324 Antonelli A, Ferrari SM, Ruffilli I, Fallahi P. Cytokines and HCV-related autoimmune disorders. Immunol Res. 2014;60:311-319. [PMID: 25381483 DOI: 10.1007/s12026-014-8569-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
325 Piccioli D, Tavarini S, Nuti S, Colombatto P, Brunetto M, Bonino F, Ciccorossi P, Zorat F, Pozzato G, Comar C. Comparable functions of plasmacytoid and monocyte-derived dendritic cells in chronic hepatitis C patients and healthy donors. J Hepatol. 2005;42:61-67. [PMID: 15629508 DOI: 10.1016/j.jhep.2004.09.014] [Cited by in Crossref: 80] [Cited by in F6Publishing: 82] [Article Influence: 4.7] [Reference Citation Analysis]
326 Cusick MF, Yang M, Gill JC, Eckels DD. Naturally occurring CD4+ T-cell epitope variants act as altered peptide ligands leading to impaired helper T-cell responses in hepatitis C virus infection. Hum Immunol 2011;72:379-85. [PMID: 21377503 DOI: 10.1016/j.humimm.2011.02.010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
327 Warshow UM, Riva A, Hegazy D, Thurairajah PH, Kaminski E, Chokshi S, Cramp ME. Cytokine profiles in high risk injection drug users suggests innate as opposed to adaptive immunity in apparent resistance to hepatitis C virus infection: Cytokine profiles in IDU. Journal of Viral Hepatitis 2012;19:501-8. [DOI: 10.1111/j.1365-2893.2011.01574.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
328 Shin EC, Capone S, Cortese R, Colloca S, Nicosia A, Folgori A, Rehermann B. The kinetics of hepatitis C virus-specific CD8 T-cell responses in the blood mirror those in the liver in acute hepatitis C virus infection. J Virol. 2008;82:9782-9788. [PMID: 18667501 DOI: 10.1128/jvi.00475-08] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
329 Lapierre P, Janelle V, Langlois MP, Tarrab E, Charpentier T, Lamarre A. Expression of Viral Antigen by the Liver Leads to Chronic Infection Through the Generation of Regulatory T Cells. Cell Mol Gastroenterol Hepatol 2015;1:325-341.e1. [PMID: 28210682 DOI: 10.1016/j.jcmgh.2015.02.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
330 Bes M, Esteban JI, Casamitjana N, Piron M, Quer J, Cubero M, Puig L, Guardia J, Sauleda S. Hepatitis C virus (HCV)-specific T-cell responses among recombinant immunoblot assay-3-indeterminate blood donors: a confirmatory evidence of HCV exposure. Transfusion 2009;49:1296-305. [DOI: 10.1111/j.1537-2995.2009.02103.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
331 Neumann-Haefelin C, Frick DN, Wang JJ, Pybus OG, Salloum S, Narula GS, Eckart A, Biezynski A, Eiermann T, Klenerman P, Viazov S, Roggendorf M, Thimme R, Reiser M, Timm J. Analysis of the evolutionary forces in an immunodominant CD8 epitope in hepatitis C virus at a population level. J Virol 2008;82:3438-51. [PMID: 18216107 DOI: 10.1128/JVI.01700-07] [Cited by in F6Publishing: 30] [Reference Citation Analysis]
332 Bowen DG, Walker CM. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 2005;436:946-52. [PMID: 16107834 DOI: 10.1038/nature04079] [Cited by in Crossref: 557] [Cited by in F6Publishing: 523] [Article Influence: 32.8] [Reference Citation Analysis]
333 Wodarz D. Mathematical models of immune effector responses to viral infections: Virus control versus the development of pathology. Journal of Computational and Applied Mathematics 2005;184:301-19. [DOI: 10.1016/j.cam.2004.08.016] [Cited by in Crossref: 29] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
334 Cox AL, Mosbruger T, Lauer GM, Pardoll D, Thomas DL, Ray SC. Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C. Hepatology. 2005;42:104-112. [PMID: 15962289 DOI: 10.1002/hep.20749] [Cited by in Crossref: 154] [Cited by in F6Publishing: 167] [Article Influence: 9.1] [Reference Citation Analysis]
335 Gamadia LE, Remmerswaal EBM, Weel JF, Bemelman F, van Lier RAW, Ten Berge IJM. Primary immune responses to human CMV: a critical role for IFN-γ–producing CD4+ T cells in protection against CMV disease. Blood 2003;101:2686-92. [DOI: 10.1182/blood-2002-08-2502] [Cited by in Crossref: 306] [Cited by in F6Publishing: 302] [Article Influence: 16.1] [Reference Citation Analysis]
336 Urbani S, Amadei B, Fisicaro P, Tola D, Orlandini A, Sacchelli L, Mori C, Missale G, Ferrari C. Outcome of acute hepatitis C is related to virus-specific CD4 function and maturation of antiviral memory CD8 responses. Hepatology. 2006;44:126-139. [PMID: 16799989 DOI: 10.1002/hep.21242] [Cited by in Crossref: 139] [Cited by in F6Publishing: 136] [Article Influence: 8.7] [Reference Citation Analysis]
337 Bozzano F, Picciotto A, Costa P, Marras F, Fazio V, Hirsch I, Olive D, Moretta L, De Maria A. Activating NK cell receptor expression/function (NKp30, NKp46, DNAM-1) during chronic viraemic HCV infection is associated with the outcome of combined treatment. Eur J Immunol. 2011;41:2905-2914. [PMID: 21695691 DOI: 10.1002/eji.201041361] [Cited by in Crossref: 59] [Cited by in F6Publishing: 61] [Article Influence: 5.4] [Reference Citation Analysis]
338 Ulsenheimer A, Lucas M, Seth NP, Tilman Gerlach J, Gruener NH, Loughry A, Pape GR, Wucherpfennig KW, Diepolder HM, Klenerman P. Transient immunological control during acute hepatitis C virus infection: ex vivo analysis of helper T-cell responses. J Viral Hepat 2006;13:708-14. [PMID: 16970603 DOI: 10.1111/j.1365-2893.2006.00747.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 1.9] [Reference Citation Analysis]
339 Walewska-Zielecka B, Madalinski K, Jablonska J, Godzik P, Cielecka-Kuszyk J, Litwinska B. Composition of inflammatory infiltrate and its correlation with HBV/HCV antigen expression. World J Gastroenterol 2008; 14(25): 4040-4046 [PMID: 18609688 DOI: 10.3748/wjg.14.4040] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
340 Racanelli V, Rehermann B. Hepatitis C virus infection: when silence is deception. Trends Immunol. 2003;24:456-464. [PMID: 12909460 DOI: 10.1016/s1471-4906(03)00178-9] [Cited by in Crossref: 77] [Cited by in F6Publishing: 28] [Article Influence: 4.1] [Reference Citation Analysis]
341 Shrivastava S, Wilson E, Poonia B, Tang L, Osinusi A, Kohli A, Kottilil S. Augmentation of hepatitis C virus-specific immunity and sustained virologic response. J Viral Hepat 2017;24:742-9. [PMID: 28267900 DOI: 10.1111/jvh.12702] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
342 Hartlage AS, Kapoor A. Hepatitis C Virus Vaccine Research: Time to Put Up or Shut Up. Viruses 2021;13:1596. [PMID: 34452460 DOI: 10.3390/v13081596] [Reference Citation Analysis]
343 Irshad M. Retracted: Genetic diversity in hepatitis C virus (HCV): A brief review. Rev Med Virol 2008;19. [PMID: 19089864 DOI: 10.1002/rmv.603] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.1] [Reference Citation Analysis]
344 Jensen T, Gottwein J, Scheel T, Hoegh A, Eugen‐olsen J, Bukh J. Highly Efficient JFH1‐Based Cell‐Culture System for Hepatitis C Virus Genotype 5a: Failure of Homologous Neutralizing‐Antibody Treatment to Control Infection. J INFECT DIS 2008;198:1756-65. [DOI: 10.1086/593021] [Cited by in Crossref: 84] [Cited by in F6Publishing: 84] [Article Influence: 6.0] [Reference Citation Analysis]
345 Kemming J, Reeves E, Nitschke K, Widmeier V, Emmerich F, Hermle T, Gostick E, Walker A, Timm J, Price DA, Hofmann M, Thimme R, James E, Neumann-Haefelin C. ERAP1 allotypes shape the epitope repertoire of virus-specific CD8+ T cell responses in acute hepatitis C virus infection. J Hepatol 2019;70:1072-81. [PMID: 30769005 DOI: 10.1016/j.jhep.2019.01.034] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
346 Huang MH, Jiang JD, Peng ZG. Recent advances in the anti-HCV mechanisms of interferon. Acta Pharmaceutica Sinica B. 2014;4:241-247. [PMID: 26579391 DOI: 10.1016/j.apsb.2014.06.010] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
347 Logvinoff C, Major ME, Oldach D, Heyward S, Talal A, Balfe P, Feinstone SM, Alter H, Rice CM, McKeating JA. Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc Natl Acad Sci USA. 2004;101:10149-10154. [PMID: 15220475 DOI: 10.1073/pnas.0403519101] [Cited by in Crossref: 303] [Cited by in F6Publishing: 298] [Article Influence: 16.8] [Reference Citation Analysis]
348 Movita D, van de Garde MD, Biesta P, Kreefft K, Haagmans B, Zuniga E, Herschke F, De Jonghe S, Janssen HL, Gama L, Boonstra A, Vanwolleghem T. Inflammatory monocytes recruited to the liver within 24 hours after virus-induced inflammation resemble Kupffer cells but are functionally distinct. J Virol 2015;89:4809-17. [PMID: 25673700 DOI: 10.1128/JVI.03733-14] [Cited by in Crossref: 28] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
349 Chen A, Wang L, Zhang J, Zou L, Jia Z, Zhou W, Wan Y, Wu Y. H-2 Kd-restricted hepatitis B virus-derived epitope whose specific CD8+ T lymphocytes can produce gamma interferon without cytotoxicity. J Virol 2005;79:5568-76. [PMID: 15827171 DOI: 10.1128/JVI.79.9.5568-5576.2005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
350 Accapezzato D, Francavilla V, Paroli M, Casciaro M, Chircu LV, Cividini A, Abrignani S, Mondelli MU, Barnaba V. Hepatic expansion of a virus-specific regulatory CD8(+) T cell population in chronic hepatitis C virus infection. J Clin Invest. 2004;113:963-972. [PMID: 15057302 DOI: 10.1172/jci200420515] [Cited by in Crossref: 235] [Cited by in F6Publishing: 4] [Article Influence: 13.1] [Reference Citation Analysis]
351 Sung PS, Racanelli V, Shin EC. CD8(+) T-Cell Responses in Acute Hepatitis C Virus Infection. Front Immunol 2014;5:266. [PMID: 24936203 DOI: 10.3389/fimmu.2014.00266] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
352 Gao B, Hong F, Radaeva S. Host factors and failure of interferon-alpha treatment in hepatitis C virus. Hepatology. 2004;39:880-890. [PMID: 15057887 DOI: 10.1002/hep.20139] [Cited by in Crossref: 120] [Cited by in F6Publishing: 115] [Article Influence: 6.7] [Reference Citation Analysis]
353 Huang Y, Chen XC, Konduri M, Fomina N, Lu J, Jin L, Kolykhalov A, Tan SL. Mechanistic link between the anti-HCV effect of interferon gamma and control of viral replication by a Ras-MAPK signaling cascade. Hepatology 2006;43:81-90. [PMID: 16374867 DOI: 10.1002/hep.21011] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 2.1] [Reference Citation Analysis]
354 Wang Y, Keck ZY, Foung SK. Neutralizing antibody response to hepatitis C virus. Viruses. 2011;3:2127-2145. [PMID: 22163337 DOI: 10.3390/v3112127] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 4.6] [Reference Citation Analysis]
355 Strickland GT. Liver disease in Egypt: Hepatitis C superseded schistosomiasis as a result of iatrogenic and biological factors. Hepatology 2006;43:915-22. [DOI: 10.1002/hep.21173] [Cited by in Crossref: 161] [Cited by in F6Publishing: 136] [Article Influence: 10.1] [Reference Citation Analysis]
356 Li S, Gowans EJ, Chougnet C, Plebanski M, Dittmer U. Natural regulatory T cells and persistent viral infection. J Virol 2008;82:21-30. [PMID: 17855537 DOI: 10.1128/JVI.01768-07] [Cited by in Crossref: 116] [Cited by in F6Publishing: 69] [Article Influence: 7.7] [Reference Citation Analysis]
357 Seal KH, Monto A, Dove L, Shen H, Vittinghoff E, Tracy D, Miller E, Lau E, Wright TL. The Association of Human Immunodeficiency Virus Infection with Spontaneously Resolved Hepatitis C Virus Infection and Level of Viremia Among Injection Drug Users. Dig Dis Sci 2007;52:3423-30. [DOI: 10.1007/s10620-006-9277-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
358 van de Laar TJ, Matthews GV, Prins M, Danta M. Acute hepatitis C in HIV-infected men who have sex with men: an emerging sexually transmitted infection. AIDS. 2010;24:1799-1812. [PMID: 20601854 DOI: 10.1097/qad.0b013e32833c11a5] [Cited by in Crossref: 180] [Cited by in F6Publishing: 69] [Article Influence: 16.4] [Reference Citation Analysis]
359 Lang PA, Meryk A, Pandyra AA, Brenner D, Brüstle A, Xu HC, Merches K, Lang F, Khairnar V, Sharma P, Funkner P, Recher M, Shaabani N, Duncan GS, Duhan V, Homey B, Ohashi PS, Häussinger D, Knolle PA, Honke N, Mak TW, Lang KS. Toso regulates differentiation and activation of inflammatory dendritic cells during persistence-prone virus infection. Cell Death Differ 2015;22:164-73. [PMID: 25257173 DOI: 10.1038/cdd.2014.138] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
360 Barrett L, Gallant M, Howley C, Ian Bowmer M, Hirsch G, Peltekian K, Grant M. Stronger hepatitis C virus-specific CD8+ T-cell responses in HIV coinfection. J Viral Hepat 2011;18:170-80. [PMID: 20497309 DOI: 10.1111/j.1365-2893.2010.01293.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
361 Mengshol JA, Golden-mason L, Rosen HR. Mechanisms of Disease: HCV-induced liver injury. Nat Rev Gastroenterol Hepatol 2007;4:622-34. [DOI: 10.1038/ncpgasthep0961] [Cited by in Crossref: 72] [Cited by in F6Publishing: 71] [Article Influence: 4.8] [Reference Citation Analysis]
362 Fogle JE, Tompkins WA, Tompkins MB. CD4+CD25+ T regulatory cells from FIV+ cats induce a unique anergic profile in CD8+ lymphocyte targets. Retrovirology 2010;7:97. [PMID: 21092106 DOI: 10.1186/1742-4690-7-97] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
363 Kobayashi K, Ishii M, Shiina M, Ueno Y, Kondo Y, Kanno A, Miyazaki Y, Yamamoto T, Kobayashi T, Niitsuma H, Kikumoto Y, Takizawa H, Shimosegawa T. Interferon-gamma is produced by CD8 T cells in response to HLA-A24-restricted hepatitis C virus epitopes after sustained virus loss. Clin Exp Immunol 2005;141:81-8. [PMID: 15958073 DOI: 10.1111/j.1365-2249.2005.02018.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
364 Polyak SJ. Resistance of hepatitis C virus to the host antiviral response. Future Virology 2006;1:89-98. [DOI: 10.2217/17460794.1.1.89] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
365 Dring MM, Morrison MH, McSharry BP, Guinan KJ, Hagan R, O’Farrelly C, Gardiner CM. Innate immune genes synergize to predict increased risk of chronic disease in hepatitis C virus infection. Proc Natl Acad Sci USA. 2011;108:5736-5741. [PMID: 21402922 DOI: 10.1073/pnas.1016358108] [Cited by in Crossref: 101] [Cited by in F6Publishing: 96] [Article Influence: 9.2] [Reference Citation Analysis]
366 Schlaphoff V, Lunemann S, Suneetha PV, Jaroszewicz J, Grabowski J, Dietz J, Helfritz F, Bektas H, Sarrazin C, Manns MP, Cornberg M, Wedemeyer H. Dual function of the NK cell receptor 2B4 (CD244) in the regulation of HCV-specific CD8+ T cells. PLoS Pathog 2011;7:e1002045. [PMID: 21625589 DOI: 10.1371/journal.ppat.1002045] [Cited by in Crossref: 86] [Cited by in F6Publishing: 86] [Article Influence: 7.8] [Reference Citation Analysis]
367 Zeisel MB, Fafi-Kremer S, Fofana I, Barth H, Stoll-Keller F, Doffoël M, Baumert TF. Neutralizing antibodies in hepatitis C virus infection. World J Gastroenterol 2007; 13(36): 4824-4830 [PMID: 17828813 DOI: 10.3748/wjg.v13.i36.4824] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 30] [Article Influence: 2.2] [Reference Citation Analysis]
368 Yao ZQ, Waggoner SN, Cruise MW, Hall C, Xie X, Oldach DW, Hahn YS. SOCS1 and SOCS3 are targeted by hepatitis C virus core/gC1qR ligation to inhibit T-cell function. J Virol 2005;79:15417-29. [PMID: 16306613 DOI: 10.1128/JVI.79.24.15417-15429.2005] [Cited by in Crossref: 30] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
369 Boni C, Amadei B, Urbani S, Fisicaro P, Zerbini A, Mori C, Missale G, Bertoni R, Azzurri A, Del Prete G, Ferrari C. Antiviral CD8-mediated responses in chronic HCV carriers with HBV superinfection. Hepatology 2004;40:289-99. [DOI: 10.1002/hep.20332] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
370 Gholizadeh M, Khanahmad H, Memarnejadian A, Aghasadeghi MR, Roohvand F, Sadat SM, Cohan RA, Nazemi A, Motevalli F, Asgary V, Arezumand R. Design and expression of fusion protein consists of HBsAg and Polyepitope of HCV as an HCV potential vaccine. Adv Biomed Res 2015;4:243. [PMID: 26682209 DOI: 10.4103/2277-9175.168610] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
371 Hammond T, Lee S, Watson MW, Flexman JP, Cheng W, Fernandez S, Price P. Toll-like receptor (TLR) expression on CD4+ and CD8+ T-cells in patients chronically infected with hepatitis C virus. Cell Immunol 2010;264:150-5. [PMID: 20579979 DOI: 10.1016/j.cellimm.2010.06.001] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
372 Spada E, Sagliocca L, Sourdis J, Garbuglia AR, Poggi V, De Fusco C, Mele A. Use of the minimum spanning tree model for molecular epidemiological investigation of a nosocomial outbreak of hepatitis C virus infection. J Clin Microbiol 2004;42:4230-6. [PMID: 15365016 DOI: 10.1128/JCM.42.9.4230-4236.2004] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 1.8] [Reference Citation Analysis]
373 Luciani F, Alizon S. The evolutionary dynamics of a rapidly mutating virus within and between hosts: the case of hepatitis C virus. PLoS Comput Biol 2009;5:e1000565. [PMID: 19911046 DOI: 10.1371/journal.pcbi.1000565] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 2.5] [Reference Citation Analysis]
374 Gewaid H, Mesalam AA, Ibrahim AA, Abdel Shafy DN, Abdel Shafy RN, Emara N, Hamdy SM, Gewaid M, Bahgat MM. Establishment of a platform for molecular and immunological characterization of the RNA-dependent-RNA-polymerase NS5B of an Egyptian HCV isolate. J Med Virol 2018;90:545-58. [PMID: 29064582 DOI: 10.1002/jmv.24977] [Reference Citation Analysis]
375 Spengler U, Nischalke HD, Nattermann J, Strassburg CP. Between Scylla and Charybdis: The role of the human immune system in the pathogenesis of hepatitis C. World J Gastroenterol 2013; 19(44): 7852-7866 [PMID: 24307779 DOI: 10.3748/wjg.v19.i44.7852] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
376 Xiong H, Huang J, Rong X, Zhang M, Huang K, Xu R, Wang M, Li C, Liao Q, Xia W, Luo G, Ye X, Lu L, Fu Y, Guo T, Nelson K. HLA-B alleles B*15:01 and B*15:02: opposite association with hepatitis C virus infection in Chinese voluntary blood donors. Intervirology 2015;58:80-7. [PMID: 25677350 DOI: 10.1159/000369209] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
377 Crispe IN. APC licensing and CD4+T cell help in liver-stage malaria. Front Microbiol 2014;5:617. [PMID: 25426113 DOI: 10.3389/fmicb.2014.00617] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
378 Lang Kuhs KA, Toporovski R, Ginsberg AA, Olsen AL, Shedlock DJ, Morrow MP, Yan J, Wells RG, Weiner DB. Peripheral immunization induces functional intrahepatic hepatitis C specific immunity following selective retention of vaccine-specific CD8 T cells by the liver. Hum Vaccin 2011;7:1326-35. [PMID: 22108033 DOI: 10.4161/hv.7.12.18279] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
379 Penna A, Missale G, Lamonaca V, Pilli M, Mori C, Zanelli P, Cavalli A, Elia G, Ferrari C. Intrahepatic and circulating HLA class II-restricted, hepatitis C virus-specific T cells: functional characterization in patients with chronic hepatitis C. Hepatology. 2002;35:1225-1236. [PMID: 11981773 DOI: 10.1053/jhep.2002.33153] [Cited by in Crossref: 57] [Cited by in F6Publishing: 53] [Article Influence: 2.9] [Reference Citation Analysis]
380 Spear TT, Riley TP, Lyons GE, Callender GG, Roszkowski JJ, Wang Y, Simms PE, Scurti GM, Foley KC, Murray DC, Hellman LM, McMahan RH, Iwashima M, Garrett-Mayer E, Rosen HR, Baker BM, Nishimura MI. Hepatitis C virus-cross-reactive TCR gene-modified T cells: a model for immunotherapy against diseases with genomic instability. J Leukoc Biol 2016;100:545-57. [PMID: 26921345 DOI: 10.1189/jlb.2A1215-561R] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
381 Katsounas A, Schlaak JF, Lempicki RA. CCL5: a double-edged sword in host defense against the hepatitis C virus. Int Rev Immunol 2011;30:366-78. [PMID: 22053974 DOI: 10.3109/08830185.2011.593105] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
382 He X, Greenberg HB. CD8 + T-Cell Response Against Hepatitis C Virus. Viral Immunology 2002;15:121-31. [DOI: 10.1089/088282402317340279] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.5] [Reference Citation Analysis]
383 Kuprianov VV, Nikolaeva LI, Zykova AA, Dedova AV, Grishechkin AE, Kapustin IV, Kotlyarov RY, Ravin NV. Combination of three adjuvants enhances the immunogenicity of a recombinant protein containing the CTL epitopes of non-structural proteins of hepatitis C virus. Virus Res 2020;284:197984. [PMID: 32325116 DOI: 10.1016/j.virusres.2020.197984] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
384 Szabo G, Dolganiuc A. HCV Immunopathogenesis: Virus-Induced Strategies against Host Immunity. Clinics in Liver Disease 2006;10:753-71. [DOI: 10.1016/j.cld.2006.08.028] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
385 Stehbens WE. Oxidative stress in viral hepatitis and AIDS. Exp Mol Pathol. 2004;77:121-132. [PMID: 15351235 DOI: 10.1016/j.yexmp.2004.04.007] [Cited by in Crossref: 83] [Cited by in F6Publishing: 73] [Article Influence: 4.6] [Reference Citation Analysis]
386 Liu X, Guan JH, Jiang BC, Li ZS, Zhu GZ. Toll-Like Receptor 2 Modulates the Balance of Regulatory T Cells and T Helper 17 Cells in Chronic Hepatitis C. Viral Immunol 2016;29:322-31. [PMID: 27082819 DOI: 10.1089/vim.2016.0013] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
387 Chang KM. Immunopathogenesis of hepatitis C virus infection. Clin Liver Dis. 2003;7:89-105. [PMID: 12691460 DOI: 10.1016/S1089-3261(02)00068-5] [Cited by in Crossref: 65] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
388 Kamal SM. Hepatitis C Treatment in the Era of Direct-Acting Antiviral Agents. Hepatitis C in Developing Countries. Elsevier; 2018. pp. 209-46. [DOI: 10.1016/b978-0-12-803233-6.00017-5] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
389 Nellore A, Fishman JA. NK cells, innate immunity and hepatitis C infection after liver transplantation. Clin Infect Dis. 2011;52:369-377. [PMID: 21217184 DOI: 10.1093/cid/ciq156] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
390 Tarantino G, Marco VD, Petta S, Almasio PL, Barbaria F, Licata A, Bosco GL, Tripodo C, Stefano RD, Craxì A. Serum BLyS/BAFF predicts the outcome of acute hepatitis C virus infection. Journal of Viral Hepatitis 2009;16:397-405. [DOI: 10.1111/j.1365-2893.2009.01093.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
391 Page K, Osburn W, Evans J, Hahn JA, Lum P, Asher A, Delwart E, Tobler L, Cox AL, Busch MP. Frequent longitudinal sampling of hepatitis C virus infection in injection drug users reveals intermittently detectable viremia and reinfection. Clin Infect Dis 2013;56:405-13. [PMID: 23090930 DOI: 10.1093/cid/cis921] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
392 Leroux-Roels G. Development of prophylactic and therapeutic vaccines against hepatitis C virus. Expert Rev Vaccines 2005;4:351-71. [PMID: 16026249 DOI: 10.1586/14760584.4.3.351] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
393 Burke Schinkel SC, Carrasco-Medina L, Cooper CL, Crawley AM. Generalized Liver- and Blood-Derived CD8+ T-Cell Impairment in Response to Cytokines in Chronic Hepatitis C Virus Infection. PLoS One 2016;11:e0157055. [PMID: 27315061 DOI: 10.1371/journal.pone.0157055] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
394 Wietzke-braun P, Maouzi AB, M??nhardt LB, Bickeb??ller H, Ramadori G, Mihm S. Interferon regulatory factor-1 promoter polymorphism and the outcome of hepatitis C virus infection: . European Journal of Gastroenterology & Hepatology 2006;18:991-7. [DOI: 10.1097/01.meg.0000224478.89545.76] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 1.3] [Reference Citation Analysis]
395 Weseslindtner L, Neumann-haefelin C, Viazov S, Haberstroh A, Kletzmayr J, Aberle JH, Timm J, Ross SR, Klauser-braun R, Baumert TF, Roggendorf M, Thimme R, Holzmann H. Acute infection with a single hepatitis C virus strain in dialysis patients: Analysis of adaptive immune response and viral variability. Journal of Hepatology 2009;50:693-704. [DOI: 10.1016/j.jhep.2008.11.023] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
396 Jagannathan P, Osborne CM, Royce C, Manion MM, Tilton JC, Li L, Fischer S, Hallahan CW, Metcalf JA, McLaughlin M, Pipeling M, McDyer JF, Manley TJ, Meier JL, Altman JD, Hertel L, Davey RT Jr, Connors M, Migueles SA. Comparisons of CD8+ T cells specific for human immunodeficiency virus, hepatitis C virus, and cytomegalovirus reveal differences in frequency, immunodominance, phenotype, and interleukin-2 responsiveness. J Virol 2009;83:2728-42. [PMID: 19129459 DOI: 10.1128/JVI.02128-08] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 2.8] [Reference Citation Analysis]
397 Meyer MF, Lehmann M, Cornberg M, Wiegand J, Manns MP, Klade C, Wedemeyer H. Clearance of low levels of HCV viremia in the absence of a strong adaptive immune response. Virol J 2007;4:58. [PMID: 17562015 DOI: 10.1186/1743-422X-4-58] [Cited by in Crossref: 32] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
398 Davenport MP, Belz GT, Ribeiro RM. The race between infection and immunity: how do pathogens set the pace? Trends Immunol 2009;30:61-6. [PMID: 19138564 DOI: 10.1016/j.it.2008.11.001] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
399 Schulze Zur Wiesch J, Lauer GM, Timm J, Kuntzen T, Neukamm M, Berical A, Jones AM, Nolan BE, Longworth SA, Kasprowicz V, McMahon C, Wurcel A, Lohse AW, Lewis-Ximenez LL, Chung RT, Kim AY, Allen TM, Walker BD. Immunologic evidence for lack of heterologous protection following resolution of HCV in patients with non-genotype 1 infection. Blood 2007;110:1559-69. [PMID: 17475911 DOI: 10.1182/blood-2007-01-069583] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 1.5] [Reference Citation Analysis]
400 Zabaleta A, Riezu-Boj JI, Larrea E, Villanueva L, Lasarte JJ, Guruceaga E, Fisicaro P, Ezzikouri S, Missale G, Ferrari C. Gene expression analysis during acute hepatitis C virus infection associates dendritic cell activation with viral clearance. J Med Virol. 2016;88:843-851. [PMID: 26447929 DOI: 10.1002/jmv.24399] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
401 Jacene HA, Stearns V, Wahl RL. Lymphadenopathy Resulting From Acute Hepatitis C Infection Mimicking Metastatic Breast Carcinoma on FDG PET/CT: . Clinical Nuclear Medicine 2006;31:379-81. [DOI: 10.1097/01.rlu.0000222675.10765.14] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
402 Oldach D. Multidose jeopardy: HCV transmission risk and management of acute HCV in hospital settings: Multidose jeopardy: HCV transmission risk and management of acute HCV in hospital settings. Hepatology 2002;36:1020-1. [DOI: 10.1053/jhep.2002.36777] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
403 Lee S, Hammond T, Watson MW, Flexman JP, Cheng W, Fernandez S, Price P. Could a loss of memory T cells limit responses to hepatitis C virus (HCV) antigens in blood leucocytes from patients chronically infected with HCV before and during pegylated interferon-alpha and ribavirin therapy? Clin Exp Immunol 2010;161:118-26. [PMID: 20408862 DOI: 10.1111/j.1365-2249.2010.04141.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
404 Lang K, Weiner DB. Immunotherapy for HCV infection: next steps. Expert Rev Vaccines 2008;7:915-23. [PMID: 18767942 DOI: 10.1586/14760584.7.7.915] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
405 Piazzolla G, Nuzzaci M, Tortorella C, Panella E, Natilla A, Boscia D, De Stradis A, Piazzolla P, Antonaci S. Immunogenic Properties of a Chimeric Plant Virus Expressing a Hepatitis C Virus (HCV)-Derived Epitope: New Prospects for an HCV Vaccine. J Clin Immunol 2005;25:142-52. [DOI: 10.1007/s10875-005-2820-4] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 1.8] [Reference Citation Analysis]
406 Plauzolles A, Lucas M, Gaudieri S. Influence of host resistance on viral adaptation: hepatitis C virus as a case study. Infect Drug Resist 2015;8:63-74. [PMID: 25897250 DOI: 10.2147/IDR.S49891] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
407 Rallón NI, Soriano V, Benito JM. [Adaptive cell immune response against the hepatitis C virus infection]. Med Clin (Barc) 2007;129:469-76. [PMID: 17953913 DOI: 10.1157/13111005] [Reference Citation Analysis]
408 Dahari H, Major M, Zhang X, Mihalik K, Rice CM, Perelson AS, Feinstone SM, Neumann AU. Mathematical modeling of primary hepatitis C infection: Noncytolytic clearance and early blockage of virion production. Gastroenterology 2005;128:1056-66. [DOI: 10.1053/j.gastro.2005.01.049] [Cited by in Crossref: 81] [Cited by in F6Publishing: 71] [Article Influence: 4.8] [Reference Citation Analysis]
409 Kim AY, Chung RT. Coinfection with HIV-1 and HCV-a one-two punch. Gastroenterology. 2009;137:795-814. [PMID: 19549523 DOI: 10.1053/j.gastro.2009.06.040] [Cited by in Crossref: 125] [Cited by in F6Publishing: 112] [Article Influence: 9.6] [Reference Citation Analysis]
410 Masavuli MG, Wijesundara DK, Underwood A, Christiansen D, Earnest-Silveira L, Bull R, Torresi J, Gowans EJ, Grubor-Bauk B. A Hepatitis C Virus DNA Vaccine Encoding a Secreted, Oligomerized Form of Envelope Proteins Is Highly Immunogenic and Elicits Neutralizing Antibodies in Vaccinated Mice. Front Immunol. 2019;10:1145. [PMID: 31178869 DOI: 10.3389/fimmu.2019.01145] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
411 Hong B, Lee SH, Song XT, Jones L, Machida K, Huang XF, Chen SY. A super TLR agonist to improve efficacy of dendritic cell vaccine in induction of anti-HCV immunity. PLoS One 2012;7:e48614. [PMID: 23144910 DOI: 10.1371/journal.pone.0048614] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
412 Kumar SRP, Hoffman BE, Terhorst C, de Jong YP, Herzog RW. The Balance between CD8+ T Cell-Mediated Clearance of AAV-Encoded Antigen in the Liver and Tolerance Is Dependent on the Vector Dose. Mol Ther 2017;25:880-91. [PMID: 28284982 DOI: 10.1016/j.ymthe.2017.02.014] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 5.8] [Reference Citation Analysis]
413 Wongyanin P, Buranapraditkul S, Yoo D, Thanawongnuwech R, Roth JA, Suradhat S. Role of porcine reproductive and respiratory syndrome virus nucleocapsid protein in induction of interleukin-10 and regulatory T-lymphocytes (Treg). J Gen Virol 2012;93:1236-46. [PMID: 22422061 DOI: 10.1099/vir.0.040287-0] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 5.1] [Reference Citation Analysis]
414 Elkington R, Walker S, Crough T, Menzies M, Tellam J, Bharadwaj M, Khanna R. Ex vivo profiling of CD8+-T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers. J Virol 2003;77:5226-40. [PMID: 12692225 DOI: 10.1128/jvi.77.9.5226-5240.2003] [Cited by in Crossref: 241] [Cited by in F6Publishing: 84] [Article Influence: 12.7] [Reference Citation Analysis]
415 Inchauspé G, Michel ML. Vaccines and immunotherapies against hepatitis B and hepatitis C viruses. J Viral Hepat. 2007;14 Suppl 1:97-103. [PMID: 17958650 DOI: 10.1111/j.1365-2893.2007.00922.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 2.2] [Reference Citation Analysis]
416 Day CL, Seth NP, Lucas M, Appel H, Gauthier L, Lauer GM, Robbins GK, Szczepiorkowski ZM, Casson DR, Chung RT, Bell S, Harcourt G, Walker BD, Klenerman P, Wucherpfennig KW. Ex vivo analysis of human memory CD4 T cells specific for hepatitis C virus using MHC class II tetramers. J Clin Invest 2003;112:831-42. [PMID: 12975468 DOI: 10.1172/JCI18509] [Cited by in Crossref: 10] [Cited by in F6Publishing: 122] [Article Influence: 0.5] [Reference Citation Analysis]
417 Hassan MI, Kassim SK, Ahmad MI, Fawzy S. Antiproliferative effect of hepatitis C virus on mitogen-stimulated peripheral blood mononuclear cells: potential role in viral persistence in Egyptian patients. Clin Biochem 2007;40:1173-9. [PMID: 17888896 DOI: 10.1016/j.clinbiochem.2007.07.012] [Reference Citation Analysis]
418 Yong KSM, Her Z, Chen Q. Humanized Mouse Models for the Study of Hepatitis C and Host Interactions. Cells 2019;8:E604. [PMID: 31213010 DOI: 10.3390/cells8060604] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
419 Lasarte J. A recombinant adenovirus encoding hepatitis C virus core and E1 proteins protects mice against cytokine-induced liver damage. Hepatology 2003;37:461-70. [DOI: 10.1053/jhep.2003.50073] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.0] [Reference Citation Analysis]
420 Gallegos-Orozco JF, Arenas JI, Vargas HE, Kibler KV, Wilkinson JK, Nowicki M, Radkowski M, Nasseri J, Rakela J, Laskus T. Selection of different 5' untranslated region hepatitis C virus variants during post-transfusion and post-transplantation infection. J Viral Hepat 2006;13:489-98. [PMID: 16792543 DOI: 10.1111/j.1365-2893.2006.00724.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
421 Mosley JW, Operskalski EA, Tobler LH, Buskell ZJ, Andrews WW, Phelps B, Dockter J, Giachetti C, Seeff LB, Busch MP; Transfusion-transmitted Viruses Study and Retrovirus Epidemiology Donor Study Groups. The course of hepatitis C viraemia in transfusion recipients prior to availability of antiviral therapy. J Viral Hepat 2008;15:120-8. [PMID: 18184195 DOI: 10.1111/j.1365-2893.2007.00900.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 2.8] [Reference Citation Analysis]
422 Folgori A, Spada E, Pezzanera M, Ruggeri L, Mele A, Garbuglia AR, Perrone MP, Del Porto P, Piccolella E, Cortese R. Early impairment of hepatitis C virus specific T cell proliferation during acute infection leads to failure of viral clearance. Gut. 2006;55:1012-1019. [PMID: 16484505 DOI: 10.1136/gut.2005.080077] [Cited by in Crossref: 60] [Cited by in F6Publishing: 60] [Article Influence: 3.8] [Reference Citation Analysis]
423 Kang W, Sung PS, Park SH, Yoon S, Chang DY, Kim S, Han KH, Kim JK, Rehermann B, Chwae YJ, Shin EC. Hepatitis C virus attenuates interferon-induced major histocompatibility complex class I expression and decreases CD8+ T cell effector functions. Gastroenterology 2014;146:1351-60.e1-4. [PMID: 24486950 DOI: 10.1053/j.gastro.2014.01.054] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
424 Szabados T, Bakács T. SUFFICIENT TO RECOGNIZE SELF TO ATTACK NON-SELF: BLUEPRINT FOR A ONE-SIGNAL T CELL MODEL. J Biol Syst 2011;19:299-317. [DOI: 10.1142/s0218339011003919] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
425 Zuniga EI, Macal M, Lewis GM, Harker JA. Innate and Adaptive Immune Regulation During Chronic Viral Infections. Annu Rev Virol 2015;2:573-97. [PMID: 26958929 DOI: 10.1146/annurev-virology-100114-055226] [Cited by in Crossref: 64] [Cited by in F6Publishing: 73] [Article Influence: 9.1] [Reference Citation Analysis]
426 Ichiki Y, He XS, Shimoda S, Ishibashi H, Keeffe EB, Rossaro L, Gershwin ME. T cell immunity in hepatitis B and hepatitis C virus infection: implications for autoimmunity. Autoimmun Rev 2005;4:82-95. [PMID: 15722254 DOI: 10.1016/j.autrev.2004.12.003] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
427 Pachiadakis I, Chokshi S, Cooksley H, Farmakiotis D, Sarrazin C, Zeuzem S, Michalak TI, Naoumov NV. Early viraemia clearance during antiviral therapy of chronic hepatitis C improves dendritic cell functions. Clin Immunol 2009;131:415-25. [PMID: 19303818 DOI: 10.1016/j.clim.2009.02.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
428 Scaggiante R, Chemello L, Rinaldi R, Bartolucci GB, Trevisan A. Acute hepatitis C virus infection in a nurse trainee following a needlestick injury. World J Gastroenterol 2013; 19(4): 581-585 [PMID: 23382640 DOI: 10.3748/wjg.v19.i4.581] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
429 Bradley JS. Hepatitis. Infectious Diseases of the Fetus and Newborn Infant. Elsevier; 2006. pp. 823-43. [DOI: 10.1016/b0-72-160537-0/50027-x] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
430 van den Berg CH, Ruys TA, Nanlohy NM, Geerlings SE, van der Meer JT, Mulder JW, Lange JA, van Baarle D. Comprehensive longitudinal analysis of hepatitis C virus (HCV)-specific T cell responses during acute HCV infection in the presence of existing HIV-1 infection. J Viral Hepat 2009;16:239-48. [PMID: 19222746 DOI: 10.1111/j.1365-2893.2009.01076.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
431 Amjad M, Abdel-Haq N, Faisal M, Kamal M, Moudgal V. Decreased interferon-alpha production and impaired regulatory function of plasmacytoid dendritic cells induced by the hepatitis C virus NS 5 protein. Microbiol Immunol 2008;52:499-507. [PMID: 18822084 DOI: 10.1111/j.1348-0421.2008.00067.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
432 Zeisel MB, Fafi-Kremer S, Robinet E, Habersetzer F, Baumert TF, Stoll-Keller F. Adaptive immunity to hepatitis C virus. Viruses 2009;1:276-97. [PMID: 21994550 DOI: 10.3390/v1020276] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
433 Reluga TC, Dahari H, Perelson AS. ANALYSIS OF HEPATITIS C VIRUS INFECTION MODELS WITH HEPATOCYTE HOMEOSTASIS. SIAM J Appl Math 2009;69:999-1023. [PMID: 19183708 DOI: 10.1137/080714579] [Cited by in Crossref: 31] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
434 Rahman F, Heller T, Sobao Y, Mizukoshi E, Nascimbeni M, Alter H, Herrine S, Hoofnagle J, Liang TJ, Rehermann B. Effects of antiviral therapy on the cellular immune response in acute hepatitis C. Hepatology. 2004;40:87-97. [PMID: 15239090 DOI: 10.1002/hep.20253] [Cited by in Crossref: 95] [Cited by in F6Publishing: 101] [Article Influence: 5.3] [Reference Citation Analysis]
435 Fernandez-Ponce C, Dominguez-Villar M, Aguado E, Garcia-Cozar F. CD4+ primary T cells expressing HCV-core protein upregulate Foxp3 and IL-10, suppressing CD4 and CD8 T cells. PLoS One. 2014;9:e85191. [PMID: 24465502 DOI: 10.1371/journal.pone.0085191] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
436 Pestka JM, Zeisel MB, Bläser E, Schürmann P, Bartosch B, Cosset FL, Patel AH, Meisel H, Baumert J, Viazov S, Rispeter K, Blum HE, Roggendorf M, Baumert TF. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci U S A 2007;104:6025-30. [PMID: 17392433 DOI: 10.1073/pnas.0607026104] [Cited by in Crossref: 370] [Cited by in F6Publishing: 374] [Article Influence: 24.7] [Reference Citation Analysis]
437 Lauer GM, Barnes E, Lucas M, Timm J, Ouchi K, Kim AY, Day CL, Robbins GK, Casson DR, Reiser M. High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection. Gastroenterology. 2004;127:924-936. [PMID: 15362047 DOI: 10.1053/j.gastro.2004.06.015] [Cited by in Crossref: 221] [Cited by in F6Publishing: 221] [Article Influence: 12.3] [Reference Citation Analysis]
438 von Hahn T, Yoon JC, Alter H, Rice CM, Rehermann B, Balfe P, Mckeating JA. Hepatitis C Virus Continuously Escapes From Neutralizing Antibody and T-Cell Responses During Chronic Infection In Vivo. Gastroenterology 2007;132:667-78. [DOI: 10.1053/j.gastro.2006.12.008] [Cited by in Crossref: 297] [Cited by in F6Publishing: 275] [Article Influence: 19.8] [Reference Citation Analysis]
439 Hoofnagle JH. Course and outcome of hepatitis C. Hepatology. 2002;36:S21-S29. [PMID: 12407573 DOI: 10.1002/hep.1840360704] [Cited by in Crossref: 382] [Cited by in F6Publishing: 233] [Article Influence: 19.1] [Reference Citation Analysis]
440 Miyatake H, Kanto T, Inoue M, Sakakibara M, Kaimori A, Yakushijin T, Itose I, Miyazaki M, Kuzushita N, Hiramatsu N, Takehara T, Kasahara A, Hayashi N. Impaired ability of interferon-alpha-primed dendritic cells to stimulate Th1-type CD4 T-cell response in chronic hepatitis C virus infection. J Viral Hepat 2007;14:404-12. [DOI: 10.1111/j.1365-2893.2006.00814.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
441 Averill L, Lee WM, Karandikar NJ. Differential dysfunction in dendritic cell subsets during chronic HCV infection. Clin Immunol. 2007;123:40-49. [PMID: 17239662 DOI: 10.1016/j.clim.2006.12.001] [Cited by in Crossref: 63] [Cited by in F6Publishing: 58] [Article Influence: 4.2] [Reference Citation Analysis]
442 Honegger JR, Kim S, Price AA, Kohout JA, McKnight KL, Prasad MR, Lemon SM, Grakoui A, Walker CM. Loss of immune escape mutations during persistent HCV infection in pregnancy enhances replication of vertically transmitted viruses. Nat Med. 2013;19:1529-1533. [PMID: 24162814 DOI: 10.1038/nm.3351] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 5.2] [Reference Citation Analysis]
443 Shawa IT, Felmlee DJ, Hegazy D, Sheridan DA, Cramp ME. Exploration of potential mechanisms of hepatitis C virus resistance in exposed uninfected intravenous drug users. J Viral Hepat 2017;24:1082-8. [PMID: 28475247 DOI: 10.1111/jvh.12720] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
444 Kuntz M, Goldacker S, Blum HE, Pircher H, Stampf S, Peter HH, Thimme R, Warnatz K. Analysis of bulk and virus-specific CD8+ T cells reveals advanced differentiation of CD8+ T cells in patients with common variable immunodeficiency. Clin Immunol 2011;141:177-86. [PMID: 21873117 DOI: 10.1016/j.clim.2011.07.006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
445 Koziel MJ. Cellular immune responses against hepatitis C virus. Clin Infect Dis. 2005;41 Suppl 1:S25-S31. [PMID: 16265610 DOI: 10.1086/429492] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 2.9] [Reference Citation Analysis]
446 Watanabe T, Bertoletti A, Tanoto TA. PD-1/PD-L1 pathway and T-cell exhaustion in chronic hepatitis virus infection. J Viral Hepat 2010;17:453-8. [PMID: 20487259 DOI: 10.1111/j.1365-2893.2010.01313.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 48] [Article Influence: 0.8] [Reference Citation Analysis]
447 Urbani S, Boni C, Missale G, Elia G, Cavallo C, Massari M, Raimondo G, Ferrari C. Virus-specific CD8+ lymphocytes share the same effector-memory phenotype but exhibit functional differences in acute hepatitis B and C. J Virol. 2002;76:12423-12434. [PMID: 12438568 DOI: 10.1128/jvi.76.24.12423-12434.2002] [Cited by in Crossref: 141] [Cited by in F6Publishing: 57] [Article Influence: 7.1] [Reference Citation Analysis]
448 Franceschini D, Del Porto P, Piconese S, Trella E, Accapezzato D, Paroli M, Morrone S, Piccolella E, Spada E, Mele A, Sidney J, Sette A, Barnaba V. Polyfunctional type-1, -2, and -17 CD8⁺ T cell responses to apoptotic self-antigens correlate with the chronic evolution of hepatitis C virus infection. PLoS Pathog 2012;8:e1002759. [PMID: 22737070 DOI: 10.1371/journal.ppat.1002759] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
449 Spengler U, Nattermann J. Immunopathogenesis in hepatitis C virus cirrhosis. Clin Sci (Lond) 2007;112:141-55. [PMID: 17199558 DOI: 10.1042/CS20060171] [Cited by in Crossref: 59] [Cited by in F6Publishing: 30] [Article Influence: 3.9] [Reference Citation Analysis]
450 Bahgat MM, Ibrahim AA, Abd-Elshafy DN, Mesalam AA, Gewaid HE, Ismaeil AA, El-Waseef AM, Maghraby AS, Barakat AB, El-Far MA. Characterization of NS3 protease from an Egyptian HCV genotype 4a isolate. Arch Virol. 2009;154:1649-1657. [PMID: 19763775 DOI: 10.1007/s00705-009-0500-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
451 Nascimbeni M, Shin EC, Chiriboga L, Kleiner DE, Rehermann B. Peripheral CD4(+)CD8(+) T cells are differentiated effector memory cells with antiviral functions. Blood. 2004;104:478-486. [PMID: 15044252 DOI: 10.1182/blood-2003-12-4395] [Cited by in Crossref: 164] [Cited by in F6Publishing: 163] [Article Influence: 9.1] [Reference Citation Analysis]
452 Gottwein JM, Scheel TK, Callendret B, Li YP, Eccleston HB, Engle RE, Govindarajan S, Satterfield W, Purcell RH, Walker CM, Bukh J. Novel infectious cDNA clones of hepatitis C virus genotype 3a (strain S52) and 4a (strain ED43): genetic analyses and in vivo pathogenesis studies. J Virol 2010;84:5277-93. [PMID: 20200247 DOI: 10.1128/JVI.02667-09] [Cited by in Crossref: 106] [Cited by in F6Publishing: 64] [Article Influence: 8.8] [Reference Citation Analysis]
453 Ma CJ, Ni L, Zhang Y, Zhang CL, Wu XY, Atia AN, Thayer P, Moorman JP, Yao ZQ. PD-1 negatively regulates interleukin-12 expression by limiting STAT-1 phosphorylation in monocytes/macrophages during chronic hepatitis C virus infection. Immunology. 2011;132:421-431. [PMID: 21091911 DOI: 10.1111/j.1365-2567.2010.03382.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 46] [Article Influence: 3.4] [Reference Citation Analysis]
454 Lang PA, Contaldo C, Georgiev P, El-Badry AM, Recher M, Kurrer M, Cervantes-Barragan L, Ludewig B, Calzascia T, Bolinger B. Aggravation of viral hepatitis by platelet-derived serotonin. Nat Med. 2008;14:756-761. [PMID: 18516052 DOI: 10.1038/nm1780] [Cited by in Crossref: 164] [Cited by in F6Publishing: 156] [Article Influence: 11.7] [Reference Citation Analysis]
455 Judge CJ, Sandberg JK, Funderburg NT, Sherman KE, Butt AA, Kang M, Landay AL, Lederman MM, Anthony DD. Brief Report: CD14brightCD16- monocytes and sCD14 level negatively associate with CD4-memory T-cell frequency and predict HCV-decline on therapy. J Acquir Immune Defic Syndr 2016;73:258-62. [PMID: 27258231 DOI: 10.1097/QAI.0000000000001104] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
456 Niesen E, Schmidt J, Flecken T, Thimme R. Suppressive effect of interleukin 10 on priming of naive hepatitis C virus-specific CD8+ T cells. J Infect Dis. 2015;211:821-826. [PMID: 25355941 DOI: 10.1093/infdis/jiu541] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
457 Wilson EB, Brooks DG. The role of IL-10 in regulating immunity to persistent viral infections. Curr Top Microbiol Immunol 2011;350:39-65. [PMID: 20703965 DOI: 10.1007/82_2010_96] [Cited by in Crossref: 30] [Cited by in F6Publishing: 67] [Article Influence: 2.7] [Reference Citation Analysis]
458 Ramalingam RK, Meyer-Olson D, Shoukry NH, Bowen DG, Walker CM, Kalams SA. Kinetic analysis by real-time PCR of hepatitis C virus (HCV)-specific T cells in peripheral blood and liver after challenge with HCV. J Virol 2008;82:10487-92. [PMID: 18715926 DOI: 10.1128/JVI.00588-08] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
459 Vandegrift KJ, Critchlow JT, Kapoor A, Friedman DA, Hudson PJ. Peromyscus as a model system for human hepatitis C: An opportunity to advance our understanding of a complex host parasite system. Semin Cell Dev Biol 2017;61:123-30. [PMID: 27498234 DOI: 10.1016/j.semcdb.2016.07.031] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
460 Lanford RE, Guerra B, Chavez D, Bigger C, Brasky KM, Wang XH, Ray SC, Thomas DL. Cross-genotype immunity to hepatitis C virus. J Virol 2004;78:1575-81. [PMID: 14722311 DOI: 10.1128/jvi.78.3.1575-1581.2004] [Cited by in Crossref: 139] [Cited by in F6Publishing: 73] [Article Influence: 7.7] [Reference Citation Analysis]
461 Tobler LH, Stramer SL, Lee SR, Baggett D, Wright D, Hirschkorn D, Walsh I, Busch MP. Performance of ORTHO HCV core antigen and trak-C assays for detection of viraemia in pre-seroconversion plasma and whole blood donors. Vox Sang 2005;89:201-7. [PMID: 16262752 DOI: 10.1111/j.1423-0410.2005.00687.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
462 Siu L, Foont J, Wands JR. Hepatitis C virus and alcohol. Semin Liver Dis 2009;29:188-99. [PMID: 19387918 DOI: 10.1055/s-0029-1214374] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 3.9] [Reference Citation Analysis]
463 Houghton M, Abrignani S. Prospects for a vaccine against the hepatitis C virus. Nature. 2005;436:961-966. [PMID: 16107836 DOI: 10.1038/nature04081] [Cited by in Crossref: 234] [Cited by in F6Publishing: 208] [Article Influence: 13.8] [Reference Citation Analysis]
464 Liu L, Fisher BE, Thomas DL, Cox AL, Ray SC. Spontaneous clearance of primary acute hepatitis C virus infection correlated with high initial viral RNA level and rapid HVR1 evolution. Hepatology. 2012;55:1684-1691. [PMID: 22234804 DOI: 10.1002/hep.25575] [Cited by in Crossref: 53] [Cited by in F6Publishing: 51] [Article Influence: 5.3] [Reference Citation Analysis]
465 Alberti A, Benvegnù L. Management of hepatitis C. J Hepatol. 2003;38 Suppl 1:S104-S118. [PMID: 12591189 DOI: 10.1016/s0168-8278(03)00008-4] [Cited by in Crossref: 87] [Cited by in F6Publishing: 19] [Article Influence: 4.6] [Reference Citation Analysis]
466 Lokhande MU, Thimme R, Klenerman P, Semmo N. Methodologies for the Analysis of HCV-Specific CD4(+) T Cells. Front Immunol 2015;6:57. [PMID: 25767470 DOI: 10.3389/fimmu.2015.00057] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
467 Sung PS, Bae SH, Jang JW, Song DS, Kim HY, Yoo SH, Park CH, Kwon JH, Song MJ, You CR, Choi JY, Yoon SK. Differences in the patterns and outcomes of enhanced viral replication between hepatitis C virus and hepatitis B virus in patients with hepatocellular carcinoma during transarterial chemolipiodolization. Korean J Hepatol 2011;17:299-306. [PMID: 22310794 DOI: 10.3350/kjhep.2011.17.4.299] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
468 Moenne-Loccoz R, Razafinjatovo C, Habersetzer F, Ananna A, Doffoel M, Wolf P, Gut JP, Baumert T, Stoll-Keller F, Schvoerer E. [Tropism of hepatitis C virus for leukocytes-- importance of the analysis of viral E1 and E2 envelope glycoprotein genes by sequencing]. Pathol Biol (Paris) 2010;58:170-4. [PMID: 19892492 DOI: 10.1016/j.patbio.2009.06.010] [Reference Citation Analysis]
469 Mastroianni CM, Lichtner M, Mascia C, Zuccalà P, Vullo V. Molecular mechanisms of liver fibrosis in HIV/HCV coinfection. Int J Mol Sci 2014;15:9184-208. [PMID: 24865485 DOI: 10.3390/ijms15069184] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 5.9] [Reference Citation Analysis]
470 Seifert U, Liermann H, Racanelli V, Halenius A, Wiese M, Wedemeyer H, Ruppert T, Rispeter K, Henklein P, Sijts A. Hepatitis C virus mutation affects proteasomal epitope processing. J Clin Invest. 2004;114:250-259. [PMID: 15254592 DOI: 10.1172/jci20985] [Cited by in Crossref: 3] [Cited by in F6Publishing: 60] [Article Influence: 0.2] [Reference Citation Analysis]
471 Lapa D, Garbuglia AR, Capobianchi MR, Del Porto P. Hepatitis C Virus Genetic Variability, Human Immune Response, and Genome Polymorphisms: Which Is the Interplay? Cells 2019;8:E305. [PMID: 30987134 DOI: 10.3390/cells8040305] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
472 Szabo G, Chang S, Dolganiuc A. Altered innate immunity in chronic hepatitis C infection: cause or effect? Hepatology. 2007;46:1279-1290. [PMID: 17886338 DOI: 10.1002/hep.21938] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 2.1] [Reference Citation Analysis]
473 Thimme R, Spangenberg H, Blum HE. Bridge over troubled water: Protection against hepatitis C virus persistence?: Bridge Over Troubled Water: Protection Against Hepatitis C Virus Persistence? Hepatology 2002;36:1537-9. [DOI: 10.1002/hep.1840360631] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
474 Tsai S, Sheen I, Chien R, Chu C, Huang H, Chuang Y, Lee T, Liao S, Lin C, Kuo GC, Liaw Y. Activation of Th1 immunity is a common immune mechanism for the successful treatment of hepatitis B and C: Tetramer assay and therapeutic implications. J Biomed Sci 2003;10:120-35. [DOI: 10.1007/bf02256004] [Cited by in Crossref: 43] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
475 Barnes E, Folgori A, Capone S, Swadling L, Aston S, Kurioka A, Meyer J, Huddart R, Smith K, Townsend R. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med. 2012;4:115ra1. [PMID: 22218690 DOI: 10.1126/scitranslmed.3003155] [Cited by in Crossref: 295] [Cited by in F6Publishing: 281] [Article Influence: 29.5] [Reference Citation Analysis]
476 Shen T, Zheng J, Xu C, Liu J, Zhang W, Lu F, Zhuang H. PD-1 expression on peripheral CD8+ TEM/TEMRA subsets closely correlated with HCV viral load in chronic hepatitis C patients. Virol J 2010;7:310. [PMID: 21070674 DOI: 10.1186/1743-422X-7-310] [Cited by in Crossref: 26] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
477 Fuller MJ, Shoukry NH, Gushima T, Bowen DG, Callendret B, Campbell KJ, Hasselschwert DL, Hughes AL, Walker CM. Selection-driven immune escape is not a significant factor in the failure of CD4 T cell responses in persistent hepatitis C virus infection. Hepatology 2010;51:378-87. [PMID: 19918975 DOI: 10.1002/hep.23319] [Cited by in Crossref: 55] [Cited by in F6Publishing: 52] [Article Influence: 4.6] [Reference Citation Analysis]
478 Tawfik AK, Amin AM, Yousef M, El-Sayd NM, Elashry H, Elkadeem M, Abd-Elsalam S. IL-1α correlates with severity of hepatitis C virus-related liver diseases. J Inflamm Res 2018;11:289-95. [PMID: 30022847 DOI: 10.2147/JIR.S166564] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
479 Caraballo Cortés K, Osuch S, Perlejewski K, Pawełczyk A, Kaźmierczak J, Janiak M, Jabłońska J, Nazzal K, Stelmaszczyk-Emmel A, Berak H, Bukowska-Ośko I, Paciorek M, Laskus T, Radkowski M. Expression of programmed cell death protein 1 and T-cell immunoglobulin- and mucin-domain-containing molecule-3 on peripheral blood CD4+CD8+ double positive T cells in patients with chronic hepatitis C virus infection and in subjects who spontaneously cleared the virus. J Viral Hepat 2019;26:942-50. [PMID: 30972915 DOI: 10.1111/jvh.13108] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
480 Polyak SJ. Hepatitis C virus–cell interactions and their role in pathogenesis. Clinics in Liver Disease 2003;7:67-88. [DOI: 10.1016/s1089-3261(02)00075-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
481 Aberle JH, Formann E, Steindl-Munda P, Weseslindtner L, Gurguta C, Perstinger G, Grilnberger E, Laferl H, Dienes HP, Popow-Kraupp T. Prospective study of viral clearance and CD4(+) T-cell response in acute hepatitis C primary infection and reinfection. J Clin Virol. 2006;36:24-31. [PMID: 16483838 DOI: 10.1016/j.jcv.2005.12.010] [Cited by in Crossref: 51] [Cited by in F6Publishing: 50] [Article Influence: 3.2] [Reference Citation Analysis]
482 Forns X, Bukh J, Purcell RH. The challenge of developing a vaccine against hepatitis C virus. J Hepatol. 2002;37:684-695. [PMID: 12399239 DOI: 10.1016/s0168-8278(02)00308-2] [Cited by in Crossref: 57] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
483 Marín MQ, Pérez P, Gómez CE, Sorzano CÓS, Esteban M, García-Arriaza J. Removal of the C6 Vaccinia Virus Interferon-β Inhibitor in the Hepatitis C Vaccine Candidate MVA-HCV Elicited in Mice High Immunogenicity in Spite of Reduced Host Gene Expression. Viruses 2018;10:E414. [PMID: 30096846 DOI: 10.3390/v10080414] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
484 Woollard D. Characterization of HCV-specific Patr class II restricted CD4+ T cell responses in an acutely infected chimpanzee. Hepatology 2003;38:1297-306. [DOI: 10.1053/jhep.2003.50478] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 1.6] [Reference Citation Analysis]
485 Fuster D, Tor J, Rey-Joly C, Muga R. [Pathogenic interactions between alcohol and hepatitis C]. Med Clin (Barc). 2012;138:627-632. [PMID: 21696783 DOI: 10.1016/j.medcli.2011.04.019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
486 Bengsch B, Spangenberg HC, Kersting N, Neumann-Haefelin C, Panther E, von Weizsäcker F, Blum HE, Pircher H, Thimme R. Analysis of CD127 and KLRG1 expression on hepatitis C virus-specific CD8+ T cells reveals the existence of different memory T-cell subsets in the peripheral blood and liver. J Virol. 2007;81:945-953. [PMID: 17079288 DOI: 10.1128/jvi.01354-06] [Cited by in Crossref: 86] [Cited by in F6Publishing: 53] [Article Influence: 5.4] [Reference Citation Analysis]
487 Sheridan I, Pybus OG, Holmes EC, Klenerman P. High-resolution phylogenetic analysis of hepatitis C virus adaptation and its relationship to disease progression. J Virol 2004;78:3447-54. [PMID: 15016867 DOI: 10.1128/jvi.78.7.3447-3454.2004] [Cited by in Crossref: 70] [Cited by in F6Publishing: 32] [Article Influence: 3.9] [Reference Citation Analysis]
488 Scottà C, Garbuglia AR, Ruggeri L, Spada E, Laurenti L, Perrone MP, Girelli G, Mele A, Capobianchi MR, Folgori A. Influence of specific CD4+ T cells and antibodies on evolution of hypervariable region 1 during acute HCV infection. J Hepatol. 2008;48:216-228. [PMID: 18180071 DOI: 10.1016/j.jhep.2007.09.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
489 Choi YS, Lee DH, Shin EC. Relationship between Poor Immunogenicity of HLA-A2-Restricted Peptide Epitopes and Paucity of Naïve CD8(+) T-Cell Precursors in HLA-A2-Transgenic Mice. Immune Netw 2014;14:219-25. [PMID: 25177254 DOI: 10.4110/in.2014.14.4.219] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
490 Spada E, Mele A, Berton A, Ruggeri L, Ferrigno L, Garbuglia AR, Perrone MP, Girelli G, Del Porto P, Piccolella E, Mondelli MU, Amoroso P, Cortese R, Nicosia A, Vitelli A, Folgori A. Multispecific T cell response and negative HCV RNA tests during acute HCV infection are early prognostic factors of spontaneous clearance. Gut. 2004;53:1673-1681. [PMID: 15479691 DOI: 10.1136/gut.2003.037788] [Cited by in Crossref: 72] [Cited by in F6Publishing: 73] [Article Influence: 4.0] [Reference Citation Analysis]
491 Muhanna N, Doron S, Wald O, Horani A, Eid A, Pappo O, Friedman SL, Safadi R. Activation of hepatic stellate cells after phagocytosis of lymphocytes: A novel pathway of fibrogenesis. Hepatology. 2008;48:963-977. [PMID: 18726940 DOI: 10.1002/hep.22413] [Cited by in Crossref: 98] [Cited by in F6Publishing: 92] [Article Influence: 7.0] [Reference Citation Analysis]
492 Harfouch S, Guiguet M, Valantin M, Samri A, Ouazene Z, Slama L, Dominguez S, Simon A, Theodorou I, Thibault V, Autran B. Lack of TGF-β production by hepatitis C virus-specific T cells during HCV acute phase is associated with HCV clearance in HIV coinfection. Journal of Hepatology 2012;56:1259-68. [DOI: 10.1016/j.jhep.2012.01.021] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
493 Park SH, Rehermann B. Immune responses to HCV and other hepatitis viruses. Immunity 2014;40:13-24. [PMID: 24439265 DOI: 10.1016/j.immuni.2013.12.010] [Cited by in Crossref: 180] [Cited by in F6Publishing: 169] [Article Influence: 22.5] [Reference Citation Analysis]
494 Martin P, Parroche P, Chatel L, Barretto C, Beck A, Trépo C, Bain C, Lone Y, Inchauspé G, Fournillier A. Genetic immunization and comprehensive screening approaches in HLA-A2 transgenic mice lead to the identification of three novel epitopes in hepatitis C virus NS3 antigen: Identification of Novel Class I Epitopes of HCV. J Med Virol 2004;74:397-405. [DOI: 10.1002/jmv.20189] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
495 Rallón NI, López M, Soriano V, García-Samaniego J, Romero M, Labarga P, García-Gasco P, González-Lahoz J, Benito JM. Level, phenotype and activation status of CD4+FoxP3+ regulatory T cells in patients chronically infected with human immunodeficiency virus and/or hepatitis C virus. Clin Exp Immunol 2009;155:35-43. [PMID: 19076827 DOI: 10.1111/j.1365-2249.2008.03797.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 2.5] [Reference Citation Analysis]
496 Nitschke K, Flecken T, Schmidt J, Gostick E, Marget M, Neumann-Haefelin C, Blum HE, Price DA, Thimme R. Tetramer enrichment reveals the presence of phenotypically diverse hepatitis C virus-specific CD8+ T cells in chronic infection. J Virol 2015;89:25-34. [PMID: 25320295 DOI: 10.1128/JVI.02242-14] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
497 Lin C, Graca L, Cobbold SP, Waldmann H. Dominant transplantation tolerance impairs CD8+ T cell function but not expansion. Nat Immunol 2002;3:1208-13. [DOI: 10.1038/ni853] [Cited by in Crossref: 128] [Cited by in F6Publishing: 118] [Article Influence: 6.4] [Reference Citation Analysis]
498 Ma L, Zhou Y, Zhang Y, Li Y, Guo Y, He Y, Wang J, Lian J, Hao C, Moorman JP, Yao ZQ, Zhou Y, Jia Z. Role of A20 in interferon-α-mediated functional restoration of myeloid dendritic cells in patients with chronic hepatitis C. Immunology 2014;143:670-8. [PMID: 24965710 DOI: 10.1111/imm.12350] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
499 Meyer-Olson D, Shoukry NH, Brady KW, Kim H, Olson DP, Hartman K, Shintani AK, Walker CM, Kalams SA. Limited T cell receptor diversity of HCV-specific T cell responses is associated with CTL escape. J Exp Med. 2004;200:307-319. [PMID: 15289502 DOI: 10.1084/jem.20040638] [Cited by in Crossref: 132] [Cited by in F6Publishing: 125] [Article Influence: 7.3] [Reference Citation Analysis]
500 Inchauspé G, Feinstone S. Development of a hepatitis C virus vaccine. Clin Liver Dis. 2003;7:243-59, xi. [PMID: 12691469 DOI: 10.1016/s1089-3261(02)00067-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
501 Lewis DB, Wilson CB. Developmental Immunology and Role of Host Defenses in Fetal and Neonatal Susceptibility to Infection. Infectious Diseases of the Fetus and Newborn Infant. Elsevier; 2006. pp. 87-210. [DOI: 10.1016/b0-72-160537-0/50006-2] [Cited by in Crossref: 18] [Article Influence: 1.1] [Reference Citation Analysis]
502 Thimme R, Binder M, Bartenschlager R. Failure of innate and adaptive immune responses in controlling hepatitis C virus infection. FEMS Microbiol Rev 2012;36:663-83. [DOI: 10.1111/j.1574-6976.2011.00319.x] [Cited by in Crossref: 94] [Cited by in F6Publishing: 90] [Article Influence: 9.4] [Reference Citation Analysis]
503 Gehring AJ, Sun D, Kennedy PT, Nolte-'t Hoen E, Lim SG, Wasser S, Selden C, Maini MK, Davis DM, Nassal M, Bertoletti A. The level of viral antigen presented by hepatocytes influences CD8 T-cell function. J Virol 2007;81:2940-9. [PMID: 17202217 DOI: 10.1128/JVI.02415-06] [Cited by in Crossref: 61] [Cited by in F6Publishing: 34] [Article Influence: 4.1] [Reference Citation Analysis]
504 Wieland SF, Chisari FV. Stealth and cunning: hepatitis B and hepatitis C viruses. J Virol. 2005;79:9369-9380. [PMID: 16014900 DOI: 10.1128/jvi.79.15.9369-9380.2005] [Cited by in Crossref: 303] [Cited by in F6Publishing: 155] [Article Influence: 17.8] [Reference Citation Analysis]
505 Ward S, Lauer G, Isba R, Walker B, Klenerman P. Cellular immune responses against hepatitis C virus: the evidence base 2002. Clin Exp Immunol. 2002;128:195-203. [PMID: 11985510 DOI: 10.1046/j.1365-2249.2002.01840.x] [Cited by in Crossref: 110] [Cited by in F6Publishing: 106] [Article Influence: 5.5] [Reference Citation Analysis]
506 Caetano J, Martinho A, Paiva A, Pais B, Valente C, Luxo C. Differences in hepatitis C virus (HCV)-specific CD8 T-cell phenotype during pegylated alpha interferon and ribavirin treatment are related to response to antiviral therapy in patients chronically infected with HCV. J Virol. 2008;82:7567-7577. [PMID: 18480446 DOI: 10.1128/jvi.02175-07] [Cited by in Crossref: 21] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
507 Bharadwaj M, Thammanichanond D, Aitken CK, Moneer S, Drummer HE, Tracy S, Holdsworth R, Bowden S, Jackson D, Hellard M, Torresi J, Mccluskey J. T CD8 response in diverse outcomes of recurrent exposure to hepatitis C virus. Immunol Cell Biol 2009;87:464-72. [DOI: 10.1038/icb.2009.24] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
508 Thimme R, Bukh J, Spangenberg HC, Wieland S, Pemberton J, Steiger C, Govindarajan S, Purcell RH, Chisari FV. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci USA. 2002;99:15661-15668. [PMID: 12441397 DOI: 10.1073/pnas.202608] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
509 Zeisel MB, Cosset FL, Baumert TF. Host neutralizing responses and pathogenesis of hepatitis C virus infection. Hepatology. 2008;48:299-307. [PMID: 18508291 DOI: 10.1002/hep.22307] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 2.7] [Reference Citation Analysis]
510 Serra A, Nuti S, Tavarini S, Sammicheli C, Rosa D, Saletti G, Soldaini E, Abrignani S, Wack A. Coligation of the hepatitis C virus receptor CD81 with CD28 primes naive T lymphocytes to acquire type 2 effector function. J Immunol 2008;181:174-85. [PMID: 18566382 DOI: 10.4049/jimmunol.181.1.174] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
511 Aborsangaya KB, Dembinski I, Khatkar S, Alphonse MP, Nickerson P, Rempel JD. Impact of aboriginal ethnicity on HCV core-induced IL-10 synthesis: interaction with IL-10 gene polymorphisms. Hepatology. 2007;45:623-630. [PMID: 17326156 DOI: 10.1002/hep.21511] [Cited by in Crossref: 39] [Cited by in F6Publishing: 42] [Article Influence: 2.6] [Reference Citation Analysis]
512 Fournillier A, Gerossier E, Evlashev A, Schmitt D, Simon B, Chatel L, Martin P, Silvestre N, Balloul JM, Barry R, Inchauspé G. An accelerated vaccine schedule with a poly-antigenic hepatitis C virus MVA-based candidate vaccine induces potent, long lasting and in vivo cross-reactive T cell responses. Vaccine 2007;25:7339-53. [PMID: 17875349 DOI: 10.1016/j.vaccine.2007.08.020] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 2.3] [Reference Citation Analysis]
513 Diepolder HM. New insights into the immunopathogenesis of chronic hepatitis C. Antiviral Res 2009;82:103-9. [PMID: 19428600 DOI: 10.1016/j.antiviral.2009.02.203] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
514 Wang M, Zhu Y, Wang J, Lv T, Jin B. Identification of three novel CTL epitopes within nucleocapsid protein of Hantaan virus. Viral Immunol 2011;24:449-54. [PMID: 22111596 DOI: 10.1089/vim.2011.0026] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
515 Yoon JC, Shiina M, Ahlenstiel G, Rehermann B. Natural killer cell function is intact after direct exposure to infectious hepatitis C virions. Hepatology. 2009;49:12-21. [PMID: 19085909 DOI: 10.1002/hep.22624] [Cited by in Crossref: 82] [Cited by in F6Publishing: 78] [Article Influence: 6.3] [Reference Citation Analysis]
516 Chua BY, Healy A, Cameron PU, Stock O, Rizkalla M, Zeng W, Torresi J, Brown LE, Fowler NL, Gowans EJ, Jackson DC. Maturation of dendritic cells with lipopeptides that represent vaccine candidates for hepatitis C virus. Immunol Cell Biol 2003;81:67-72. [PMID: 12534949 DOI: 10.1046/j.1440-1711.2003.01133.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.2] [Reference Citation Analysis]
517 Tan WG, Zubkova I, Kachko A, Wells F, Adler H, Sutter G, Major ME. Qualitative differences in cellular immunogenicity elicited by hepatitis C virus T-Cell vaccines employing prime-boost regimens. PLoS One 2017;12:e0181578. [PMID: 28732046 DOI: 10.1371/journal.pone.0181578] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
518 Kamal SM. Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agents. Hepat Med. 2014;6:61-77. [PMID: 25114601 DOI: 10.2147/hmer.s41127] [Cited by in Crossref: 25] [Cited by in F6Publishing: 11] [Article Influence: 3.1] [Reference Citation Analysis]
519 Li H, Stoddard MB, Wang S, Blair LM, Giorgi EE, Parrish EH, Learn GH, Hraber P, Goepfert PA, Saag MS. Elucidation of hepatitis C virus transmission and early diversification by single genome sequencing. PLoS Pathog. 2012;8:e1002880. [PMID: 22927816 DOI: 10.1371/journal.ppat.1002880] [Cited by in Crossref: 63] [Cited by in F6Publishing: 65] [Article Influence: 6.3] [Reference Citation Analysis]
520 Masalova OV, Lesnova EI, Klimova RR, Momotyuk ED, Kozlov VV, Ivanova AM, Payushina OV, Butorina NN, Zakirova NF, Narovlyansky AN, Pronin AV, Ivanov AV, Kushch AA. Genetically Modified Mouse Mesenchymal Stem Cells Expressing Non-Structural Proteins of Hepatitis C Virus Induce Effective Immune Response. Vaccines (Basel). 2020;8. [PMID: 32024236 DOI: 10.3390/vaccines8010062] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
521 Hakamada T, Funatsuki K, Morita H, Ugajin T, Nakamura I, Ishiko H, Matsuzaki Y, Tanaka N, Imawari M. Identification of novel hepatitis C virus-specific cytotoxic T lymphocyte epitopes by ELISpot assay using peptides with human leukocyte antigen-A*2402-binding motifs. Journal of General Virology 2004;85:1521-31. [DOI: 10.1099/vir.0.79801-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
522 Willberg C, Barnes E, Klenerman P. HCV immunology--death and the maiden T cell. Cell Death Differ 2003;10 Suppl 1:S39-47. [PMID: 12655345 DOI: 10.1038/sj.cdd.4401122] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 1.2] [Reference Citation Analysis]
523 Pagliari C, Fernandes ER, Stegun FW, da Silva WLF, Seixas Duarte MI, Sotto MN. Paracoccidioidomycosis: Cells expressing IL17 and Foxp3 in cutaneous and mucosal lesions. Microbial Pathogenesis 2011;50:263-7. [DOI: 10.1016/j.micpath.2010.12.008] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.4] [Reference Citation Analysis]
524 Smith S, Honegger JR, Walker C. T-Cell Immunity against the Hepatitis C Virus: A Persistent Research Priority in an Era of Highly Effective Therapy. Cold Spring Harb Perspect Med 2021;11:a036954. [PMID: 32205413 DOI: 10.1101/cshperspect.a036954] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
525 van Lier RA, ten Berge IJ, Gamadia LE. Human CD8(+) T-cell differentiation in response to viruses. Nat Rev Immunol 2003;3:931-9. [PMID: 14647475 DOI: 10.1038/nri1254] [Cited by in Crossref: 214] [Cited by in F6Publishing: 207] [Article Influence: 11.9] [Reference Citation Analysis]
526 Verstrepen BE, Boonstra A, Koopman G. Immune mechanisms of vaccine induced protection against chronic hepatitis C virus infection in chimpanzees. World J Hepatol 2015; 7(1): 53-69 [PMID: 25624997 DOI: 10.4254/wjh.v7.i1.53] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
527 Huang YH, Tao MH, Hu CP, Syu WJ, Wu JC. Identification of novel HLA-A*0201-restricted CD8+ T-cell epitopes on hepatitis delta virus. J Gen Virol 2004;85:3089-98. [PMID: 15448372 DOI: 10.1099/vir.0.80183-0] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 2.4] [Reference Citation Analysis]
528 Ishii S, Koziel MJ. Immune responses during acute and chronic infection with hepatitis C virus. Clin Immunol. 2008;128:133-147. [PMID: 18514579 DOI: 10.1016/j.clim.2008.03.525] [Cited by in Crossref: 62] [Cited by in F6Publishing: 62] [Article Influence: 4.4] [Reference Citation Analysis]
529 Makowska Z, Heim MH. Interferon signaling in the liver during hepatitis C virus infection. Cytokine 2012;59:460-6. [DOI: 10.1016/j.cyto.2012.06.015] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
530 Wang JH, Zheng X, Ke X, Dorak MT, Shen J, Boodram B, O'Gorman M, Beaman K, Cotler SJ, Hershow R, Rong L. Ethnic and geographical differences in HLA associations with the outcome of hepatitis C virus infection. Virol J 2009;6:46. [PMID: 19409091 DOI: 10.1186/1743-422X-6-46] [Cited by in Crossref: 25] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
531 Gamadia LE, Rentenaar RJ, van Lier RA, ten Berge IJ. Properties of CD4+ T cells in human cytomegalovirus infection. Human Immunology 2004;65:486-92. [DOI: 10.1016/j.humimm.2004.02.020] [Cited by in Crossref: 68] [Cited by in F6Publishing: 66] [Article Influence: 3.8] [Reference Citation Analysis]
532 Parker R, Dutrieux J, Beq S, Lemercier B, Rozlan S, Fabre-Mersseman V, Rancez M, Gommet C, Assouline B, Rancé I, Lim A, Morre M, Cheynier R. Interleukin-7 treatment counteracts IFN-α therapy-induced lymphopenia and stimulates SIV-specific cytotoxic T lymphocyte responses in SIV-infected rhesus macaques. Blood 2010;116:5589-99. [PMID: 20841508 DOI: 10.1182/blood-2010-03-276261] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
533 Sainz B, Chisari FV. Production of infectious hepatitis C virus by well-differentiated, growth-arrested human hepatoma-derived cells. J Virol. 2006;80:10253-10257. [PMID: 17005703 DOI: 10.1128/jvi.01059-06] [Cited by in Crossref: 77] [Cited by in F6Publishing: 51] [Article Influence: 4.8] [Reference Citation Analysis]
534 Abdel-Hakeem MS, Shoukry NH. Protective immunity against hepatitis C: many shades of gray. Front Immunol. 2014;5:274. [PMID: 24982656 DOI: 10.3389/fimmu.2014.00274] [Cited by in Crossref: 51] [Cited by in F6Publishing: 60] [Article Influence: 6.4] [Reference Citation Analysis]
535 Salem ML, El-Badawy A. Programmed death-1/programmed death-L1 signaling pathway and its blockade in hepatitis C virus immunotherapy. World J Hepatol 2015; 7(23): 2449-2458 [PMID: 26483866 DOI: 10.4254/wjh.v7.i23.2449] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
536 Zingaretti C, De Francesco R, Abrignani S. Why is it so difficult to develop a hepatitis C virus preventive vaccine? Clin Microbiol Infect 2014;20 Suppl 5:103-9. [PMID: 24829939 DOI: 10.1111/1469-0691.12493] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
537 Fahey LM, Brooks DG. Opposing positive and negative regulation of T cell activity during viral persistence. Curr Opin Immunol 2010;22:348-54. [PMID: 20381328 DOI: 10.1016/j.coi.2010.03.004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
538 Mbow ML, Sarisky RT. What is disrupting IFN-alpha's antiviral activity? Trends Biotechnol 2004;22:395-9. [PMID: 15283983 DOI: 10.1016/j.tibtech.2004.06.002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 1.5] [Reference Citation Analysis]
539 Castelain S, Schnuriger A, François C, Nguyen‐khac E, Fournier C, Schmit J, Capron D, Dubuisson J, Wychowski C, Thibault V, Duverlie G. Low Levels of Hepatitis C Virus (HCV) Neutralizing Antibodies in Patients Coinfected with HCV and Human Immunodeficiency Virus. J INFECT DIS 2008;198:332-5. [DOI: 10.1086/589777] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
540 Kardani K, Sadat SM, Kardani M, Bolhassani A. The next generation of HCV vaccines: a focus on novel adjuvant development. Expert Rev Vaccines 2021;20:839-55. [PMID: 34114513 DOI: 10.1080/14760584.2021.1941895] [Reference Citation Analysis]
541 Llorens-Revull M, Costafreda MI, Rico A, Guerrero-Murillo M, Soria ME, Píriz-Ruzo S, Vargas-Accarino E, Gabriel-Medina P, Rodríguez-Frías F, Riveiro-Barciela M, Perales C, Quer J, Sauleda S, Esteban JI, Bes M. Partial restoration of immune response in Hepatitis C patients after viral clearance by direct-acting antiviral therapy. PLoS One 2021;16:e0254243. [PMID: 34242330 DOI: 10.1371/journal.pone.0254243] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
542 Accapezzato D, Francavilla V, Paroli M, Casciaro M, Chircu LV, Cividini A, Abrignani S, Mondelli MU, Barnaba V. Hepatic expansion of a virus-specific regulatory CD8(+) T cell population in chronic hepatitis C virus infection. J Clin Invest. 2004;113:963-972. [PMID: 15057302 DOI: 10.1172/jci20515] [Cited by in Crossref: 4] [Cited by in F6Publishing: 97] [Article Influence: 0.2] [Reference Citation Analysis]
543 Gao J, Gong Y, Zhao P, Zhu Q, Yang X, Qi Z. Construction and characterization of an HCV-derived multi-epitope peptide antigen containing B-cell HVR1 mimotopes and T-cell conserved epitopes. SCI CHINA SER C 2006;49:490-9. [DOI: 10.1007/s11427-006-2020-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
544 Donnison T, von Delft A, Brown A, Swadling L, Hutchings C, Hanke T, Chinnakannan S, Barnes E. Viral vectored hepatitis C virus vaccines generate pan-genotypic T cell responses to conserved subdominant epitopes. Vaccine 2020;38:5036-48. [PMID: 32532545 DOI: 10.1016/j.vaccine.2020.05.042] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
545 Ohno S, Moriya O, Yoshimoto T, Hayashi H, Akatsuka T, Matsui M. Immunogenic variation between multiple HLA-A*0201-restricted, Hepatitis C Virus-derived epitopes for cytotoxic T lymphocytes. Viral Immunol 2006;19:458-67. [PMID: 16987064 DOI: 10.1089/vim.2006.19.458] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
546 Castello G, Costantini S, Scala S. Targeting the inflammation in HCV-associated hepatocellular carcinoma: a role in the prevention and treatment. J Transl Med 2010;8:109. [PMID: 21047421 DOI: 10.1186/1479-5876-8-109] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
547 Yu H, Babiuk LA, van Drunen Littel-van den Hurk S. Priming with CpG-enriched plasmid and boosting with protein formulated with CpG oligodeoxynucleotides and Quil A induces strong cellular and humoral immune responses to hepatitis C virus NS3. J Gen Virol. 2004;85:1533-1543. [PMID: 15166437 DOI: 10.1099/vir.0.79821-0] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 1.5] [Reference Citation Analysis]
548 Hartoonian C, Sepehrizadeh Z, Mahdavi M, Arashkia A, Jang YS, Ebtekar M, Yazdi MT, Negahdari B, Nikoo A, Azadmanesh K. Modulation of hepatitis C virus core DNA vaccine immune responses by co-immunization with CC-chemokine ligand 20 (CCL20) gene as immunoadjuvant. Mol Biol Rep 2014;41:5943-52. [PMID: 24972567 DOI: 10.1007/s11033-014-3470-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
549 Sundström S, Ota S, Dimberg LY, Masucci MG, Bergqvist A. Hepatitis C virus core protein induces an anergic state characterized by decreased interleukin-2 production and perturbation of mitogen-activated protein kinase responses. J Virol 2005;79:2230-9. [PMID: 15681425 DOI: 10.1128/JVI.79.4.2230-2239.2005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
550 Takaki A, Tatsukawa M, Iwasaki Y, Koike K, Noguchi Y, Shiraha H, Sakaguchi K, Nakayama E, Yamamoto K. Hepatitis C virus NS4 protein impairs the Th1 polarization of immature dendritic cells. J Viral Hepat. 2010;17:555-562. [PMID: 19804500 DOI: 10.1111/j.1365-2893.2009.01213.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
551 Zhou Y, Callendret B, Xu D, Brasky KM, Feng Z, Hensley LL, Guedj J, Perelson AS, Lemon SM, Lanford RE. Dominance of the CD4(+) T helper cell response during acute resolving hepatitis A virus infection. J Exp Med. 2012;209:1481-1492. [PMID: 22753925 DOI: 10.1084/jem.20111906] [Cited by in Crossref: 65] [Cited by in F6Publishing: 54] [Article Influence: 6.5] [Reference Citation Analysis]
552 Brooks DG, Ha SJ, Elsaesser H, Sharpe AH, Freeman GJ, Oldstone MB. IL-10 and PD-L1 operate through distinct pathways to suppress T-cell activity during persistent viral infection. Proc Natl Acad Sci U S A 2008;105:20428-33. [PMID: 19075244 DOI: 10.1073/pnas.0811139106] [Cited by in Crossref: 143] [Cited by in F6Publishing: 144] [Article Influence: 10.2] [Reference Citation Analysis]
553 Karimzadeh H, Kiraithe MM, Oberhardt V, Salimi Alizei E, Bockmann J, Schulze Zur Wiesch J, Budeus B, Hoffmann D, Wedemeyer H, Cornberg M, Krawczyk A, Rashidi-Alavijeh J, Rodríguez-Frías F, Casillas R, Buti M, Smedile A, Alavian SM, Heinold A, Emmerich F, Panning M, Gostick E, Price DA, Timm J, Hofmann M, Raziorrouh B, Thimme R, Protzer U, Roggendorf M, Neumann-Haefelin C. Mutations in Hepatitis D Virus Allow It to Escape Detection by CD8+ T Cells and Evolve at the Population Level. Gastroenterology 2019;156:1820-33. [PMID: 30768983 DOI: 10.1053/j.gastro.2019.02.003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
554 Cusick MF, Schiller JJ, Gill JC, Eckels DD. Hepatitis C virus induces regulatory T cells by naturally occurring viral variants to suppress T cell responses. Clin Dev Immunol 2011;2011:806061. [PMID: 21197453 DOI: 10.1155/2011/806061] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
555 Delgado-Ortega M, Marc D, Dupont J, Trapp S, Berri M, Meurens F. SOCS proteins in infectious diseases of mammals. Vet Immunol Immunopathol 2013;151:1-19. [PMID: 23219158 DOI: 10.1016/j.vetimm.2012.11.008] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 3.9] [Reference Citation Analysis]
556 Schmidt J, Thimme R, Neumann-Haefelin C. Host genetics in immune-mediated hepatitis C virus clearance. Biomark Med. 2011;5:155-169. [PMID: 21473719 DOI: 10.2217/bmm.11.19] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
557 Lukacher AE. Pathogen-host standoff: immunity to polyomavirus infection and neoplasia. Immunol Res 2004;29:139-50. [PMID: 15181277 DOI: 10.1385/IR:29:1-3:139] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
558 Barnes E, Folgori A, Capone S, Swadling L, Aston S, Kurioka A, Meyer J, Huddart R, Smith K, Townsend R. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med. 2012;4:115ra1. [PMID: 22218690 DOI: 10.1126/scitranslmed.300315] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
559 Plotkin SA. Sang Froid in a time of trouble: is a vaccine against HIV possible? J Int AIDS Soc 2009;12:2. [PMID: 19187552 DOI: 10.1186/1758-2652-12-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
560 Guglietta S, Garbuglia AR, Pacciani V, Scottà C, Perrone MP, Laurenti L, Spada E, Mele A, Capobianchi MR, Taliani G. Positive selection of cytotoxic T lymphocyte escape variants during acute hepatitis C virus infection. Eur J Immunol. 2005;35:2627-2637. [PMID: 16114108 DOI: 10.1002/eji.200526067] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 1.8] [Reference Citation Analysis]
561 Bowen DG, Walker CM. The origin of quasispecies: cause or consequence of chronic hepatitis C viral infection? Journal of Hepatology 2005;42:408-17. [DOI: 10.1016/j.jhep.2004.12.013] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 2.4] [Reference Citation Analysis]
562 Hofmann M, Tauber C, Hensel N, Thimme R. CD8+ T Cell Responses during HCV Infection and HCC. J Clin Med 2021;10:991. [PMID: 33801203 DOI: 10.3390/jcm10050991] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
563 Osuch S, Laskus T, Berak H, Perlejewski K, Metzner KJ, Paciorek M, Radkowski M, Caraballo Cortés K. Decrease of T-cells exhaustion markers programmed cell death-1 and T-cell immunoglobulin and mucin domain-containing protein 3 and plasma IL-10 levels after successful treatment of chronic hepatitis C. Sci Rep 2020;10:16060. [PMID: 32994477 DOI: 10.1038/s41598-020-73137-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
564 Chakrabarty SP, Murray JM. Modelling hepatitis C virus infection and the development of hepatocellular carcinoma. J Theor Biol. 2012;305:24-29. [PMID: 22575547 DOI: 10.1016/j.jtbi.2012.03.030] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
565 Urbani S, Amadei B, Fisicaro P, Pilli M, Missale G, Bertoletti A, Ferrari C. Heterologous T cell immunity in severe hepatitis C virus infection. J Exp Med 2005;201:675-80. [PMID: 15753202 DOI: 10.1084/jem.20041058] [Cited by in Crossref: 111] [Cited by in F6Publishing: 101] [Article Influence: 6.5] [Reference Citation Analysis]
566 Fang Z, Zhu K, Guo N, Zhang N, Guan M, Yang C, Pan Q, Wei R, Yang C, Deng C, Liu X, Zhao P, Leng Q. HCV J6/JFH1 tilts the capability of myeloid-derived dendritic cells to favor the induction of immunosuppression and Th17-related inflammatory cytokines. Pharm Res 2015;32:741-8. [PMID: 23619596 DOI: 10.1007/s11095-013-1050-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
567 Lauer GM. Immune responses to hepatitis C virus (HCV) infection and the prospects for an effective HCV vaccine or immunotherapies. J Infect Dis. 2013;207 Suppl 1:S7-S12. [PMID: 23390305 DOI: 10.1093/infdis/jis762] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 3.9] [Reference Citation Analysis]
568 Zeng QL, Yang B, Sun HQ, Feng GH, Jin L, Zou ZS, Zhang Z, Zhang JY, Wang FS. Myeloid-derived suppressor cells are associated with viral persistence and downregulation of TCR ζ chain expression on CD8(+) T cells in chronic hepatitis C patients. Mol Cells 2014;37:66-73. [PMID: 24552712 DOI: 10.14348/molcells.2014.2282] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 4.6] [Reference Citation Analysis]
569 Gehring S, Gregory SH, Wintermeyer P, Aloman C, Wands JR. Generation of immune responses against hepatitis C virus by dendritic cells containing NS5 protein-coated microparticles. Clin Vaccine Immunol 2009;16:163-71. [PMID: 19091993 DOI: 10.1128/CVI.00287-08] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
570 Barnes E, Lauer G, Walker B, Klenerman P. T cell failure in hepatitis C virus infection. Viral Immunol 2002;15:285-93. [PMID: 12081013 DOI: 10.1089/08828240260066233] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 0.8] [Reference Citation Analysis]
571 Moriishi K, Matsuura Y. Mechanisms of hepatitis C virus infection. Antivir Chem Chemother 2003;14:285-97. [PMID: 14968935 DOI: 10.1177/095632020301400601] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 1.8] [Reference Citation Analysis]
572 Benito JM, García-Samaniego J, García M, Madejón A, Martín-Carbonero L, Cabello A, Álvarez B, Górgolas M, Rallón N. Both Hepatitis C Virus-Specific T Cell Responses and IL28B rs12979860 Single-Nucleotide Polymorphism Genotype Influence Antihepatitis C Virus Treatment Outcome in Patients with Chronic Hepatitis C. J Interferon Cytokine Res 2017;37:278-86. [PMID: 28440692 DOI: 10.1089/jir.2016.0078] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
573 Radziewicz H, Ibegbu CC, Fernandez ML, Workowski KA, Obideen K, Wehbi M, Hanson HL, Steinberg JP, Masopust D, Wherry EJ, Altman JD, Rouse BT, Freeman GJ, Ahmed R, Grakoui A. Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression. J Virol 2007;81:2545-53. [PMID: 17182670 DOI: 10.1128/JVI.02021-06] [Cited by in Crossref: 340] [Cited by in F6Publishing: 239] [Article Influence: 21.3] [Reference Citation Analysis]
574 Ulsenheimer A, Paranhos-Baccalà G, Komurian-Pradel F, Raziorrouh B, Kurktschiev P, Diepolder HM, Zachoval R, Spannagl M, Jung MC, Gruener NH. Lack of variant specific CD8+ T-cell response against mutant and pre-existing variants leads to outgrowth of particular clones in acute hepatitis C. Virol J 2013;10:295. [PMID: 24073713 DOI: 10.1186/1743-422X-10-295] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
575 Larrubia JR, Benito-Martínez S, Calvino M, Sanz-de-Villalobos E, Parra-Cid T. Role of chemokines and their receptors in viral persistence and liver damage during chronic hepatitis C virus infection. World J Gastroenterol. 2008;14:7149-7159. [PMID: 19084927 DOI: 10.3748/wjg.14.7149.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
576 Neumann-Haefelin C, Timm J, Spangenberg HC, Wischniowski N, Nazarova N, Kersting N, Roggendorf M, Allen TM, Blum HE, Thimme R. Virological and immunological determinants of intrahepatic virus-specific CD8+ T-cell failure in chronic hepatitis C virus infection. Hepatology 2008;47:1824-36. [PMID: 18454507 DOI: 10.1002/hep.22242] [Cited by in Crossref: 87] [Cited by in F6Publishing: 87] [Article Influence: 6.2] [Reference Citation Analysis]
577 Day CL, Lauer GM, Robbins GK, McGovern B, Wurcel AG, Gandhi RT, Chung RT, Walker BD. Broad specificity of virus-specific CD4+ T-helper-cell responses in resolved hepatitis C virus infection. J Virol 2002;76:12584-95. [PMID: 12438584 DOI: 10.1128/jvi.76.24.12584-12595.2002] [Cited by in Crossref: 192] [Cited by in F6Publishing: 80] [Article Influence: 9.6] [Reference Citation Analysis]
578 Perrella A, Borgia G, Perrella O. Immune system homeostasis during acute hepatitis C: viral escape or T-cell regulation? Hepatology 2004;40:1229; author reply 1229-30. [PMID: 15486981 DOI: 10.1002/hep.20470] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
579 Lang PA, Xu HC, Grusdat M, McIlwain DR, Pandyra AA, Harris IS, Shaabani N, Honke N, Maney SK, Lang E, Pozdeev VI, Recher M, Odermatt B, Brenner D, Häussinger D, Ohashi PS, Hengartner H, Zinkernagel RM, Mak TW, Lang KS. Reactive oxygen species delay control of lymphocytic choriomeningitis virus. Cell Death Differ 2013;20:649-58. [PMID: 23328631 DOI: 10.1038/cdd.2012.167] [Cited by in F6Publishing: 28] [Reference Citation Analysis]
580 Sugimoto K, Ikeda F, Stadanlick J, Nunes FA, Alter HJ, Chang KM. Suppression of HCV-specific T cells without differential hierarchy demonstrated ex vivo in persistent HCV infection. Hepatology 2003;38:1437-48. [PMID: 14647055 DOI: 10.1016/j.hep.2003.09.026] [Cited by in Crossref: 21] [Cited by in F6Publishing: 127] [Article Influence: 1.1] [Reference Citation Analysis]
581 Santantonio T, Wiegand J, Gerlach JT. Acute hepatitis C: current status and remaining challenges. J Hepatol. 2008;49:625-633. [PMID: 18706735 DOI: 10.1016/j.jhep.2008.07.005] [Cited by in Crossref: 97] [Cited by in F6Publishing: 79] [Article Influence: 6.9] [Reference Citation Analysis]
582 Osokine I, Snell LM, Cunningham CR, Yamada DH, Wilson EB, Elsaesser HJ, de la Torre JC, Brooks D. Type I interferon suppresses de novo virus-specific CD4 Th1 immunity during an established persistent viral infection. Proc Natl Acad Sci U S A 2014;111:7409-14. [PMID: 24799699 DOI: 10.1073/pnas.1401662111] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 7.0] [Reference Citation Analysis]
583 Tedaldi EM, Chen L, Markowitz N, Kelly L, Abrams D; CPCRA Hepatitis Working Group. Effect of IL-2 on hepatitis C virus RNA levels in patients co-infected with human immunodeficiency virus receiving HAART. J Viral Hepat 2005;12:414-20. [PMID: 15985013 DOI: 10.1111/j.1365-2893.2005.00610.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
584 Smyk-Pearson S, Tester IA, Klarquist J, Palmer BE, Pawlotsky JM, Golden-Mason L, Rosen HR. Spontaneous recovery in acute human hepatitis C virus infection: functional T-cell thresholds and relative importance of CD4 help. J Virol. 2008;82:1827-1837. [PMID: 18045940 DOI: 10.1128/jvi.01581-07] [Cited by in Crossref: 63] [Cited by in F6Publishing: 40] [Article Influence: 4.2] [Reference Citation Analysis]
585 Baré P, Massud I, Belmonte L, Corti M, Villafañe M, Pérez Bianco R, de Tezanos-pinto M, de Bracco MM, Ruibal-Ares B. HCV recovery from peripheral blood mononuclear cell culture supernatants derived from HCV-HIV co-infected haemophilic patients with undetectable HCV viraemia. Haemophilia 2003;9:598-604. [PMID: 14511301 DOI: 10.1046/j.1365-2516.2003.00808.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
586 Bengsch B, Thimme R. CD8 + T-cell differentiation in chronic HCV infection. Future Virology 2011;6:249-58. [DOI: 10.2217/fvl.10.84] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
587 Zhang X, Dou J, Germann MW. Characterization of the cellular immune response in hepatitis C virus infection. Med Res Rev 2009;29:843-66. [PMID: 19378287 DOI: 10.1002/med.20157] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
588 Golden-Mason L, Burton JR Jr, Castelblanco N, Klarquist J, Benlloch S, Wang C, Rosen HR. Loss of IL-7 receptor alpha-chain (CD127) expression in acute HCV infection associated with viral persistence. Hepatology 2006;44:1098-109. [PMID: 17058243 DOI: 10.1002/hep.21365] [Cited by in Crossref: 80] [Cited by in F6Publishing: 88] [Article Influence: 5.0] [Reference Citation Analysis]
589 Sulkowski MS, Thomas DL. Epidemiology and natural history of hepatitis C virus infection in injection drug users: implications for treatment. Clin Infect Dis 2005;40 Suppl 5:S263-9. [PMID: 15768333 DOI: 10.1086/427440] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 1.9] [Reference Citation Analysis]
590 Koziel MJ. NK cells: natural born killers in the conflict between humans and HCV. Hepatology. 2006;43:395-397. [PMID: 16496351 DOI: 10.1002/hep.21127] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
591 Zeremski M, Petrovic LM, Talal AH. The role of chemokines as inflammatory mediators in chronic hepatitis C virus infection. J Viral Hepat 2007;0:070124051929001-???. [DOI: 10.1111/j.1365-2893.2006.00838.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 77] [Article Influence: 0.9] [Reference Citation Analysis]
592 Berger A, Giroglou T, Leutz A, Ogbomo H, Pfaff K, Teuber G, Cinatl J, van Laer D, Doerr HW. Measurements of HCV neutralizing antibodies and of HCV-specific CD4+ and CD8+ cells using hepatitis C virus pseudo-particles (HCVpp). J Clin Virol 2009;46:55-60. [PMID: 19560398 DOI: 10.1016/j.jcv.2009.05.036] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
593 Mina M, Underwood A, Eltahla A, Wu BR, Walker MR, Bull RA, Lloyd AR. Anti-envelope antibody responses in highly exposed seronegative individuals may be associated with protection from HCV infection. J Viral Hepat 2020;27:1012-21. [PMID: 32497370 DOI: 10.1111/jvh.13339] [Reference Citation Analysis]
594 Gunderson A, Said A. Liver disease in kidney transplant recipients. Transplantation Reviews 2015;29:1-7. [DOI: 10.1016/j.trre.2014.08.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
595 Hartnell F, Esposito I, Swadling L, Brown A, Phetsouphanh C, de Lara C, Gentile C, Turner B, Dorrell L, Capone S, Folgori A, Barnes E, Klenerman P. Characterizing Hepatitis C Virus-Specific CD4+ T Cells Following Viral-Vectored Vaccination, Directly Acting Antivirals, and Spontaneous Viral Cure. Hepatology 2020;72:1541-55. [PMID: 32012325 DOI: 10.1002/hep.31160] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
596 Billerbeck E, Thimme R. CD8+ regulatory T cells in persistent human viral infections. Hum Immunol 2008;69:771-5. [PMID: 18789990 DOI: 10.1016/j.humimm.2008.07.016] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
597 Blindenbacher A, Duong FH, Hunziker L, Stutvoet ST, Wang X, Terracciano L, Moradpour D, Blum HE, Alonzi T, Tripodi M. Expression of hepatitis c virus proteins inhibits interferon alpha signaling in the liver of transgenic mice. Gastroenterology. 2003;124:1465-1475. [PMID: 12730885 DOI: 10.1016/s0016-5085(03)00290-7] [Cited by in Crossref: 131] [Cited by in F6Publishing: 43] [Article Influence: 6.9] [Reference Citation Analysis]
598 Bocharov G, Ludewig B, Bertoletti A, Klenerman P, Junt T, Krebs P, Luzyanina T, Fraser C, Anderson RM. Underwhelming the immune response: effect of slow virus growth on CD8+-T-lymphocyte responses. J Virol 2004;78:2247-54. [PMID: 14963121 DOI: 10.1128/jvi.78.5.2247-2254.2004] [Cited by in Crossref: 76] [Cited by in F6Publishing: 26] [Article Influence: 4.2] [Reference Citation Analysis]
599 Saito H, Umemura T, Joshita S, Yamazaki T, Fujimori N, Kimura T, Komatsu M, Matsumoto A, Tanaka E, Ota M. KIR2DL2 combined with HLA-C1 confers risk of hepatitis C virus-related hepatocellular carcinoma in younger patients. Oncotarget 2018;9:19650-61. [PMID: 29731972 DOI: 10.18632/oncotarget.24752] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
600 Lang Kuhs KA, Ginsberg AA, Yan J, Wiseman RW, Khan AS, Sardesai NY, O'Connor DH, Weiner DB. Hepatitis C virus NS3/NS4A DNA vaccine induces multiepitope T cell responses in rhesus macaques mimicking human immune responses [corrected]. Mol Ther. 2012;20:669-678. [PMID: 21952169 DOI: 10.1038/mt.2011.188] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.4] [Reference Citation Analysis]
601 Burton JR, Klarquist J, Im K, Smyk-Pearson S, Golden-Mason L, Castelblanco N, Terrault N, Rosen HR. Prospective analysis of effector and regulatory CD4+ T cells in chronic HCV patients undergoing combination antiviral therapy. J Hepatol. 2008;49:329-338. [PMID: 18644644 DOI: 10.1016/j.jhep.2008.05.020] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 2.1] [Reference Citation Analysis]
602 Romani S, Stafford K, Nelson A, Bagchi S, Kottilil S, Poonia B. Peripheral PD-1+ T Cells Co-expressing Inhibitory Receptors Predict SVR With Ultra Short Duration DAA Therapy in HCV Infection. Front Immunol 2019;10:1470. [PMID: 31316516 DOI: 10.3389/fimmu.2019.01470] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
603 Rehermann B, Shin EC. Private aspects of heterologous immunity. J Exp Med 2005;201:667-70. [PMID: 15753200 DOI: 10.1084/jem.20050220] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 1.9] [Reference Citation Analysis]
604 Sharma SA, Feld JJ. Acute Hepatitis C: Management in the Rapidly Evolving World of HCV. Curr Gastroenterol Rep 2014;16. [DOI: 10.1007/s11894-014-0371-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
605 Wedemeyer H, He XS, Nascimbeni M, Davis AR, Greenberg HB, Hoofnagle JH, Liang TJ, Alter H, Rehermann B. Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J Immunol. 2002;169:3447-3458. [PMID: 12218168 DOI: 10.4049/jimmunol.169.6.3447] [Cited by in Crossref: 487] [Cited by in F6Publishing: 472] [Article Influence: 24.4] [Reference Citation Analysis]
606 Bogdanos DP, Gao B, Gershwin ME. Liver immunology. Compr Physiol. 2013;3:567-598. [PMID: 23720323 DOI: 10.1002/cphy.c120011] [Cited by in Crossref: 31] [Cited by in F6Publishing: 55] [Article Influence: 3.4] [Reference Citation Analysis]
607 Thorén F, Romero A, Lindh M, Dahlgren C, Hellstrand K. A hepatitis C virus-encoded, nonstructural protein (NS3) triggers dysfunction and apoptosis in lymphocytes: role of NADPH oxidase-derived oxygen radicals. J Leukoc Biol. 2004;76:1180-1186. [PMID: 15371490 DOI: 10.1189/jlb.0704387] [Cited by in Crossref: 68] [Cited by in F6Publishing: 60] [Article Influence: 3.8] [Reference Citation Analysis]
608 Coss SL, Torres-Cornejo A, Prasad MR, Moore-Clingenpeel M, Grakoui A, Lauer GM, Walker CM, Honegger JR. CD4+ T cell restoration and control of hepatitis C virus replication after childbirth. J Clin Invest 2020;130:748-53. [PMID: 31904583 DOI: 10.1172/JCI123623] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
609 Larrubia JR, Moreno-Cubero E, Lokhande MU, García-Garzón S, Lázaro A, Miquel J, Perna C, Sanz-de-Villalobos E. Adaptive immune response during hepatitis C virus infection. World J Gastroenterol 2014; 20(13): 3418-3430 [PMID: 24707125 DOI: 10.3748/wjg.v20.i13.3418] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 37] [Article Influence: 4.8] [Reference Citation Analysis]
610 Walker CM. Adaptive immunity to the hepatitis C virus. Adv Virus Res 2010;78:43-86. [PMID: 21040831 DOI: 10.1016/B978-0-12-385032-4.00002-1] [Cited by in Crossref: 51] [Cited by in F6Publishing: 38] [Article Influence: 4.6] [Reference Citation Analysis]
611 Desombere I, Van Vlierberghe H, Weiland O, Hultgren C, Sällberg M, Quiroga J, Carreño V, Leroux-roels G. Serum levels of anti-NS4a and anti-NS5a predict treatment response of patients with chronic hepatitis C. J Med Virol 2007;79:701-13. [DOI: 10.1002/jmv.20846] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
612 Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol. 2005;5:215-229. [PMID: 15738952 DOI: 10.1038/nri1573] [Cited by in Crossref: 1133] [Cited by in F6Publishing: 1075] [Article Influence: 66.6] [Reference Citation Analysis]
613 Rist M, Cooper L, Elkington R, Walker S, Fazou C, Tellam J, Crough T, Khanna R. Ex vivo expansion of human cytomegalovirus-specific cytotoxic T cells by recombinant polyepitope: implications for HCMV immunotherapy. Eur J Immunol 2005;35:996-1007. [PMID: 15726667 DOI: 10.1002/eji.200425746] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
614 Satoh K, Takahashi H, Matsuda C, Tanaka T, Miyasaka M, Zeniya M, Kohara M. Natural killer cells target HCV core proteins during the innate immune response in HCV transgenic mice. J Med Virol 2010;82:1545-53. [PMID: 20648608 DOI: 10.1002/jmv.21859] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
615 Martini H, Citro A, Martire C, D'Ettorre G, Labbadia G, Accapezzato D, Piconese S, De Marzio P, Cavallari EN, Calvo L, Rizzo F, Severa M, Coccia EM, Grazi GL, Di Filippo S, Sidney J, Vullo V, Sette A, Barnaba V. Apoptotic Epitope-Specific CD8+ T Cells and Interferon Signaling Intersect in Chronic Hepatitis C Virus Infection. J Infect Dis 2016;213:674-83. [PMID: 26386427 DOI: 10.1093/infdis/jiv460] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
616 Fafi-Kremer S, Zeisel MB, Schvoerer E, Soulier E, Habersetzer F, Wolf P, Doffoel M, Baumert TF, Stoll-Keller F. [Neutralizing antibodies in hepatitis C virus infection]. Gastroenterol Clin Biol 2008;32:491-8. [PMID: 18467058 DOI: 10.1016/j.gcb.2008.02.026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
617 Rouse BT, Sarangi PP, Suvas S. Regulatory T cells in virus infections. Immunol Rev 2006;212:272-86. [DOI: 10.1111/j.0105-2896.2006.00412.x] [Cited by in Crossref: 194] [Cited by in F6Publishing: 185] [Article Influence: 12.1] [Reference Citation Analysis]
618 Li W, Krishnadas DK, Kumar R, Tyrrell DLJ, Agrawal B. Priming and stimulation of hepatitis C virus-specific CD4+ and CD8+ T cells against HCV antigens NS4, NS5a or NS5b from HCV-naive individuals: implications for prophylactic vaccine. International Immunology 2007;20:89-104. [DOI: 10.1093/intimm/dxm121] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
619 Hoofnagle JH. Course and outcome of hepatitis C. Hepatology. 2002;36:S21-S29. [PMID: 12407573 DOI: 10.1053/jhep.2002.36227] [Cited by in Crossref: 94] [Cited by in F6Publishing: 362] [Article Influence: 4.7] [Reference Citation Analysis]
620 van den Berg CH, Grady BP, Schinkel J, van de Laar T, Molenkamp R, van Houdt R, Coutinho RA, van Baarle D, Prins M. Female sex and IL28B, a synergism for spontaneous viral clearance in hepatitis C virus (HCV) seroconverters from a community-based cohort. PLoS One 2011;6:e27555. [PMID: 22110669 DOI: 10.1371/journal.pone.0027555] [Cited by in Crossref: 63] [Cited by in F6Publishing: 66] [Article Influence: 5.7] [Reference Citation Analysis]
621 Capone S, Naddeo M, D'Alise AM, Abbate A, Grazioli F, Del Gaudio A, Del Sorbo M, Esposito ML, Ammendola V, Perretta G, Taglioni A, Colloca S, Nicosia A, Cortese R, Folgori A. Fusion of HCV nonstructural antigen to MHC class II-associated invariant chain enhances T-cell responses induced by vectored vaccines in nonhuman primates. Mol Ther 2014;22:1039-47. [PMID: 24476798 DOI: 10.1038/mt.2014.15] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
622 Saha B, Choudhary MC, Sarin SK. Expression of inhibitory markers is increased on effector memory T cells during hepatitis C virus/HIV coinfection as compared to hepatitis C virus or HIV monoinfection. AIDS 2013;27:2191-200. [PMID: 23820090 DOI: 10.1097/QAD.0b013e32836285e4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
623 Umemura T, Wang RY, Schechterly C, Shih JW, Kiyosawa K, Alter HJ. Quantitative analysis of anti-hepatitis C virus antibody-secreting B cells in patients with chronic hepatitis C. Hepatology 2006;43:91-9. [DOI: 10.1002/hep.20917] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 1.5] [Reference Citation Analysis]
624 Ruys TA, Nanlohy NM, van den Berg CH, Hassink E, Beld M, van de Laar T, Bruisten S, Wit F, Krol A, Prins M, Lange J, van Baarle D. HCV-specific T-cell responses in injecting drug users: evidence for previous exposure to HCV and a role for CD4+ T cells focussing on nonstructural proteins in viral clearance. J Viral Hepat 2008;15:409-20. [PMID: 18221302 DOI: 10.1111/j.1365-2893.2007.00963.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
625 Fuster D, Sanvisens A, Bolao F, Rivas I, Tor J, Muga R. Alcohol use disorder and its impact on chronic hepatitis C virus and human immunodeficiency virus infections. World J Hepatol 2016; 8(31): 1295-1308 [PMID: 27872681 DOI: 10.4254/wjh.v8.i31.1295] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 4.5] [Reference Citation Analysis]
626 Yeung A, Terentis A, King N, Thomas S. Role of indoleamine 2,3-dioxygenase in health and disease. Clinical Science 2015;129:601-72. [DOI: 10.1042/cs20140392] [Cited by in Crossref: 122] [Cited by in F6Publishing: 69] [Article Influence: 17.4] [Reference Citation Analysis]
627 Shin EC, Park SH, Nascimbeni M, Major M, Caggiari L, de Re V, Feinstone SM, Rice CM, Rehermann B. The frequency of CD127(+) hepatitis C virus (HCV)-specific T cells but not the expression of exhaustion markers predicts the outcome of acute HCV infection. J Virol 2013;87:4772-7. [PMID: 23388706 DOI: 10.1128/JVI.03122-12] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 3.9] [Reference Citation Analysis]
628 Goodridge JP, Lathbury LJ, Steiner NK, Shulse CN, Pullikotil P, Seidah NG, Hurley CK, Christiansen FT, Witt CS. Three common alleles of KIR2DL4 (CD158d) encode constitutively expressed, inducible and secreted receptors in NK cells. Eur J Immunol 2007;37:199-211. [PMID: 17171757 DOI: 10.1002/eji.200636316] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 3.3] [Reference Citation Analysis]
629 Vo M, Holz LE, Wong YC, English K, Benseler V, McGuffog C, Azuma M, McCaughan GW, Bowen DG, Bertolino P. Effector T cell function rather than survival determines extent and duration of hepatitis in mice. J Hepatol 2016;64:1327-38. [PMID: 26924452 DOI: 10.1016/j.jhep.2016.01.040] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
630 Wuensch SA, Spahn J, Crispe IN. Direct, help-independent priming of CD8+ T cells by adeno-associated virus-transduced hepatocytes. Hepatology 2010;52:1068-77. [PMID: 20607836 DOI: 10.1002/hep.23745] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
631 Bailey J. An assessment of the use of chimpanzees in hepatitis C research past, present and future: 1. Validity of the chimpanzee model. Altern Lab Anim 2010;38:387-418. [PMID: 21105756 DOI: 10.1177/026119291003800501] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
632 Binder B, Thimme R. CD4+ T cell responses in human viral infection: lessons from hepatitis C. J Clin Invest 2020;130:595-7. [PMID: 31904589 DOI: 10.1172/JCI133222] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
633 Vambutas A, DeVoti J, Nouri M, Drijfhout JW, Lipford GB, Bonagura VR, van der Burg SH, Melief CJ. Therapeutic vaccination with papillomavirus E6 and E7 long peptides results in the control of both established virus-induced lesions and latently infected sites in a pre-clinical cottontail rabbit papillomavirus model. Vaccine 2005;23:5271-80. [PMID: 16054734 DOI: 10.1016/j.vaccine.2005.04.049] [Cited by in Crossref: 77] [Cited by in F6Publishing: 67] [Article Influence: 4.5] [Reference Citation Analysis]
634 Lange CM, Bojunga J, Ramos-Lopez E, von Wagner M, Hassler A, Vermehren J, Herrmann E, Badenhoop K, Zeuzem S, Sarrazin C. Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy. J Hepatol. 2011;54:887-893. [PMID: 21145801 DOI: 10.1016/j.jhep.2010.08.036] [Cited by in Crossref: 169] [Cited by in F6Publishing: 173] [Article Influence: 15.4] [Reference Citation Analysis]
635 Kelly C, Klenerman P, Barnes E. Interferon lambdas: the next cytokine storm. Gut 2011;60:1284-93. [PMID: 21303914 DOI: 10.1136/gut.2010.222976] [Cited by in Crossref: 76] [Cited by in F6Publishing: 75] [Article Influence: 6.9] [Reference Citation Analysis]
636 Dominguez-Molina B, Ferrando-Martinez S, Tarancon-Diez L, Hernandez-Quero J, Genebat M, Vidal F, Muñoz-Fernandez MA, Leal M, Koup R, Ruiz-Mateos E. Immune Correlates of Natural HIV Elite Control and Simultaneous HCV Clearance-Supercontrollers. Front Immunol 2018;9:2897. [PMID: 30619267 DOI: 10.3389/fimmu.2018.02897] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
637 Murakami H, Akbar SM, Matsui H, Horiike N, Onji M. Decreased interferon-alpha production and impaired T helper 1 polarization by dendritic cells from patients with chronic hepatitis C. Clin Exp Immunol 2004;137:559-65. [PMID: 15320906 DOI: 10.1111/j.1365-2249.2004.02550.x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 50] [Article Influence: 2.8] [Reference Citation Analysis]
638 Liu L, Fisher BE, Dowd KA, Astemborski J, Cox AL, Ray SC. Acceleration of hepatitis C virus envelope evolution in humans is consistent with progressive humoral immune selection during the transition from acute to chronic infection. J Virol 2010;84:5067-77. [PMID: 20200239 DOI: 10.1128/JVI.02265-09] [Cited by in Crossref: 58] [Cited by in F6Publishing: 42] [Article Influence: 4.8] [Reference Citation Analysis]
639 Dreux M, Cosset F. The scavenger receptor BI and its ligand, HDL: partners in crime against HCV neutralizing antibodies. J Viral Hepat 2007;14:68-76. [DOI: 10.1111/j.1365-2893.2007.00919.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
640 Tarr AW, Backx M, Hamed MR, Urbanowicz RA, McClure CP, Brown RJP, Ball JK. Immunization with a synthetic consensus hepatitis C virus E2 glycoprotein ectodomain elicits virus-neutralizing antibodies. Antiviral Res 2018;160:25-37. [PMID: 30217650 DOI: 10.1016/j.antiviral.2018.09.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
641 Simmonds P. Genetic diversity and evolution of hepatitis C virus--15 years on. J Gen Virol 2004;85:3173-88. [PMID: 15483230 DOI: 10.1099/vir.0.80401-0] [Cited by in Crossref: 590] [Cited by in F6Publishing: 582] [Article Influence: 32.8] [Reference Citation Analysis]
642 Zhang X, Jiang Z, Gu Y, Liu Y, Cao X, Han Y. Inflammation-induced CD69+ Kupffer cell feedback inhibits T cell proliferation via membrane-bound TGF-β1. Sci China Life Sci 2016;59:1259-69. [PMID: 27933593 DOI: 10.1007/s11427-016-0357-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
643 Brewczyńska A, Depczyńska D, Borecka A, Winnicka I, Kubiak L, Skopińska-Różewska E, Niemcewicz M, Kocik J. The influence of the workplace-related biological agents on the immune systems of emergency medical personnel. Cent Eur J Immunol 2015;40:243-8. [PMID: 26557040 DOI: 10.5114/ceji.2015.52838] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
644 Ernst JD. The immunological life cycle of tuberculosis. Nat Rev Immunol 2012;12:581-91. [DOI: 10.1038/nri3259] [Cited by in Crossref: 320] [Cited by in F6Publishing: 290] [Article Influence: 32.0] [Reference Citation Analysis]
645 Pasetto A, Frelin L, Aleman S, Holmström F, Brass A, Ahlén G, Brenndörfer ED, Lohmann V, Bartenschlager R, Sällberg M, Bertoletti A, Chen M. TCR-redirected human T cells inhibit hepatitis C virus replication: hepatotoxic potential is linked to antigen specificity and functional avidity. J Immunol 2012;189:4510-9. [PMID: 23024278 DOI: 10.4049/jimmunol.1201613] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
646 Radziewicz H, Uebelhoer L, Bengsch B, Grakoui A. Memory CD8+ T cell differentiation in viral infection: A cell for all seasons. World J Gastroenterol 2007; 13(36): 4848-4857 [PMID: 17828816 DOI: 10.3748/wjg.v13.i36.4848] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
647 Hahn YS. Subversion of immune responses by hepatitis C virus: immunomodulatory strategies beyond evasion? Curr Opin Immunol. 2003;15:443-449. [PMID: 12900277 DOI: 10.1016/s0952-7915(03)00076-1] [Cited by in Crossref: 49] [Cited by in F6Publishing: 23] [Article Influence: 2.7] [Reference Citation Analysis]
648 Takaki A, Yagi T, Yamamoto K. Contradictory immune response in post liver transplantation hepatitis B and C. Int J Inflam 2014;2014:814760. [PMID: 25215259 DOI: 10.1155/2014/814760] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
649 Fichter M, Piradashvili K, Pietrzak-Nguyen A, Pretsch L, Kuhn G, Strand S, Knuf M, Zepp F, Wurm FR, Mailänder V, Landfester K, Gehring S. Polymeric hepatitis C virus non-structural protein 5A nanocapsules induce intrahepatic antigen-specific immune responses. Biomaterials 2016;108:1-12. [PMID: 27614817 DOI: 10.1016/j.biomaterials.2016.08.046] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
650 Hughes MG Jr, Rosen HR. Human liver transplantation as a model to study hepatitis C virus pathogenesis. Liver Transpl 2009;15:1395-411. [PMID: 19877210 DOI: 10.1002/lt.21866] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
651 Rehermann B. Natural Killer Cells in Viral Hepatitis. Cell Mol Gastroenterol Hepatol 2015;1:578-88. [PMID: 26682281 DOI: 10.1016/j.jcmgh.2015.09.004] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 6.7] [Reference Citation Analysis]
652 Ferrari C. T and B cells in hepatitis C virus control: what they do and when they fail. Gastroenterology. 2007;132:801-805. [PMID: 17261303 DOI: 10.1053/j.gastro.2007.01.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
653 Talal AH, Canchis PW, Jacobson IM. The HCV and HIV coinfected patient: What have we learned about pathophysiology? Curr Gastroenterol Rep 2002;4:15-22. [DOI: 10.1007/s11894-002-0033-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
654 Urbani S, Amadei B, Cariani E, Fisicaro P, Orlandini A, Missale G, Ferrari C. The Impairment of CD8 Responses Limits the Selection of Escape Mutations in Acute Hepatitis C Virus Infection. J Immunol 2005;175:7519-29. [DOI: 10.4049/jimmunol.175.11.7519] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 2.4] [Reference Citation Analysis]
655 Chen JY, Lin CY, Wang CM, Lin YT, Kuo SN, Shiu CF, Chang SW, Wu J, Sheen IS. IL28B genetic variations are associated with high sustained virological response (SVR) of interferon-α plus ribavirin therapy in Taiwanese chronic HCV infection. Genes Immun. 2011;12:300-309. [PMID: 21346780 DOI: 10.1038/gene.2011.1] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 3.5] [Reference Citation Analysis]
656 Rempel JD, Aborsangaya KB, Alphonse MP, Minuk GY. The influence of North American Aboriginal ethnicity on pro-inflammatory and anti-inflammatory cytokine responses to IFN-alpha. J Viral Hepat 2009;16:292-7. [PMID: 19175873 DOI: 10.1111/j.1365-2893.2008.01063.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
657 Arzumanyan A, Reis HM, Feitelson MA. Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat Rev Cancer. 2013;13:123-135. [PMID: 23344543 DOI: 10.1038/nrc3449] [Cited by in Crossref: 505] [Cited by in F6Publishing: 481] [Article Influence: 56.1] [Reference Citation Analysis]
658 Rouse BT, Suvas S. Regulatory T cells and immunity to pathogens. Expert Opinion on Biological Therapy 2007;7:1301-9. [DOI: 10.1517/14712598.7.9.1301] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
659 Edlin BR, Carden MR. Injection drug users: the overlooked core of the hepatitis C epidemic. Clin Infect Dis. 2006;42:673-676. [PMID: 16447113 DOI: 10.1086/499960] [Cited by in Crossref: 48] [Cited by in F6Publishing: 51] [Article Influence: 3.0] [Reference Citation Analysis]
660 Spear TT, Callender GG, Roszkowski JJ, Moxley KM, Simms PE, Foley KC, Murray DC, Scurti GM, Li M, Thomas JT, Langerman A, Garrett-Mayer E, Zhang Y, Nishimura MI. TCR gene-modified T cells can efficiently treat established hepatitis C-associated hepatocellular carcinoma tumors. Cancer Immunol Immunother 2016;65:293-304. [PMID: 26842125 DOI: 10.1007/s00262-016-1800-2] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 4.5] [Reference Citation Analysis]
661 Zubkova I, Choi YH, Chang E, Pirollo K, Uren T, Watanabe H, Wells F, Kachko A, Krawczynski K, Major ME. T-cell vaccines that elicit effective immune responses against HCV in chimpanzees may create greater immune pressure for viral mutation. Vaccine. 2009;27:2594-2602. [PMID: 19428866 DOI: 10.1016/j.vaccine.2009.02.045] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
662 Makarem MAAE, Eslam M, Sayed D, Shawkat M, Idriss NK, Soliman EM, Sherif T, Abdelshaheed R, Abdelhailm H, Sahrawi MA, Elheney S. Diabetes worsening of hepatitis C cirrhosis: Are alterations in monocytic tissue factor (CD 142) is the cause? Annals of Hepatology 2014;13:27-37. [DOI: 10.1016/s1665-2681(19)30901-9] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
663 Gowans EJ, Jones KL, Bharadwaj M, Jackson DC. Prospects for dendritic cell vaccination in persistent infection with hepatitis C virus. J Clin Virol 2004;30:283-90. [PMID: 15163415 DOI: 10.1016/j.jcv.2004.03.006] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.3] [Reference Citation Analysis]
664 Torresi J, Johnson D, Wedemeyer H. Progress in the development of preventive and therapeutic vaccines for hepatitis C virus. J Hepatol. 2011;54:1273-1285. [PMID: 21236312 DOI: 10.1016/j.jhep.2010.09.040] [Cited by in Crossref: 93] [Cited by in F6Publishing: 90] [Article Influence: 8.5] [Reference Citation Analysis]
665 Folgori A, Capone S, Ruggeri L, Meola A, Sporeno E, Ercole BB, Pezzanera M, Tafi R, Arcuri M, Fattori E. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat Med. 2006;12:190-197. [PMID: 16462801 DOI: 10.1038/nm1353] [Cited by in Crossref: 237] [Cited by in F6Publishing: 220] [Article Influence: 14.8] [Reference Citation Analysis]
666 Cusick MF, Libbey JE, Fujinami RS, Eckels DD. In vitro antigen-specific induction of IL-22 in human subjects that resolved HCV infection. Future Virol 2012;7:719-28. [PMID: 23185211 DOI: 10.2217/fvl.12.58] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
667 Kamal SM. Acute hepatitis C: a systematic review. Am J Gastroenterol 2008;103:1283-97; quiz 1298. [PMID: 18477352 DOI: 10.1111/j.1572-0241.2008.01825.x] [Cited by in Crossref: 103] [